

EXHIBIT B

**IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA
CHARLESTON DIVISION**

IN RE: ETHICON, INC. PELVIC REPAIR SYSTEM PRODUCTS LIABILITY LITIGATION	Master File No. 2:12-MD-02327 MDL No. 2327
THIS DOCUMENT RELATES TO: ALL WAVE 1 CASES INVOLVING PROLIFT, GYNEMESH PS, & PROLENE	JOSEPH R. GOODWIN U.S. DISTRICT JUDGE

RULE 26 REPORT OF DONALD R. OSTERGARD, M.D.

The following report is provided pursuant to Rule 26 of the Federal Rules of Civil Procedure. The opinions are held and expressed as follows:

1. I am a physician licensed to practice medicine in the State of California. I attended the University of California (Los Angeles) followed by medical school. I received a Bachelor of Science degree in 1960 from the University of California (San Francisco) and a medical and master's (anatomy) degrees in 1963. I completed my Residency in Obstetrics and Gynecology at Los Angeles County Harbor General Hospital in 1968 and I have been a board-certified obstetrician and gynecologist since 1970. I have been a faculty member of the UCLA School of Medicine. From 1979 to 2011, I was a Professor or Professor Emeritus of Obstetrics and Gynecology at the University of California, Irvine. I am currently Professor-in-Residence at the UCLA School of Medicine, Harbor-UCLA Medical Center, Torrance, CA. A copy of my current CV is attached as Exhibit A.

2. I am aware of the Protective Order in this matter and expect that because I refer to documents identified as CONFIDENTIAL by ETHICON that my entire declaration will be submitted to the Court in a sealed envelope.

3. Pelvic Organ Prolapse (POP) may consist of a cystocele, rectocele and stress urinary incontinence (a cystocele consists of a herniation of the anterior vaginal wall with the bladder behind it; a rectocele consists of a herniation of the posterior vaginal wall with the rectum behind it; stress urinary incontinence occurs with any increase in intraabdominal pressure, such as, with coughing). This type of prolapse may produce symptoms of a vaginal bulge, the sensation that the woman is sitting on something, pelvic pressure felt in the lower abdomen, and painful intercourse (dyspareunia). Patients may abstain from sexual relations because of the protrusion of the bladder to the outside or because of the incontinence. The POP may sufficiently interfere with the patient's lifestyle that she becomes sedentary and avoids any type of activity. As the prolapse develops it may create a kinking of the urethra through which urine travels from the bladder to the outside. This kinking obstructs the flow of urine and creates a very slow egress of urine from the bladder

and may result in the inability to empty the bladder with retention of urine within the bladder. Since urine is a very good culture medium for bacteria to grow in, this retention of urine can be productive in bladder infections that may back up into the kidneys and produce a kidney infection which can be life threatening.

4. Medical treatment for a patient with pelvic organ prolapse and stress urinary incontinence can be accomplished with the insertion into the vagina of a vaginal pessary which is a ring or cube shaped device which will keep the prolapsed bladder inside the vagina. Stress incontinence may be treated with a pessary containing a knob, Kegel's exercises and electrical stimulation. This is considered temporary therapy in a sexually active woman because of the need to remove it for intercourse. Replacement of the bladder in a woman with obstruction to urine flow may also be treated by the insertion of a pessary. Surgical treatment of the prolapse can be accomplished using native tissue by an anterior and posterior colporrhaphy, abdominal sacral colpopexy, LeFort colpocleisis (vaginal closure) or total vaginal excision. Surgical treatment of stress incontinence can be done by a sub-urethral sling, Burch procedure or intra-urethral injections.

5. When complications develop from the defective Ethicon vaginal mesh devices, such as, vaginal mucosal dehiscence, mesh exposure, chronic pelvic, lower abdominal and vaginal pain along with urinary frequency, recurrent urinary tract infections, painful intercourse, vaginal/mesh tenderness, vaginal rigidity, the treatment is to remove the device. If an erosion/exposure is early and small it may respond to the use of intravaginal estrogen to stimulate the growth of the vaginal lining to cover the area of exposure. When pain or allergic reaction to the device develops or if the device erodes into adjacent organs, such as, the urethra, anal sphincter, rectum, or other bowel, the device must be removed. Generally this is very difficult due to the intense inflammatory reaction and the resultant fibrosis and scarring of the tissues where the device resides. This is especially prominent with the Gynemesh devices. Complete removal generally is not possible due to the degradation of the polypropylene which weakens the mesh to the point that it literally falls apart during dissection. Removal attempts may also damage the nearby organs listed above due to the adherence of the device to these structures. Multiple surgeries are frequently required in attempts to remove the device. Patients also experience contracture and shrinkage of the device and the vagina which decreases the lumen of the vagina which makes intercourse painful and sometimes impossible. When the device cannot be removed totally, a pelvic pain syndrome occurs which is very difficult to treat and narcotics may be required to control the pain. Acupuncture, tibial nerve stimulation, physical therapy and a lot of emotional support may be helpful, but will not treat the basic problem since mesh frequently remains in the body in varying amounts.

6. I submit that I am also familiar with warnings associated with transvaginal mesh implant products, including the warnings on Ethicon's Prolift, Prolene, Gynemesh and Gynemesh PS implant products. My opinions set forth in this declaration are based on my education, experience and qualification and are made to a reasonable degree of medical certainty.

7. The polypropylene mesh used in the manufacture of Gynemesh is defective in the following ways:

- a. The weave of the mesh produces very small interstices which allow bacteria to enter and to hide from the host defenses designed to eliminate them. The bacteria can secrete an

encasing slime (biofilm) which further serves to protect them from destruction by white blood cells and macrophages. (Osterberg B. Acta Chir Scand 1979;145:431, Merritt K. J Biomat Appl 1991;5:185, An Y. J Biomed Mater Res (Appl Biomat) 1998;43:338)

- b. The polypropylene is impure. There is no such thing as pure polypropylene (PP). PP contains about 15 additional compounds which are leached from the PP and are toxic to tissue which enhances the inflammatory reaction and the intensity of fibrosis. (Sternschuss G. J Urol 2012;188:27-32)
- c. Prolene mesh was shown to be not inert in 2003 with flaking and fissuring demonstrated by scanning electron microscopy. (Coda A. Hernia 2003;7:29 and confirmed in Yahi Y. Int Urogyn J 2007;18(Suppl 1):S6)
- d. With loss of PP due to degradation, the surface area is greatly increased thus providing greater areas for bacterial adherence and more elution of toxic compounds from the PP and also the freed toxic PP itself, all of which increases the inflammatory reaction and intensity of fibrosis. (Jongebloed W. Doc Ophth 1986;64:143, Sternschuss G. J Urol 2012;188:xxx, Clave A. Int Urogyn J 2010;21:261)
- e. Polypropylene mesh in 1998 was known to shrink 30-50%. This was subsequently confirmed for Prolene mesh. (Klinge U. Eur J Surg 1998;164:965, Jacquetin B. Int Urogyn J 2009;20:893)
- f. Heat begins the process of degradation. Gynemesh mesh is cut by a high heat laser. (Serbetci K. 2007;195:375, 20111213110058384)
- g. Predominate infection/inflammation was noted in 2007 in explanted samples from Dr. Cosson's series of patients. (Yahi Y. Int Urogyn J 2007;18(Suppl 1):S149)
- h. The large surface area promotes wicking of fluids and bacteria and is a "bacterial super highway" which provides a safe haven for bacteria which attached themselves to the mesh during the insertion process. (Mahmoud W. J Biomat Sci Polymer Ed 1996;7:751, Klinge U. J Biomed Mater Res 2002;63:765, Vollebregt A. Int Urogyn J 2009;20:1345)
- i. As indicated by the publication dates in many of the above items, due diligence would have detected all of these mesh defects and helped to predict the complications now known to occur before the introduction of Gynemesh to the medical marketplace. Such adverse events became apparent after patient experimentation paid for by insurance companies.
- j. Animal studies were not done using the currently available PP mesh used in Gynemesh. The original prolene mesh studies were not conducted to the steady state where there is no longer any inflammation. Gynemesh mesh produces a persistent foreign body reaction. (20111213110058384, Elmer C. J Urol 2009;181:1189)
- k. Gynecare Gynemesh PS is a heavy weight mesh of 44 gm/m² compared to Polyform at 40 gm/m² and Popmesh at 19 gm/m². Because of the high rate of adverse events, lighter

weight meshes are preferred to reduce complications. (KA Jones. Internat Urogyn J Pelvic Floor Dysfunction 2009;20:847-53)

- l. Gynecare Gynemesh PS is also a high stiffness mesh when compared to Polyform, Pelvitex and Timesh. This is a detrimental quality since increased mesh stiffness has been correlated with an increased erosion rate. (KA Jones. Internat Urogyn J Pelvic Floor Dysfunction 2009;20:847-53; M Huebner et al. Internat J Obstet Gynec 2006;92:279-88)

- m. In the situation where a hysterectomy is done followed by an abdominal sacral colpopexy, some surgeons will place the GYNEMESH down the entire posterior vaginal wall to the perineum for treatment of rectocele. If there is a perineal descent syndrome present, this might be a good choice. In other situations this treatment should be avoided.

8. The placement of Gynemesh in the vagina is dangerous to the patient:

- a. The placement violates one of the most basic tenets of surgical teachings in that the placement of a permanent implant into the human through a contaminated surgical field (the vagina can never be sterilized) and makes the implantation by this route contraindicated. With Avaulta 96% of the mesh arms were found to be contaminated with bacteria by culture of specimens removed during the surgical procedure. (Culligan P. Infect Dis Obstet Gynec 2003;11:161, Vollebregt A. Int Urogyn J 2009;20:1345)
- b. Even though the bladder is susceptible to injury, cystoscopy is not advised to detect intraoperative injuries during cystocele repair. (Prolene, Gynemesh and Gynemesh PS mesh IFU's from 1996 through today)
- c. The size of the mesh placed equates to a very large surface area with many places for bacteria to hide, protected from host defenses. (Mahmoud W. J Biomat Sci Polymer Ed 1996;7:751, Klinge U. J Biomed Mater Res 2002;63:765, Vollebregt A. Int Urogyn J 2009;20:1345)

9. Clinical use has demonstrated many injuries to patients. Items 'a' to 'm' are from the Ethicon funded study of French and US women:

- a. Mesh exposure rate was 14% in the US portion of the Ethicon funded study of French and US women. Yet Ethicon allowed minimization of the rate of mesh exposure with Jacquetin reporting 2.4% in the total Ethicon study and Cosson reporting 10% in the French women in the study. (Prolift IFU after FDA clearance, Jacquetin B. Neurourol Urodyn 2006;25:Suppl. Abst. 291)
- b. An unacceptably high urinary incontinence rate of 20% was found in the US portion and 27% in the French portion of the Ethicon funded Prolift study. (01082002)
- c. Vesicovaginal fistulae occurred in 2 women the Ethicon Prolift study and this was reported at an international meeting by Jacquetin but, Lucente, reporting on the same group of patients divulged only one such fistula. Ethicon allowed minimization of this serious adverse event. (Jacquetin B. Neurourol Urodyn 2006;25:Suppl. Abst. 291, Lucente V. Neurourol Urodyn 2005;24:Suppl. Abst 406)

- d. The number of women in the US portion of the study is reported as 83. (Prolift IFU after FDA clearance, 90 by Lucente V. Neurourol Urodyn 2005;24:Suppl. Abst 406, and 85 by Jacquetin B. Neurourol Urodyn 2006;25:Suppl. Abst. 291). Ethicon allowed this confusion.
- e. Severe adverse events with Prolift were reported in 2.4% of the US compared to 10% in the French study population. (080907 includes partial 510k for Gynemesh)
- f. The anatomical failure rate with Prolift was unacceptably high at 18% in the French portion of the study at 12 months. (Prolift IFU after FDA clearance)
- g. Moderate to severe contraction of the vaginal walls occurred in 3.6% of US patients and 12.6% of French Prolift study patients. (Prolift IFU after FDA clearance, 080907 includes partial 510k for Gynemesh)
- h. Pain was unacceptably high postoperatively with Jacquetin reported 7% in the total Prolift study (Jacquetin B. Neurourol Urodyn 2006;25:Suppl. Abst. 291) whereas Cosson reported 14% in French part of study. Ethicon documents place it at a 16% rate in the French part of the study. (Cosson M. IntUrogyn J 2006;17(Suppl 1) S139, 080907 includes partial 510k for Gynemesh). Ethicon allowed minimization of this serious adverse event.
- i. One patient had a ureteral stricture in the Prolift study and another had a ureteral injury requiring reimplantation of the ureter which was not reported to the FDA. (080907 includes partial 510k for Gynemesh)
- j. A vesicovaginal fistula in the Prolift study was associated with with ureteral reimplantation in one patient. (080907 includes partial 510k for Gynemesh)
- k. 76% of French Prolift study patients had one or more adverse events compared to 66% in the US part of the study. (080907 includes partial 510k for Gynemesh)
- l. 10% of French Prolift study patients had severe adverse events compared to 2.4% in the US study population. (080907 includes partial 510k for Gynemesh)
- m. Vaginal retraction occurred in 13% of French Prolift study patients. (080907 includes partial 510k for Gynemesh)
- n. In a draft publication submitted to the International Urogynecology Journal entitled "A Systematic Review of the GYNECARE PROLIFT Pelvic Floor Repair System in Pelvic Organ Prolapse" the Ethicon employee authors concluded that "This review suggests that GYNECARE Prolift has good anatomic success, limited complications and statistically significant improvement in patient reported outcomes". I could find no indication that this was published. (ETH.MESH.00596225-64) This manuscript was rejected for publication in two journals. (ETH.MESH.00578261-63, 01798401-11)
- o. In a cytotoxicity test of Ulmsten's Prolene Polypropylene mesh done in 1997, it failed the test by demonstrating moderate toxicity. Ethicon continued to market this mesh. (ETH.MESH.02614726-33)

- p. In a power point presentation for GYNECARE PROLIFT+M, Ethicon states that customers are asking for grafts with less foreign material to improve clinical outcomes. It was espoused for younger and active patients. There was no evidence that these goals could be met. (ETH.MESH.00002652)
- q. Ethicon was willing to use 3 month data in sales pieces and was willing to launch with soft or no data. (ETH.MESH.00075064-70)
- r. In a power point presentation Ethicon acknowledges that the vagina is not the abdomen nor similar to any other surgical environment, yet animal studies were carried out in other locations than the vagina. Ethicon also recognized that the vagina cannot be sterilized. (ETH.MESH.00164606-11)
- s. In the TVM study in the US and France, some of the mesh was hand cut, but this was not factored in to the analysis. (ETH.MESH.00401457-58)
- t. In a Prolift surgical technique document, Ethicon advises that antiseptic vaginal preparation should occur knowing that the vagina can never be sterilized. (ETH.MESH.00419571-600)
- u. In January of 2005, Ethicon spoke to Dr. Cervigni who warned about infection with GYNEMESH for tension free repair in 8% of his cases and if there is an erosion he always sees a low grade fever. He further told Ethicon that mesh contraction causes pain, it causes a hard tissue that can be felt by the patient and partner, the mesh can ball up which is painful, it can lead to suture line dehiscence and prolapse recurrence. (ETH.MESH.00442831-34)
- v. In 2004, Ethicon was warned about contracture of the mesh leading to pain and dyspareunia by Drs. Jacquetin and Cosson. (ETH.MESH.00584846-47)
- w. In 2006, Ethicon was asked if sexual function data should be used and said that without a solid case for Prolift, this should be avoided. (ETH.MESH.00741137-40)
- x. Dr. Butrick voiced concern about Prolift patients with bad myofascial pain stating doctors should not place mesh through these spastic muscles. He doesn't consider that the mesh is causing these spastic muscles. (ETH.MESH.00847816)
- y. In November of 2001, Ethicon states that polypropylene is not subject to degradation. Due diligence would have found evidence to the contrary. (ETH.MESH.01160158-59)
- z. In a discussion of the 5 week results with the TVT Secur the following were noted: bladder perforation, de novo urgency, persistent urgency, worsening SUI, tape exposure, groin pain and vaginal hematoma. It concluded that there was a lack of serious complications. (ETH.MESH.02289896)
- aa. In a report entitled "Investigating Mesh Erosion in Pelvic Floor Repair" in May of 2011 Ethicon acknowledged that commonly noted manifestations of mesh infection are pelvic pain, persistent vaginal discharge or bleeding, dyspareunia and urinary or fecal incontinence. Ethicon also knew that the vaginal infection rate of mesh was expected to

be higher than the rate for abdominal implantation. Numerous artifacts were found on the mesh surfaces using high power magnification for Gynemesh PS, Prolift +M, and Prosima where samples of competitor's mesh did not show these artifacts. The cause of Ethicon mesh artifacts was not determined. (ETH.MESH.02589032-72)

- bb. In the same report Ethicon acknowledged that polypropylene suffers from degradation, a process that begins a few days after implantation in animal studies through oxidation. The Jongebloed article from 1986 is quoted as an example of degradation and the Costello article showing SEM images of degraded meshes in 2007. Pre-release due diligence of Gynemesh PS and subsequent products for sale would have alerted Ethicon of these issues with polypropylene mesh. (ETH.MESH.02589032-72)
- cc. In August of 2008, Ethicon discusses T-Pro and states that there is no patient-centric pelvic floor material, that pelvic floor materials are still over-engineered and that we need less foreign body material. Ethicon proposes that different mechanical properties are needed in different areas of the pelvic floor. The post-implantation scar tissue and scar plate formation is not recognized to alter mechanical properties. (ETH.MESH.03021946)
- dd. In a discussion of meshes for pelvic floor repair in June of 2000, Ethicon was told regarding Prolene/Gynemesh that it was too thick and bulky, too stiff, and releases particles when cut. The interviewed physicians thought that the mesh was inert and well tolerated. (ETH.MESH.03904451-80)
- ee. In August of 2007, Ethicon discusses ureteral injury in 6 patients and acknowledged that this was not mentioned in the PROLIFT IFU. (ETH.MESH.04096233-34)
- ff. In a communication to the FDA regarding the marketing of Prolift without FDA notification, Ethicon attempts to convince the FDA that it was an insignificant change from Gynemesh PS to Prolift as it was considered to be a line extension of Gynemesh PS consisting of a shape change and the addition of insertion tools to create a procedural kit. This would indicate that the FDA was supposed to accept this information transforming a sheet of mesh into a surgical procedure complete with instructions on how to perform the procedure. (ETH.MESH.01383-01637)
- gg. In 2002 Ethicon held a TVT Summit Gynemesh PS panel where a strategy was discussed to convert high volume pelvic floor surgeon specialists who can publish and document good results with Gynemesh PS and support Gynecare's leadership. (ETH.MESH.08158-20115)
- hh. In November of 2004, Ethicon stated "cadaveric evaluations of prototype Prolift components have demonstrated that these devices and the system as a whole are suitable for performing pelvic floor repairs". What about in live women? (ETH.MESH.41142)
- ii. Ethicon wanted to know if it could rely on Prolift data to support Prolift+M, or, will we be reliant on the new +M data? No need to study a new product? (ETH.MESH.049512-916)

- jj. Ethicon discussed 4 cases of inability to void after Prolift surgery which took a year to resolve. "But, if this gets reported, it is going to scare the daylights out of docs". There is no record of this being told to physicians. (ETH.MESH.80249)
- kk. In August of 2005, Ethicon is warned by Dr. Linda Cardozo that the Prolift safety profile is worrying especially since there is no efficacy data to review. Her concern was about the severity and type of complications in the perioperative period. (ETH.MESH.02923305-06)
- ll. In a discussion of mesh, Ethicon compares propylene mesh to rebar in concrete. It also believes that to maximize sexual function, use soft/flexible material. Scar plate formation is not mentioned. (P1593.Depo exhibit 127)
- mm. Ethicon states that in the absence of strong clinical evidence the surgeon will have to rely on other sources of information: science of textiles and hernia surgery. The difficulties in finding hard data is mentioned as is the fact that the prosthetic material is placed through a septic cavity and there is a high risk of infection especially since there are tiny spaces known as interstices which can harbor bacteria. Ethicon also acknowledges that mesh shrinkage occurs and may be associated with mesh stiffness and tenderness, dyspareunia, pelvic pain urinary or defecatory dysfunction and prolapse recurrence. With Prolift the shrinkage rates were 0-17%. (SP1659)
- nn. In a discussion of publications for Prolift +M, no publications are listed.
- oo. In 1996, Julian reported a series of patients using Gynecare Gynemesh which was anchored anteriorly and posteriorly as well as laterally in the pelvis. He recommended that this mesh be used only after 2 surgical failures and should not be used as a primary procedure. The erosion rate was 4%. (Am J Obstet Gynec 1996;175:1472-5)
- pp. In 1998, Nicita et al reported a series of patients using Gynecare Gynemesh which was only anchored laterally in the pelvis. They recommended longer term studies. The erosion rate was 2.2% in 44 patients. (J Urol 1998;160:741-5)
- qq. In 2000, Mighari et al reported a series of patients using Gynecare Gynemesh which was only anchored anteriorly and posteriorly. There were no erosions in 12 patients. They advised a long term study. (Eur Urol 2000;38:151-5)
- rr. In 2002, DeTayrac et al reported a series of patients using Gynecare Gynemesh which was placed from the retropubic space to the inferior part of the bladder. During a followup of 18 months the vaginal erosion rate was 8.3%. (J Gynec Obstet Biol Repro (Paris) 2002;31:597-9)
- ss. In 2004, Bader et al which was placed from under the bladder to the para-vesical spaces bilaterally in contact with the arcus tendineous fascia pelvis. No fixation was done. Of 40 women the erosion rate was 7.5%. In this series 75% were incontinent and had a concomitant TVT device implantation. Mean follow up was 16.4 months +/- 4.7 months. (Bader G et al. Gynecol Obstet Fertil 2004;32:280-4)

- tt. In 2005, de Tayrac et al reported a series of patients using Gynecare Gynemesh which was placed from the retropubic space to the inferior part of the bladder. During follow up of 24 +/- 9.6 months the vaginal erosion rate was 8.3%. (J Reprod Med 2005;50:75-80)
- uu. In 2006, the inventor of the Ethicon Prolift kit published indicating that it was a safe procedure to correct pelvic organ prolapse. There was no acknowledgement of this conflict of interest in the manuscript. (Fatton B, Dibodinance P, Cosson M, Jacquetin B. IUJ 2006)
- vv. In 2006, Benhaim et al, reported on a series of patients using Gynecare Gynemesh for treatment of cystocele, rectocele together or separately. Of the 20 women in this study, 17 had had prior mesh insertion. The anterior vaginal erosion rate was 10%. Twenty-six percent experienced sexual deterioration and 4 patients developed de novo dyspareunia. (Benhaim Y et al.J Gynecol Obstet Biol Reprod (Paris) 2006;35:219-26)
- ww. In 2006, de Tayrac et al reported a series of patients using Gynecare Gynemesh for rectocele which was placed from the sacrospinous ligaments to the perineum. During a median follow up of 22.7 +/- 9.2 months the vaginal erosion rate was 12% and the de novo dyspareunia rate was 7.7%. (Internat Urogyn J Pelvic Floor Dysfunct 2006;17:100-5)
- xx. In 2006, de Tayrac et al reported a series of patients using Gynecare Gynemesh for cystocele which was only anchored anteriorly and posteriorly. They reported a 9.1% erosion rate, 16.7% with dyspareunia, and 5.5% with pain. They concluded that the mesh had to be improved and randomized clinical trials needed before recommended in clinical practice. (R deTayrac et al. Internat Urogyn J 2006;17:483-8)
- yy. In 2007, Deffieux et al reported a series of patients using Gynecare Gynemesh compared to Gynecare Gynemesh PS which was not anchored in any fashion. In the former the erosion rate was 16% and in the latter they reported a 24% erosion rate. 55% of the entire group required mesh removal. The dyspareunia rate was 9% in patients with vaginal erosion and 11% in patients without erosion. (X Deffieux et al. Internat Urogyn J 2007;18:73-9)
- zz. In 2007, a study of Prolift prolapse repair found visceral injury in 4.4% of patients. (Altman et al. ObstGynec 2007;109:303)
- aaa. In 2007, a retrovesical hematoma was reported with Anterior Prolift. (Ignjatovic et al. IUJ 2007;18:1495)
- bbb. In 2008, in a study of Prolift on a teaching service found few perioperative complications, however, 34% required catheterization for urinary retention prior to discharge. (Alperin et al. IUJ 2008;19:1617)
- ccc. In 2008, in a 6 month study of Prolift prolapse repair, during the first month abscesses, hematomas, vesicovaginal fistulas, a rectovaginal fistula and one pelvic cellulitis. Subsequently, 11.3% erosions, 11.7% retractions, 5.4% de novo stress incontinence and 6.9% recurrences of prolapse were found. (Caquant et al. J Ob Gyn Res 2008;34:449)
- ddd. In 2008, a study of Prolift treatment of prolapse found a 16.7% dyspareunia rate. (Lowman et al. AJOG 2008;199:707.e1-707.e6)

- eee. In 2008, Prolift treated patients showed significant anatomic and quality of life improvements. (van Raalte et al. AJOG 2008;199:694.e1-694.e6)
- fff. In 2009, Letouzey et al reported on the shrinkage rate of Gynemesh after implantation for cystocele repair over a 9 year period in 40 patients evaluated with ultrasound. They found a 10% per year shrink rate up to 85% at 8 years. (Int Urogyn J 2009; 20 (Suppl.2): S205-6)
- ggg. In 2009, a study of Prolift prolapse repair found a 6.6% visceral injury rate, a 24.3% de novo stress incontinence rate and 18% had pelvic muscle dysfunction symptoms. (Aungst et al. AJOG 2009;201:74.e1-7)
- hhh. In 2009, in a study of Prolift prolapse repair anatomical success for cystocele was 79%, bladder and rectal perforation rate was 3.4% and vaginal erosions in 11%. (Elmer et al. ObstetGynec 2009;113:17)
- iii. In 2009, a study of Gymemesh mesh contraction showed that Gynemesh contracted at a rate of 10% per year, up to 85% at 8 years. (Letouzey et al IUJ 2009;20 (suppl 2):S205)
- jjj. In 2009, 2 cases of Prolift deep dyspareunia requiring multiple excisions of apical mesh. (Walid et al. Arch Gyn Ob 2009;DOI 10.1007)
- kkk. In 2009, a Prolift study showed a 73% satisfaction rate and low complication rate and significant anatomical improvement. (Wetta et al. IUJ 2009;DOI 10.1007)
- lll. In 2010, a study of prolapse repair using the Prolift system showed good anatomical success and symptom improvement over 2 years. (Huang et al. IUJ DOI 10.1007)
- mmm. In 2010, Lin et al reported a series of patients using Gynecare Gynemesh for cystocele and rectocele with the mesh being placed from the bladder or rectum to the white line on the pelvic sidewall. Anteriorly the mesh was fixed anteriorly and posteriorly and posteriorly it was fixed to the sacrospinous ligament and the perineum. In the 39 women in this study. The complication rate was 10.3% with a 2.6 % erosion rate. (Lin TY et al. J Obstet Gynec Res 2010;36:1059)
- nnn. In 2010, an ultrasonographic study of Prolift mesh contraction found that of 91 patients, >50% had severe contraction and prolapse recurrence appeared to be associated with loss of mesh support. (Velemir L. Ultrasound Ob Gyn, 2010;35:474)
- ooo. In 2010, in a study of anterior Prolift results, this procedure was found to provoke prolapse in other not treated compartments of the vagina. (Withagen et al. IUJ 2010; 21:271)
- ppp. In 2010, the inventor of the Prolift Kit for Ethicon stated that "Medium-term results demonstrate that the TVM technique provides a durable prolapse repair in spite of a 20% anatomical failure at 3 years and a 14.4% rate of mesh extrusion. (Jacquetin et al. IUJ 2010;21:1455)

- qqq. In 2010, Prolift surgery in women over the age of 80 showed retention in 25.8%, moderate to severe pain in 17.7% and recurrence in 8.3%. (Gabriel et al. IUJ 2010; 21:1463)
- rrr. In 2010, ultrasound evaluation of Prolift mesh postoperatively compared to the preoperative measurements, showed folding at 4 days post surgery and a further reduction in mesh length later. (Svabik et al. IUJ 2010;DOI 10.1007)
- sss. In 2011, in a study of Anterior Prolift for recurrent bladder prolapse there was a 53% anatomical success rate and an exposure rate of 19%. (Fayyad et al. 2011;22:157)
- ttt. In 2011, a study of Prolift versus native tissue repair on sexual function and improvement was noted on the native tissue arm and deterioration was noted on the mesh arm and mesh exposure was independently associated with deterioration in the mesh arm. (Milani et al. J Sex Med 2011;DOI:10.1111)
- uuu. In 2011, in a study of Prolift for prolapse repair over 6 months there were 5.3% failures and 12.3% rate of exposures. (Kaufman et al. IUJ 2011;22:307)
- vvv. In 2011, a study comparing Prolift with abdominal sacral colpopexy using Prolene showed that "At 2 years, the laparoscopic sacral colpopexy had a higher satisfaction rate and objective success rate than the total vaginal mesh with lower perioperative morbidity and reoperation rate. (AJOG 2011;204:360.e1-7)
- www. In 2011, a comparison of anterior colporrhaphy and the Prolift mesh kit was published indicating that the mesh kit resulted in higher rates of surgical retention, vaginal dehiscence and pelvic or genital pain. (Altman et al. NEJM 2011;364:1826)
- xxx. In 2011, in a comparison of native tissue prolapse repair and Prolift mesh repair, the anatomical results were better mesh, yet symptom decrease and quality of life were equal in both groups. (Withagen et al. ObstetGynec 2011;117:242)
- yyy. In 2011, after Prolift vaginal repair the reoperation rate was 11.6% for urinary incontinence, mesh related complications and prolapse recurrence. (de Landscheer et al. AJOG 2015;205:xxx)
- zzz. In 2011, a study of the Prolift +M showed that the anatomical success rate was 77.4% and the mesh exposure rate was 10.2% at 1 year. (Milani et al. AJOG 2011;204:74.e1-8)
- aaaa. In 2011, Miller et al reported a series of patients using Gynecare Gynemesh PS for multiple compartments which was anchored by the TVM technique. The erosion rate was 18.8% and the dyspareunia rate 3.5%. There was one rectovaginal fistula, 2 ureteral injuries and one ureterovaginal fistula. (D Miller et al. Female Pelvic Med Reconstr Surg 2011; 17:139-43)
- bbbb. In 2011, a study of Prolift for prolapse revealed that it had an 85% anatomical success in the medium term but with a 15% mesh exposure rate. (Nair et al. Eur J ObGyn Repro Biol 2011;158:358)

- cccc. In 2011, the effects of the Prolift procedure on bladder function were found to be a reduced storage function and impaired bladder capacity with reduced urethral closure pressure. (Su et al. IUJ 2011;22:285)
- dddd. In 2012, a study of the Prolift kit for anterior prolapse showed an 18.2% erosion rate. (Vaiyapuri et al. Sing Med 2012;53:664)
- eeee. In 2012, a study of Prolift prolapse repair found that sexual function was not negatively affected 12-18 months after surgery. (Bartuzi et al. Eur J ObGyn Repro Biol 2012; 165:295)
- ffff. In 2012, Prolift prolapse repair was compared to sacrospinous ligament suspension for vault prolapse and showed recurrence rates of 16.9% and 39.4% respectively. The mesh exposure rate was 20.8%. (Halaska et al. AJOG 2012;207:301e.1-7)
- gggg. In 2012, in a comparison of Gynemesh and Prolift repair of prolapse anatomical outcomes were comparable as were adverse events. (Chen et al. Eur J ObGyn Repro Biol 2012;164:221)
- hhhh. In 2012, in a study of elderly women treated for prolapse with Prolift showed a 97.1% success rate, but with 29.4% de novo stress incontinence, 22.2% de novo dyspareunia and a 1.5% erosion rate. (J Min Inv Surg 2012; 19:307)
- iiii. In 2012, in a study of Prolift efficacy and complications after 4.5 years found that it was efficacious with a 14.7% failure rate and the following adverse events were reported: de novo OAB and stress incontinence, erosion, dyschesia, constipation, pelvic pain, chronic urinary retention and pain requiring surgery. (Benbouzid et al. Int J Urol 2012;19:1010)
- jjjj. In 2012, prolapse repair with Prolift was compared with native tissue repair and found that with Prolapse there was a higher rate of de novo prolapse in other non-treated compartments than with native tissue repair. (Withagen et al. BJOG 2012;119:354)
- kkkk. In 2012, in a comparison of native tissue repair and Prolift mesh repair found that the two procedures had similar objective and subjective improvement, but mesh repair had a higher reoperation rate and did not improve 1 year cure. (Sokol et al. AJOG 2012; 206:86.e1-9)
- llll. In 2013, in a study of Prolift prolapse repair, it was found a mesh exposure rate of 13%. (Alperin et al. Fem Pelv Med Recon surg 2013;19:72)
- mmmm. In 2013, in an ultrasound study of Anterior Prolift found a correlation between mesh contraction with the severity of vaginal pain and de novo OAB symptoms. (Rogowski et al. IUJ DOI 10.1007)
- nnnn. In 2013, in a comparison of the Prolift total vaginal mesh kit with sacral colpopexy using Ethicon mesh sheet showed that in obese women the colpopexy group had better anatomical outcomes. (McDermott et al. J ObGyn Canad 2013;35:461)

oooo. In 2013, Prolift was found to have a 12% mesh exposure rate which was greater anteriorly (8.7%) than posteriorly (2.9%). (Frankman et al. *ObGyn Internat* 2013;article ID 926313)

pppp. In 2013, traditional vaginal prolapse surgery was compared to Prolift mesh kit implantation, and because of an erosion rate of 15.6% the study was stopped prematurely. There was no difference in cure rates between the two groups. (Gutman et al. *ObstetGynec* 2013;122:770)

qqqq. In 2013, Prolift +M was reported to have a 2.2% exposure rate and a 6% de novo dyspareunia rate. (Khandwala S. *Female Pelvic Med Recon Surg* 2013;19:84)

rrrr. In 2014, a study of Prolift for anterior prolapse repair with and without mid-urethral slings found that the addition of a mid-urethral sling decreased the incidence of OAB symptoms from 23.3% with Prolift alone to 10.5% when a sling was added. (Futyma et al. *Ginekol Pol* 2014;85:652)

ssss. In 2014, an erosion rate for the Prolift mesh kit was reported to be 5.6%. (Khan et al. *ActaGynOb* 2014;290:1151)

tttt. In 2015, a study of Prolift post-operative voiding difficulties and complications found that 31.25% of patients demonstrated this problem. (Zhang et al. *Menopause* 2015;22:885)

uuuu. In 2015, a randomized trial of native tissue repair compared to Prolift kit repair revealed that complications were significantly higher in the mesh group. (da Silveira et al. *IUJ* 2015;26:335)

10. Gynecare Gynemesh basic science articles:

- a. In 2010, Svabik performed ultrasound evaluations of implanted mesh to determine shrinkage in length of the Gynecare Gynemesh. A 16 to 20% rate of decreasing length by shrinkage was found after 3-4 months. (K Svabik et al. *Ceska Gynekol* 2010;75:123-5)
- b. In 2006, Krause studied the biocompatibility of Gynecare Gynemesh in rats along with four other meshes. The results with all type I mesh types were the same. (HG Krause et al. *Aust N Z J Obstet Gynec* 2006;46:42-5)
- c. In 2013, Liang et al studied vaginal degeneration in primates with meshes of increased stiffness using Gynecare Gynemesh PS compared to two other lower stiffness meshes. The stiffer Gynecare Gynemesh PS had the greatest negative impact on vaginal histomorphology and composition. This mesh caused a substantial thinning of the vaginal smooth muscle layer, increased apoptosis in the area of the mesh fibers, decreased collagen and elastin content and increased collagenase activity. Glycosamineglycan, a marker of tissue injury, was highest with Gynecare Gynemesh PS. This mesh induced a maladaptive modeling response consistent with vaginal degeration. (Liang et al. *BJOG* 2013;120:233-43)
- d. In 2013, Feola et al. studied deterioration in biomechanical properties of the vagina after implantation of a high-stiffness mesh in the form of Gynecare Gynemesh PS compared to

two lower stiffness meshes. The greatest reduction in vaginal contractility occurred with Gynecare Gynemesh PS at 80% reduction and the tissue contribution to the passive mechanical behavior of the mesh-vaginal complex was drastically reduced for Gynecare Gynemesh PS. (A Feola et al. BJOG 2013;120:224-32)

- e. In 2013, Feola et al reported on the structural properties of synthetic meshes. Gynecare Gynemesh PS was compared to four other meshes. Porosity decreased by 21% for Gynecare Gynemesh PS while Poliform decreased by 28%. These two meshes were 60% and 42% stiffer respectively, than two other meshes. (Int Urogynecol J 2013;24:559-64)
- f. In 2013, Edwards found that newer fabricated meshes were uniaxially less stiff than Gynecare Gynemesh PS. (SL Edwards et al. J Mech Behav Biomed Mater 2013;23:53-61)
- g. In 2014, at the joint AUGS/IUGA meeting, Moalli in a workshop handout states that Gynemesh PS, a heavier weight, lower porosity, stiffer mesh, causes a 60% decreased in thickness of the vaginal muscularis, a 170% increase in apoptotic cells, and decreased collagen in the grafted vagina. The stress shielded vagina “then undergoes maladaptive remodeling characterized by degeneration and atrophy (loss of collagen, elastin and muscle)”. “Prosthetic devices that are significantly stiffer than the native tissue they are designed to augment are associated with increased rate of long term complications”. (aug-s-iuga2014.org/d/do/3031)
- h. In 2014, in a study of Prolift pore changes under load, it was shown that there was a complete loss of porosity. (Otto et al. J Biomed Mater Res Part A2014;102A:1079)
- i. Ethicon was aware that the Prolene Soft mesh had significantly different pore sizes down to 0.29mm. (ETH-83788)
- j. In 2008, Ethicon said that the pore size was 2.1mm. (ETH.MESH.02212838)
- k. In a discussion of the final 6 month TVM safety data, Ethicon comments that it is a great surprise that we have miraculously managed to reduce the failure rate from 15.2% to 12%. This information was to be presented in 2 weeks at an international meeting. (ETH.MESH.02095523)
- l. In 2004, in a discussion of a clinical expert report that indicated that the product is to be used to “obtain an in-vivo assessment of system performance” and to confirm “that evaluations made in cadaveric specimens reflect actual use”. It appeared that Ethicon was entering into a clinical investigation and not a post-market study. (ETH.MESH.02280771-72)
- m. In a clinical expert report on Gynemesh, Ethicon acknowledges that the mesh is passed through a contaminated field and infection is a theoretical risk and in a series of patients no erosion was described. It was also deemed to be safe and efficacious based on the large scale use of predicate devices. (ETH.MESH.01154031)
- n. In a discussion of lessons learned from the Prolift experience in 2008, needle passages seemed to be the best for Prolift, but Ethicon is sure that the next generation products will

get rid of these needle passages and the fear of major bleeding and nerve injuries. Two common injuries remain: exposure and shrinkage. (ETH.MESH.01218423-24)

- o. In 2004, Dr. Cosson relates that he has seen tissue tearing many times and the mesh already shrinking at the end of the procedure. (ETH.MESH.00900574-75)
- p. In 2006, Ethicon was aware that since there are irregular pore geometries and pore sizes, it is not accurate to report a distinct pore size. (P1565.ETH-83454-55)
- q. In an Ethicon document entitled “When the implant worries the body”, Ethicon states that “no mesh is the best mesh”. (ETH.MESH.02587926)
- r. In a discussion of Gynemesh and mesh strategy, it is suggested that the animal studies be bypassed and go direct to patient implantations. (ETH.MESH.03160750)
- s. In a mesh discussion, Ethicon states that fibrosis is more pronounced in meshes with small pores forming scar plates rather than scar nets in meshes with large pores. (ETH.MESH.00152985-013)
- t. In October of 2008, Ethicon stated that polypropylene is the best of a bad lot re integration and retraction. Need to develop grafts that mimic human tissue mechanical properties. Ethicon still overlooks the fact that with fibrosis and scar plate formation the end result of the graft cannot be predicted. (ETH.MESH.00271215)
- u. In 2015, Badylak, states “...the vagina undergoes a maladaptive remodeling response following Gynemesh PS implantation...”. (Host Response to Biomaterials, Stephen F. Badylak, Editor, 2015, Academic Press, ISBN 9780128001967)
- v. In 2015, Liang et al reported on the effect of mesh on the metabolism of vaginal extracellular matrix in primates. Gynecare Gynemesh PS was found to have a degradative impact on the metabolism of both collagen and elastin which exceeded the synthesis of these compounds. (R Liang et al. Am J Obstet Gynec 2015;212:174.e1-7)
- w. In 2015, Jallah et al reported that mesh stiffness of Gynecare Gynemesh PS was a significant predictor of the negative affect on muscle function and nerve density in primates. (Z Jallah et al. BJOG 2015;Aug 20)
- x. In an undated abstract, Jallah et al of the University of Pittsburgh, Magee Women’s Hospital, state referring to Gynemesh PS implantation “...that mesh implantation increased smooth muscle cell apoptosis, and decreased smooth muscle thickness, function, and innervation in the underlying grafted tissue, all of which could contribute to the high complication rates reported”.
(<https://imgsvr.eventrebels.com/ERImg/00/91/88/2338073/27532-2-10311.pdf>)

11. Gynecare Gynemesh PS specific documents from Ethicon:

- a. When discussing a new mesh design for Gynemesh in August of 1998, Ethicon states “At this time it was recognized that PROLENE is far from being the ideal material for...” repair of anterior prolapse. Ms. Angelini stated without evidence that the product “was

better than the alternatives available for patients” and “absolutely the right thing to do”. (ETH.MESH.12009028-35, Angelini Deposition 6-19-15 p. 32)

- b. In this same document, Ethicon states that the Gynecare division should launch this product for the following reasons: to increase awareness of mesh for prolapse repair, gain entry into this market before competitors, seek out key surgeons and product champions and to allow time to do market research into what the ideal product for this indication might be. There is no indication that the patient might benefit from this new product. (ETH.MESH.12009028-35)
- c. In this same document Ethicon states that “In this case absorption is not an issue, as the mesh would be permanent.” Due diligence was not done to reveal that polypropylene degrades in the body and is not permanent. (ETH.MESH.12009028-35)
- d. Ethicon also recognizes the “potentially highly infectious site of implantation (the vagina).” Ethicon did not warn physicians of this fact. (ETH.MESH.12009028-35)
- e. In this same document Ethicon discusses the disadvantages of native tissue prolapse repair: vaginal narrowing, compromising sexual function, incomplete relief of symptoms, and the emergence of new symptoms not there before implantation, such as, incontinence, incomplete fecal emptying. Ethicon had not studied this device to recognize that these same symptoms and many more would occur after Gynecare Gynemesh implantation. (ETH.MESH. 12009028-35)
- f. In an email chain between various Ethicon employees regarding replacing Gynemesh PS with Ultrapro mesh with Mr. Kammerer stating that “...if we substitute UltraPro we would like to say it produces, either less scar, a softer scar, less scar contraction or the potential for less contraction based on the collagen deposition of the myofibroblast.” This would indicate that Ethicon was not pleased with the scar formation or its contracture in patients. (ETH.MESH.03915567-72)
- g. In a Next Generation Mesh Discussion document, it is assumed that MINT will use GYNEMESH PS (even though UltraPro is available) but a technical assessment of UltraPro compared to GYNEMESH PS would be completed for competitive reasons to decide if UltraPro should be considered for Pelvic Floor, while continuing basic science research to define requirements for the next generation mesh. Ethicon is looking for a better mesh than Gynemesh PS. (ETH.MESH.05246527-28)
- h. In an email discussion it is asked “Have any ideas on gynemesh erosion where only jagged edges are sticking out...I see 4 ‘whiskers’ only but it’s a painful French tickler for the patient’s husband.” Ethicon is noting that this is a problem with Gynemesh. (ETH.MESH.03738826-27)
- i. In an email discussion of a conversation with Prof. Jacquetin, it is related that this prominent French physician gave his opinion that Ethicon should focus on reducing the stiffness of the area after incorporation of the material and the shrinking effect in the search for the ideal material. He felt that the mesh was too stiff. (ETH.MESH.02770857-58)

- j. Prof. Jacquetin went on to say “do not repeat the same mistake that you have done with TVT, once launched you have been closed to innovation until you were forced into it”. He wanted Ethicon to look immediately into what can be improved. (ETH.MESH.02770857-58).
- k. In a 91 day study of tissue reaction in the subcutaneous tissue of rats, the following statement was generated and placed in the Prolift IFU according to Dr. Charlotte Owens, World Wide Medical Director for Ethicon who signed off on the safety and efficacy of Prolift before marketing: “Animal studies show that implantation of Gynecare Gynemesh PS mesh elicits a minimum to slight inflammatory reaction, which is transient and is followed by deposition of a thin, fibrous layer of tissue which can grow through the interstices of the mesh, thus incorporating the mesh into adjacent tissue. The mesh remains soft and pliable, and normal wound healing is not noticeably impaired. The material is not absorbed, nor is it subject to degradation or weakening by the action of tissue enzymes”. The mesh was not placed in the vagina of a living human to generate this information, only the subcutaneous tissue of rats. The duration of this study (91 days) would be insufficient to determine the presence or absence of the mesh being absorbed, i.e., mesh degradation. (ETH.MESH.02341454-65, Barbold deposition 10-10-12, pages 297-8).
- l. In this same study there was evidence of fibrotic bridging which could lead to scar plate formation. Ethicon did not take this into consideration and did not know in which patients this might occur. (Barbold deposition 10-10-12, pages 493-4)
- m. Dr. Hinoul World Wide Medical Affairs Director for Ethicon in his sworn testimony indicated that physicians could rely on this information. (ETH.MESH.02341454-65, Barbold deposition 10-10-12, page 306).
- n. In an Ethicon discussion of constructing a Gynemesh Vypro combination product for use in pelvic floor repair, it is stated that there is “Positive anecdotal clinical evidence of safety and efficacy of Vypro for repair of vaginal wall prolapse in Europe.” It also restates the Ethicon position that Prolene Soft Mesh is “too stiff for use in vaginal tissues”. (Project Gynemesh Vypro PD 00/3, ETH.MESH.00959923, T-3743)
- o. In this discussion Option 1 is to pursue pelvic floor indication for Prolene Soft mesh. Ms. Angelini agrees that this was a hernia mesh. (Project Gynemesh Vypro PD 00/3, ETH.MESH.00959923, T-3743, Angelini deposition 6-19-15 page 142-143)
- p. In the Hellhammer deposition, she recalled that the Gynemesh Vypro Project was trying to “create a mesh with larger pores to prevent bridging fibrosis and complications in the pelvic area.” This indicates that Ethicon was aware of this issue. (Hellhammer deposition 9-12-13, p. 430)
- q. In this deposition she further indicates that UltraPro is lighter than Gynemesh PS with larger pores of 3-5mm compared to Gynemesh’s 0.3 to 2.4mm. (Hellhammer deposition 9-12-13, p. 571)
- r. She indicates that the learnings from hernia repair proves that UltraPro causes less inflammation than traditional meshes, induce less fibrosis, generate less foreign body reaction, better integrated to host tissues, provokes less pain, improves quality of life with

outstanding biocompatibility. She believed all these statements. Ethicon had no evidence that UltraPro would behave as indicated above when implanted into the vagina. (Hellhammer deposition 9-12-13, p. 573-4)

- s. She also discusses a Gynemesh PS mesh that was implanted in a cadaver where the mesh arms were rolling and appeared to be crumbling. Ethicon did not incorporate these findings into its product development. (Hellhammer deposition 9-12-13, p. 574-5)
- t. She further discusses the over-engineering of meshes for hernia repair and that it was a problem due to the fact that the meshes were too rigid and not as elastic as the tissue into which it was implanted. This rigidity would lead to complications. This same mesh was then used in pelvic floor repair. (Hellhammer deposition 9-12-13, p. 577-8)
- u. In an email chain between Ethicon employees in November of 2006, Ethicon states that “UltraPro could be a solution for this problem” of mesh shrinkage. Shrinkage is stated to be a problem with Prolift mesh which “can be more severe than erosion”. (ETH.MESH.03915790-92)
- v. In this same email chain Ethicon states that it was a bit “frightened to see that we are currently building a full business story on that, not having yet validated the proof of concept, neither from animal experiments nor from clinical use”. Ethicon indicates that it has no information in any form from implantations of UltraPro. (ETH.MESH.03915790-92)
- w. Find option 1 pursue pelvic floor indication for Prolene Soft Mesh which is a hernia mesh
- x. Ethicon further states that the UltraPro could be introduced on the market “since the concept of light mesh is appealing on a surgical standpoint”. Ethicon would introduce to the market with only intuitive data. (ETH.MESH.03915790-92)
- y. Ethicon goes on to say that a comparative study would not be the best option as it would be expensive, long and risky. Ethicon is willing to put on the market without regard for human safety, and would avoid a study due the risk of adverse outcomes from the study for the product. (ETH.MESH.03915790-92)

12. Many patients had implants of Gynemesh since the early 2000’s. The following from ‘a’ to ‘o’ are from the FDA’s MAUDE database covering the years 2005 to 2008 and represent the numbers of patients with these serious adverse events which was or should have been known to Ethicon (Accessed November 2015):

- a. Vesicovaginal Fistula-1
- b. Rectovaginal fistula-1
- c. Ureteral obstruction-3
- d. Ureterovaginal fistula-1
- e. Pain-5

- f. Vaginal pressure-1
- g. Vaginal discharge-1
- h. Vaginal stenosis-2
- i. Hematoma or serious bleeding-3
- j. Bleeding-5
- k. Mesh exposures-31
- l. Dyspareunia-7
- m. Scarring-1
- n. Placed in bladder-2
- o. Prolapse recurrence-4

13. In 2010, Chien reported a patient treated for prolapse with transvaginal Gynecare Gynemesh who developed a retroperitoneal abscess, ileosacral arthritis with osteolysis. She experienced left buttock pain extending to the lower limb. (HW Chien. Int Urogynecol J 2010; 21:753-5)

14. Clinical trials were paid for by insurance companies even though the procedure was noted to be experimental by the American College of Obstetricians and Gynecologists. (ACOG Practice Bulletin #79, Pelvic Organ Prolapse, February 2007)

15. Claims:

- a. Long lasting stabilization of fascial structures in vaginal wall prolapse. There is no fascia between either the bladder or the rectum and the vaginal epithelium except in the distal ~1.5 cm of the posterior vaginal wall. (Prolift IFU, 2004, and Prolift IFU after clearance, Weber A. Obstet Gynec 1997;89:311)
- b. Bridging of fascial defect although there is no fascia to bridge. (Prolift IFU, 2004, and IFU after clearance, Weber A. Obstet Gynec 1997;89:311)
- c. Gynemesh mesh is inert (not degradable). Polypropylene degrades in the human body. Prolene mesh was shown to be not inert in 2003 with flaking and fissuring demonstrated by scanning electron microscopy. (Prolene, Gynemesh and Gynemesh PS most mesh IFU's from 1996 through today; Prolift IFU 2004, and Prolift IFU after clearance; Coda A. Hernia 2003;7:29; and confirmed in Yahi Y. Int Urogyn J 2007;18(Suppl 1):S6, Cosson in Volpe 2012-02-29 1029 on Feb 23, 2007)
- d. Not subject to weakening by the action of enzymes. During degradation the mesh is weakened. (Prolene, Gynemesh and Gynemesh PS most mesh IFU's from 1996 through today; Prolift IFU 2004 and Prolift IFU after clearance; and number "c" above, Sternschuss G. J Urol 2012;188:37-32)

- e. Reported to be non-reactive. Polypropylene Gynemesh mesh causes a persistent inflammatory reaction (Gynemesh IFU 2007; Prolift IFU 2004 and Prolift IFU after clearance; Yahi Y. Int Urogyn J 2007;18(Suppl 1): S149)
- f. Mesh doesn't weaken. During degradation the mesh weakens. (Prolift IFU 2004 and Prolift IFU after clearance; Sternschuss G. J Urol 2012;188:27-32; Cosson in Volpe 2012-02-29 1029 on Feb 23, 2007)
- g. Mesh remains soft and pliable. The presence of the mesh and its subsequent degradation demonstrates moderate to severe vaginal retraction. (Prolene, Gynemesh and Gynemesh PS most mesh IFU's from 1996 through today; Prolift IFU 2004 and Prolift IFU after clearance)
- h. Mesh elicits a minimum to slight inflammatory reaction which is transient. The inflammatory reaction is persistent. (Prolene, Gynemesh and Gynemesh PS IFU's from 1996 through today; Prolift IFU 2004 and Prolift IFU after clearance; Yahi Y. Int Urogyn J 2007;18(Suppl 1): S149)
- i. Monofilaments identical to PP suture. (Prolene, Gynemesh and Gynemesh PS IFU's from 1996 through today; Prolift IFU 2004 and Prolift IFU after clearance)
- j. Extruded polypropylene reported to be non-reactive. In 1986 Jongebloed showed prolene suture to be reactive and degraded. (Prolene, Gynemesh and Gynemesh PS IFU's from 1996 through today; Prolift IFU 2004 and Prolift IFU after clearance; Yahi Y. Int Urogyn J 2007;18(Suppl 1): S149; Jongebloed W. DocOphth 1986;64:143)
- k. PP sutures with long established history of safe clinical use. In 1986 Jongebloed showed prolene suture to be reactive and degraded. (Prolift IFU 2004 and Prolift IFU after clearance; Yahi Y. Int Urogyn J 2007;18(Suppl 1): S149; Jongebloed W. DocOphth 1986;64:143)
- l. Mesh with long established history of safe clinical use. See MAUDE data base discussion above (Accessed April 2012)
- m. Bidirectional elasticity allows adaptation to stresses in the body. Once implanted and the deposition of collagen occurs the mesh is no longer pliable. (Prolene, Gynemesh and Gynemesh PS IFU's from 1996 through today; Prolift IFU 2004 and Prolift IFU after clearance; Ethicon study with moderate to severe vaginal retraction)
- n. Retains strength indefinitely in clinical use. During degradation the mesh is weakened. (Prolene, Gynemesh and Gynemesh PS most mesh IFU's from 1996 through today; Prolift IFU 2004 and Prolift IFU after clearance; and number "c" above, Sternschuss G. J Urol 2012;188:27-32)
- o. Mesh affords excellent surgical adaptability. With vaginal retraction caused by scarification the mesh is no longer adaptable. During degradation the mesh is weakened. (Prolene, Gynemesh and Gynemesh PS IFU's from 1996 through today; Prolift IFU 2004 and Prolift IFU after clearance; and number "c" above, Sternschuss G. J Urol 2012;188:27-32)

- p. Not subject to weakening. During degradation the mesh is weakened. (Prolene, Gynemesh and Gynemesh PS IFU's from 1996 through today; Prolift IFU 2004 and Prolift IFU after clearance; and number "c" above, Sternschuss G. J Urol 2012;188:27-32)
- q. No issues of safety or efficacy in US and French studies. Examples of lack of safety and of poor efficacy are found in the Ethicon sponsored study. (20111213110058384, Prolift IFU after FDA clearance)
- r. Fascial tissue in abdomen comparable to that in pelvis. There is no fascia between either the bladder or the rectum and the vaginal epithelium except in the distal ~1.5 cm of the posterior vaginal wall. (Weber A. Obstet Gynec 1997;89:311, 20111213110058384)
- s. Users should be familiar with surgical procedures for POP. Only being familiar with surgery for POP is insufficient to surgically implant Gynemesh safely by the recommended complex procedure (Prolift IFU 2004 and Prolift IFU after clearance; Women's Health Advisory Board Aug 7, 2009)
- t. The various IFU's for Prolene mesh state that margin sutures should be placed. No indication is given as to where they should be placed or how to tension the mesh to take into account anticipated shrinkage with time. (Prolene, Gynemesh and Gynemesh PS IFU's from 1996 through today)
- u. Acceptable surgical practices should be followed in the presence of contaminated wounds. The recommended surgical implantation technique is through the vagina, an organ which can never be sterilized. Ethicon acknowledges that the vagina is a "not clean space" (Prolene, Gynemesh and Gynemesh PS most mesh IFU's from 1996 through today, Prolift IFU, 2004, and Prolift IFU after clearance, Culligan P. Infect Dis Obstet Gynec 2003;11:161, Global Launch Plan Draft)

16. Warnings:

- a. Delayed rectal erosion—none given. (Prolene, Gynemesh and Gynemesh PS most mesh IFU's from 1996 through today; Prolift IFU 2004, and Prolift IFU after clearance)
- b. Abscess—None given. (Prolene, Gynemesh and Gynemesh PS IFU's from 1996 through today; Prolift IFU 2004 and Prolift IFU after clearance)
- c. Delayed visceral erosion-None given. (Prolene, Gynemesh and Gynemesh PS h IFU's from 1996 through today; Prolift IFU 2004 and Prolift IFU after clearance)
- d. Delayed intractable and untreatable pain. None given. (Prolene, Gynemesh and Gynemesh PS IFU's from 1996 through today; Prolift IFU 2004 and Prolift IFU after clearance)
- e. Ethicon chose what information MD's needed to know in the Professional Education slides. (Pareisi Ex.127 – 2005 Professional Education Deck)
- f. Ethicon chose what information patients needed to know. (Prolift Patient Brochure, 12-04-06)

- g. Mesh removal – no mention of the removal technique or the difficulty encountered in such removals. (Prolene, Gynemesh and Gynemesh PS IFU's from 1996 through today; Prolift IFU 2004 and Prolift IFU after clearance)
- h. Ethicon made no changes the Prolift IFU after 2008 FDA Communication. (Robinson 2012-13-14 517, Post Market Surveillance)

17. Training sessions sponsored by Ethicon:

- a. Training on Prolift use is recommended and available. Physicians could then use the Prolift mesh technique without training. The Hilaire Presentation discusses the critical issue of selling to non-POP experts, beyond the low hanging fruit. (Prolift IFU 2004 and Prolift IFU after clearance; Hilaire Presentation July 13, 2006)
- b. Physicians should have experience in management of complications resulting from using surgical mesh. Yet, Ethicon targeted physicians with no experience in the use of mesh. (Prolift IFU after clearance; Jones, 2011-11-16, Plaintiff's Exhibit 59, Mitchell)
- c. Ethicon funded study: states that instrumentation instruments were not provided. Yet, they state that a simple insertion instrument was used. (Prolift IFU after clearance, 20111213110058384)
- d. Ethicon did not teach removal technique which is like learning to fly an airplane without learning how to land it. (2005 and 2007 Professional Education Decks)
- e. MD's could insert Prolift without attending training since it was only recommended. (Prolift IFU 2004 and Prolift IFU after FDA clearance)
- f. Training and performance of pelvic floor surgery by those physicians trained is not verified in any Ethicon documents reviewed.
- g. No follow up information on physician performance with use of Ethicon products is verified in any Ethicon documents reviewed.
- h. Ethicon told attending physicians that Prolift was safe when there were many indications that it was not safe that were known or should have been known to Ethicon. (2007 Professional Education Decks; MAUDE data base accessed April 2012)
- i. Physicians were told that Prolift was reliable with a good success rate in spite of an 18.4% failure rate in the French part of the Ethicon funded Prolift study. Ethicon misled participants by showing the lesser 12% failure rate in the US part of the study. (2005 and 2007 Professional Education Decks; Cosson M. Int Urogyn J 2006;17(Suppl 1):S139)
- j. Ethicon told participants that mesh must be easily implanted implying that Prolift insertion is easy, when, it was known to Ethicon to be very complex. (2005 and 2007 Professional Education Decks, Women's Health Advisory Board Aug 7, 2009)
- k. Ethicon told participants that the mesh must be inert implying that Prolift mesh is inert which Ethicon knew or should have known that it is not inert. (2005 and 2007 Professional Education Decks and see above)

- l. Ethicon told participants that the mesh must not shrink when Ethicon knew or should have known that Prolift had been shown to shrink. (2005 and 2007 Professional Education Decks and see above)
- m. Ethicon told participants that Prolift was a “breakthrough” without any evidence to support this statement. (2005 and 2007 Professional Education Decks)
- n. Ethicon told participants only that fistula has been reported and did not mention the 3 fistulae in its funded Prolift study. (2005 and 2007 Professional Education Decks)
- o. Ethicon implied to participants that data from abdominal hernia repairs is applicable to the vagina by detailing such data. (2005 and 2007 Professional Education Decks)
- p. Ethicon did not teach delayed visceral erosions which was or should have been known by Ethicon to occur. (2005 and 2007 Professional Education Decks, MAUDE data base accessed April 2012)
- q. Ethicon told physicians that patients would have a quick recovery without teaching the long term adverse events which were or should have been known to Ethicon. (2005 and 2007 Professional Education Decks, MAUDE data base accessed April 2012)
- r. Ethicon did not tell attending physicians about the decision in France not to pay for mesh insertion when Prolift was included in this action. (HAS <http://www.has-sante.fr>, 2006)
- s. Ethicon did not teach variable PP reaction from patient to patient. (2005 and 2007 Professional Education Decks)
- t. Ethicon did not teach delayed bowel erosion. (2005 and 2007 Professional Education Decks)
- u. Ethicon did not teach mesh degradation. (2005 and 2007 Professional Education Decks)
- v. Ethicon did not teach mesh oxidation. (2005 and 2007 Professional Education Decks)
- w. Ethicon did not teach mesh shrinkage of up to 40%. (2005 and 2007 Professional Education Decks)
- x. Ethicon did not teach mesh infection except to state that large pores would result in non-potentialiation of infection. (2005 and 2007 Professional Education Decks)
- y. Ethicon did not teach bacterial migration on mesh. (2005 and 2007 Professional Education Decks)
- z. Ethicon did not teach bacterial silent persistence on mesh. (2005 and 2007 Professional Education Decks)
- aa. Ethicon did not teach wicking of fluids and bacteria by mesh. (2005 and 2007 Professional Education Decks)

- bb. Ethicon did not teach regarding interstices as hiding places for bacteria, but only mentioned that >10 micron interstices would result in non-potential of infection. (2005 and 2007 Professional Education Decks)
- cc. Ethicon did not teach regarding toxic byproducts released into the body. (2005 and 2007 Professional Education Decks)
- dd. Ethicon did not teach major colon surgery possible. (2005 and 2007 Professional Education Decks)
- ee. Ethicon did not teach mesh friction and relation to granulation tissue. (2005 and 2007 Professional Education Decks)
- ff. Ethicon did not teach mesh heat and relation to degradation. (2005 and 2007 Professional Education Decks)
- gg. Ethicon did not teach importance of surface area. (2005 and 2007 Professional Education Decks)
- hh. Ethicon did not teach importance of known surface roughness. (2005 and 2007 Professional Education Decks)
- ii. Ethicon taught installation of mesh in clean/contaminated environment. (2005 and 2007 Professional Education Decks)
- jj. Ethicon did not teach non-mesh surgical options. (2005 and 2007 Professional Education Decks)
- kk. Ethicon did not teach should see/or assist in some procedures before becoming competent. (2005 and 2007 Professional Education Decks)
- ll. Ethicon did not teach inflammation present for lifetime of device. (2005 and 2007 Professional Education Decks)
- mm. Ethicon did not teach that resultant dyspareunia may be incurable and prevent intercourse for the lifetime of the patient. (2005 and 2007 Professional Education Decks)
- nn. Ethicon did not teach that the above-mentioned incurable dyspareunia should be considered in sexually active women. (Eth Mesh 02286053)
- oo. Ethicon did not teach that lifetime inflammation may impact device safety. (2005 and 2007 Professional Education Decks)
- pp. Ethicon did not teach vagina with increased rate of infection. (2005 and 2007 Professional Education Decks)
- qq. Ethicon did not teach possible patient selection criteria even though it possessed knowledge regarding high and low responders in February 2007. (2005 and 2007 Professional Education Decks, D'Aversa 2012-02-28 346)

- rr. Ethicon did not tell physicians that polypropylene is the best of a bad lot regarding integration and retraction. (ETH.MESH.00271215)

18. Other Issues:

- a. Ethicon states that Prolift is safe and/or efficacious on Jan 14, 2005, without data to confirm this statement. (Beath 2012-03-27 1059, Hoffman 2012-03-15 541)
- b. Ethicon states that Prolift mesh is inert on Jan 14, 2005, without data to confirm this statement and as stated above there is contradictory data. (Beath 2012-03-27 1059)
- c. Ethicon told FDA that no further studies regarding safety and efficacy were needed because there was only a shape change (rectangular to pre-shaped) to the previously cleared Gynemesh PS plus the addition of kitting and insertion tools. (20111213105816185)
- d. Ethicon told FDA that design validation did not raise other issues of safety and efficacy of either the mesh implant or the inserter tools. (20111213105816185)
- e. Ethicon told FDA that the Prolift mesh is identical in composition to the Gynemesh PS. (20111213105816185)
- f. Ethicon told the FDA that Prolift (Gynemesh) mesh is identical to prolene mesh, yet in its sales force Primary Sales School in 2008 Ethicon stated that Gynemesh PS has 40% less mass than Prolene mesh. (Lisa 2011-12-19-137, Hoffman 2012-13-15 539; Gynecare Gynemesh PS 510k)
- g. Ethicon told FDA substantial equivalence was demonstrated using cadaver modeling and animal lab testing. (20111213110058384)
- h. Ethicon told FDA that there was no clinical investigation of Gynecare Gynemesh PS because testing had been done on the predicates. (Gynecare Gynemesh PS 510k)
- i. Ethicon told FDA that the risks associated with mesh implants are deemed appropriate given the benefit they provide. (20111213110058384)
- j. Ethicon told FDA that comparisons of mesh used for incontinence and that used for pelvic organ prolapse are not appropriate [mesh volume]. (20111213110058384)
- k. Ethicon told FDA that Prolift is designed for skilled surgeons who have great pelvic organ prolapse experience and are familiar with the anatomy of the region. (20111213110058384)
- l. Ethicon told FDA that knowledge and dissection of these spaces are part of a gynecologist's training and, therefore, not complex to a trained gynecologist. (20111213110058384)
- m. Ethicon told the FDA that existing bench testing done for hernia applications is appropriate for a pelvic floor application. (20111213110058384)

- n. Ethicon told FDA that biocompatibility testing in hernia applications represents biocompatibility of mesh in pelvic organ prolapse. (20111213110058384)
- o. Ethicon told FDA that fascial tissue in the abdomen is comparable to that in the pelvis. (20111213110058384)
- p. Ethicon told FDA that the total vaginal mesh evaluation in the US and French studies did not present issues of safety and efficacy. (20111213110058384)
- q. Ethicon told FDA that the Prolift mesh is laser cut whereas the Gynemesh is cut mechanically without indicating that the heat of the laser will enhance degradation of the mesh. (20111213110058384)
- r. The Global Launch Strategy refers to vagina as “not clean space”.
- s. The Global Launch Strategy states that prolapse repair is very complex.
- t. The Hilaire presentation of July 13, 2006 discusses selling to those who are ‘beyond the low hanging fruit’ including non-POP experts and urologists.
- u. The Hilaire presentation of July 13, 2006 states that their mesh materials are proven.
- v. Ethicon told its sales staff that the flexibility of the Gynemesh fibers help prevent vaginal stiffness, that Gynemesh is safe and that Gynemesh is a breakthrough. There is either no evidence for these statements or they are false. (Hoffman 2012 -03-15 539)
- w. Did not tell FDA of French mesh position? There is no evidence of this in the 510k’s for any Prolene product.
- x. Mersilene polyester mesh, the predicate for Prolene Soft and Gynemesh Prolene Soft (K-013718 and K-01310578), is a totally different material. How could it be a predicate? (ETH.MESH.01310586)
- y. No testing as was done as it was done for predicates (K-013718 and K-01310578)-Can such testing on another predicate product really be the same as for a new product?
- z. Ethicon expected its sales representatives to walk physicians through the surgical procedure. Is this Ethicon practicing medicine without a license? (ETH.MESH.00393223-7)
- aa. Ethicon states the Gynemesh PS is inert and that the mesh allows macrophage penetration. Physicians were not told that interstices exist in the mesh where bacteria can hide and be protected from host defenses, such as macrophages. This information was known to Ethicon. Also, they were not told that polypropylene degrades and causes a persistent inflammatory reaction. (ETH.MESH.01611832, Robinson exhibit 495)
- bb. Ethicon admits that the Prolift device was launched without clinical evidence. (ETH.MESH.00081478-9)
- cc. Ethicon marketed the Prolift device in March of 2005, yet the FDA learned of this device in 2007. (Beath Ex. 1052)

- dd. Ethicon states that the complications noted in the FDA PHN of 2008 are “included in the labeling for our products”. (Beath Ex. 1048)
- ee. In a patient brochure, Ethicon states that Prolift is revolutionary providing permanent pelvic support, promising in the long term. The mesh is stated to be a specially designed soft mesh. A minimal list of adverse events is given, omitting important ones, e.g., dyspareunia, and does not list occurrence rates of any of these events. There is no mention of scarring and scar plate formation over time leading to dyspareunia and pain. (Jones Ex. 241; Robinson Ex. 508)
- ff. In a document for Media/Analyst Inquiries, Ethicon states that the Prolift device was marketed after clearance by the FDA in 2005, contrary to what is recorded in dd above. (Lisa Ex.171)
- gg. A study originating in Scotland by Morling et al involved 18614 patients having a single prolapse procedure of which 1648 had implantation of mesh and the remainder comprised native tissue repairs. In comparison to native tissue repairs, those patients receiving mesh had statistically significant higher rates of complications for cystocele and rectocele repairs. The authors state that the use of mesh needs to be carefully considered. (The Lancet, abstract published on line November 13, 2005, p. 56)
- hh. On August 31, 2007, the Pelvic Health Coalition sent a letter to Centers for Medicare and Medicaid Services to make comments and recommendations regarding the proposed 2008 Medicare Fee Schedule. This letter tells the FDA that it is a broad based coalition representing healthcare professionals as well as industry leaders. It further tells the FDA that the “PHC is dedicated to raising awareness of the critical importance of pelvic health and to promote education about pelvic health issues”. Is the PHC a lobbying group, and if so is it registered? (CMS-1385-P15007)
- ii. In September of 2007, a supplement appeared in OBG Management with the title “Best Options, Techniques, and Coding Tips for Pelvic Prolapse Repair” with Barbara Levy, MD, as the program chair. It indicates that this publication was developed under a grant from the Pelvic Health Coalition, but does not acknowledge that the Coalition is funded by Ethicon and other companies and that this publication was organized to advertise mesh for prolapse repairs.
- jj. In an email of January 15, 2009, Ethicon discusses a meeting with the FDA after the Public Health Notification of 2008. The Pelvic Health Coalition (PHC) board members are told that Dr. Levy, co-chair of the PHC, will be present at the meeting and that a call will be held after the meeting. (ETH.MESH.02312097-98)
- kk. In February of 2008, the Pelvic Health Coalition, funded by Ethicon, takes credit for publication of the OBG Management Supplement and implementation by Medicare and Medicaid of new procedure codes. Ethicon states that industry is planning a meeting with the PHC doctors (ETH.MESH.00129134-35)
- ll. An agenda is being planned for February 2008 meeting of PHC members that includes as the first order of business an Antitrust Statement. (ETH.MESH.00129136)

- mm. On February 7, 2007, Dr. Levy, Co-Chair of the PHC, reports to PHC and industry members her contact with ACOG regarding the Practice Bulletin that described the use of mesh as experimental. She was promised that the College would let her know how it plans to respond to her concerns. The email also describes the PHC efforts to get a mesh add on code [so that physicians would be paid more by insurance to use mesh]. (ETH.MESH.02316434-36)
- nn. In July of 2007, an email to PHC members (physicians and industry) discusses the draft of the OBG Management issue and the edits proposed by Gail. (ETH.MESH.00720002-03)
- oo. In an email of August 2007, industry wants to put the OBG Management Supplement on their respective web sites in advance of its publication in September of 2007. (ETH.MESH.01280858-60)
- pp. In an email of August 2007, the mesh manufacturing companies are adding input to the OBG Management Supplement including a visual graphics for products: Commonly Used Mesh Products and Properties. (ETH.MESH.01280816-18)
- qq. In an email in July 2007, the mesh manufacturing companies including Ethicon are stating that “we want to avoid any trigger for the payor to review this academic discussion and justify a non-coverage decision. This is not a systematic review of the evidence nor a clinical guideline so it would be enhanced by some better upfront positioning....” (ETH.MESH.00738769-71)
- rr. In July the Prolapse Repair Coalition was formed by mesh manufacturing companies including Ethicon and physicians to improve prolapse reimbursement for hospitals for pelvic floor procedures which utilize synthetic or autologous products. In addition, “we are requesting new ICD.9 procedure codes for pelvic floor procedures which utilize synthetic or autologous products” to eventually increase reimbursement for these procedures. Note: the end result was that physicians were paid more by insurance payors and the Federal Government to use these products. (ETH.MESH.00136420-22)
- ss. In a document entitled “Prolapse Repair Procedures that Involve a Graft or Prosthetic Implant,” it is stated that the coding system does not have appropriate codes for procedures that are compensatory in nature. New codes were created which would indicate the use of a graft, such as, “70.54 Repair of cystocele with graft or prosthesis.” (ETH.MESH.00738636-38)
- tt. From a Google search, done on August 25, 2013, of the address of the PHC from the letter referenced in #ii above, it is clear that this is the office of the Reed Smith Law firm, attorneys for one of the manufacturing companies. Are they a front for the PHC?

19. It concerns me that Ethicon would deliberately not warn doctors about its knowledge of complications arising from implanting its Prolift, Prolift+M, Prolene, Gynemesh, or Gynemesh PS products. As I doctor, I must make decisions to benefit, and not to harm my patients. I need full and accurate information so that I can make those decisions and so that I can fully discuss benefits and risks with my patients. If I cannot rely on information provided by manufacturers, I cannot obtain full and complete consent from my patients and they could suffer harm as a result.

I consider ETHICON's actions to be an intentional disregard for the safety of my and other doctors' patients.

20. I may be asked to review additional materials and/or documentation as the case progresses and, in that event, I reserve the right to supplement this report.

I declare under penalty of perjury under the Laws of the State of Colorado that the foregoing is true and correct.

This 31st day of January 2016 at Salida, Colorado.


DONALD R. OSTERGARD, M.D., Declarant

DATA AND FACTS CONSIDERED

Attached as Exhibit B

COMPENSATION SCHEDULE

Attached as Exhibit C

LIST OF PREVIOUS TESTIMONY FOR LAST FOUR YEARS

Attached as Exhibit D

Exhibit A

DONALD R. OSTERGARD, M.D.

Place of Birth:	Los Angeles, California	
Marital Status:	Widowed	
EDUCATION:	1956-1959	Undergraduate(Chemistry) University of California (Los Angeles)
	1959-1963	Medical University of California (San Francisco)
	1960	B.S. Medical Sciences
	1963	M.A. Anatomy
	1963	M.D.
	1963-1964	Rotating Internship Los Angeles County Harbor General Hospital
	1964-1968	Residency in Obstetrics and Gynecology Los Angeles County Harbor General Hospital

ACCOMPLISHMENTS:

During his gynecological and urogynecological career, Dr. Ostergard has been the first to accomplish the following: Found the American Urogynecological Society with 4 others; found the *International Urogynecology Journal*; participate in the founding of the International Urogynecological Association; establish a urogynecological fellowship training program; publish textbooks in urogynecology and urodynamic tracings; offer postgraduate preceptorships in urogynecology; publish the concept of latent incontinence coexisting with prolapse; publish the clinical significance of the pressure urethra; North American to publish on the use of microtransducer catheters for the study of the surgical treatment of stress incontinence; North American to publish on the use of microtransducers to study detrusor overactivity; publish on multifocal carcinoma of the female genitalia and also on the pathophysiological changes of cryosurgery on the uterine cervix; publish the clinical effects of cryosurgery for benign disease of the uterine cervix; publish the clinical effects of cryosurgery for genital warts; establish and publish a clinical training program in women's health for nurses and midwives as nurse practitioners; establish a clinical training program in women's health for physician assistants; and publish a textbook for training nurse practitioners and physician assistants in women's health.

Military Service:	1964-1970	California Army National Guard
Research Fellowship:	1966-1967	USPHS Research Fellowship in Reproductive Biology (8 months)

DONALD R. OSTERGARD, M.D.

Honors:	1963	Alpha Omega Alpha Honor
	1964	Intern of the year, First Honorable Mention
		Recipient of 1972 Essay Award, Los Angeles OB/GYN Society
		Session Chairman, International Congress of Cryosurgery, Vienna, Austria, June, 1972
	1988	Session Chairman, FIGO International Congress Rio de Janeiro, Brazil
	1988	Listed in Best Doctors in America, <u>Good House-</u> <u>keeping Magazine</u>
	1992	President, Scientific Session, Invited Lectures, III Congreso Nacional de Urologia Gynecologica, Guadalajara, Jalisco, Mexico
	1992	Urogynecologic Society Prize Paper, Rejection of Suburethral Gore-tex Sling, Bent AE, Ostergard DR
	1992	American Uro-gynecological Society Meeting Moderator, Scientific Section - Cambridge, Massachusetts, August 27-30, 1992
	1993	Honorary President, Transcongress Course: Diagnostic Methods in Urogynecology - National Mexican Congress of Urogynecology
	1993	Scientific Session Chairman, 18th Annual Meeting of International Urogynecological Association, Nimes, France
	1993	Don Ostergard Gynecologic Society Established by Post-Urogynecology Fellows
	1994	Invited Professor to lecture to the 5th Congress Nacional de Uro- logia Ginecologica, Morelia, Michoacan, Mexico, May 1994

1994	Moderator, Scientific Session, International Urogynecological Association, "Behavioral Therapy," Toronto, Ontario, Canada
1994	Moderator, Scientific Sessions, The American Urogynecologic Society, September 21, 1994, Toronto, Ontario, Canada
1994	Invited Speaker, Scientific Session, International Urogynecological Association, "Education Standards in Urogynecology", Toronto, Ontario, Canada.
1994	Invited Speaker, Harbor-UCLA Women's Health Care Programs 25 th Anniversary Harbor-UCLA Medical Center, Torrance
1995	Invited professor to 6th Congress Nacional De Urologia Ginecologica, Monterrey, Nuevo Leon, Mexico
1995	Munzer Family Award for excellence in education
1995	Life Fellowship in Los Angeles Co Obstetrics/Gynecology Society.
1996	Chairman of Scientific Session & Moderator or Symposium, International Urogynecological Association 21 st Annual Meeting, Vienna, Sept 1996.
1996	Moderator, Scientific Session American Urogynecologic Society, 17th Annual Scientific Meeting, New Orleans, LA, October 1996.
1996	Listed in "Physicians, Rate Themselves," compiled for The Best Doctors in America: Pacific Region 1996-1997, Los Angeles magazine
1997	Listed in "Best Doctors for Women", Good Housekeeping Magazine August
1999	Visiting professor, Sloane Academic Assembly, New York, NY - June
2000	Honorary President, XI National Congress of Urogynecology, Mexican Urogynecology Society, Cancun, Mexico
2003	Member Medical Advisory Board, InfoMed Fax Newsletter - Eli Lilly

	2005	Nominee for Excellence in Health Care Award - ABC7 television
	2008	Invited state of the art lecture at the International Continence Society annual meeting in Cairo, Egypt regarding new mesh procedures.
	2007	Received Life Time Achievement Award from the International Urogynecology Association
	2011	Received the Jack Robertson Life Time Achievement Award from the American Urogynecologic Society
BOARD CERTIFICATION:	1970	American Board of Obstetrics and Gynecology
APPOINTMENTS:		
Faculty	1968-1974	Assistant Professor, Department of Obstetrics and Gynecology UCLA School of Medicine
Faculty	1974-1979	Associate Professor, Department of Obstetrics and Gynecology UCLA School of Medicine
Faculty	1979-2011	Professor, Professor Emeritus of Obstetrics and Gynecology, University of California, Irvine
Faculty	2011-2013	Clinical Professor of Obstetrics, Gynecology and Women's Health, University of Louisville, School of Medicine, Louisville, KY
Harbor General Hospital/ UCLA Medical Center	1969-1979	Director, Abnormal Cytology Program
	1969-1976	Director, domestic and Latin American Women's Health Care Specialist Training Programs for Nurses and Paramedical Personnel and International Consultation
	1976-1979	Chief of Gynecology and Gynecologic Urology
	1977-1979	Director, Fellowship Training Programs in Urogynecology
	2013-present	Attending Physician
Women's Hospital		

Long Beach Memorial Medical Center	1979-2006	Associate Medical Director for Gynecology
	1979-2011	Director, Urogynecology Fellowship Training Program
	2006-2011	Director, Gynecologic Education
University of California, Irvine College of Medicine	1979-2006	Director, Fellowship Training Program in Urogynecology, Pelvic and Laser Surgery
University of Louisville, School of Medicine	2011-2013	Female Pelvic Medicine and Reconstructive Surgery Faculty
	1969-1974	Member: Executive Committee and Board of Directors, Acting Chairman and Chairman of Board of Directors (1971-1974), Los Angeles Regional Family Planning Council, Inc.
	1970-2006	Medical Director, Long Beach Family Planning Clinic
	1971-1974	Member: Task Force on Family Planning Services, American Public Health Association
	1977-1978	Member: Board of Directors, Los Angeles Coastal Cities Unit, American Cancer Society
	1978-1979	Member: Board of Directors, Area 23 PSRO
	1983-1993	Medical Director, Memorial Women's Medical Group
	1994	International Scientific Committee Member, CIREF Founda- tion (Center for Incontinence and Pelvic Rehabilitation) Buenos Aires, Argentina
Consultant Positions:	1969-1975	Consultant to various groups for Family Planning, Nurse Practitioners and Physician Assistant Training, Domestic and Latin American Consultant to NIH and USPHS for Cancer Control and other aspects of health.
	1973-1975	Consultant to the American Public Health Association and U.S. Agency for International Development in

the following countries: Guatemala, Honduras, Nicaragua, El Salvador, Costa Rica, Panama, Mexico, Pakistan, Turkey, Cameroon, and Thailand.

Sabbatical Leave: 1976-1977 For the study of Gynecologic Urology.

Journals:

Reviewer Journal of Clinical Chemistry
American Journal of Obstetrics
Obstetrics and Gynecology.

Editorial Board Urogyneacologia
Journal of Gynecologic Surgery

Editor In Chief International Urogynecology
Journal (Honorary 2002)

Consultant The Medical Letter

Member Editorial Review Board Annals in Obstetrics and
Gynecology

Advisory Board International Correspondence Society
of Obstetricians & Gynecologists

Corresponding Editor Urogin (Mexico)

Societies:

Life Fellowship Los Angeles Obstetrical and
Gynecological Society

Fellow Long Beach Obstetrical and
Gynecological Society

Fellow American College of Obstetricians
and Gynecologists

Member 1972-1993 American Society for Colposcopy
and Colpomicroscopy

Member International Continence Society

Member The Urodynamics Society

Member International Urogynecologic
Association
President 1985-1988

Founding Member American Uro-Gynecologic Society
Secretary-Treasure 1979-1982
Vice-President 1982-1983
President 1984-1985
Member 1979-Present
Urogynecology Fellowship

Directors Committee
Chairman 1992-1998
Member, Board of Directors
1996-1998

Founding Member	The Urogynecology and Pelvic Floor Research Society, 1994
Honorary Member	Orange County Obstetrical and Gynecological Society
Honorary Member	Pacific Northwest Obstetrical and Gynecological Society
Honorary Member	Costa Rican Urological Society
Honorary Member	Mexican Urogynecology Society
Honorary Member	Argentine Federation of Obstetrics and Gynecology Societies (FASGO)
1964-1977	American Fertility Society
1968-1978	Pacific Coast Fertility Society
1970-1977	International Family Planning Research Association, Inc., 1974-1976
1971-1973	American Public Health Association
1968-1973	Society for Cryobiology
1967-1973	Society for Contemporary Medicine and Surgery
1970-1977	American Association of Planned Parenthood Physicians
1974-1975	Member of Executive Committee and Western Regional Representative
1975-1977	Pan American Medical Association

SCIENTIFIC EXHIBITS:

1. "Cryosurgery of the Uterine Cervix", Duane E. Townsend, M.D., and Donald R. Ostergard, M.D., as presented to ten national and local medical meetings during 1967 to 1973. First Prize and Honorable Mention at two of these meetings.
2. "International Women's Health Care Specialist Training Program", John R. Marshall, M.D., Donald R. Ostergard, M.D., John E. Gunning, M.D., et al, as presented to three national and local medical meetings during 1974-1975.
3. "Urodynamics in Gynecology", Donald R. Ostergard, M.D., David B. Herbert, M.D., Narendra N. Bhatia, M.D., et al, as presented to American College of Obstetricians and Gynecologists Meeting, 29th Annual Clinical Meeting, April 27-30, 1981.

PUBLICATIONS

BOOKS:

1. Ostergard DR, Editor: Gynecologic Urology and Urodynamics: Theory and Practice. Williams and Wilkins, Baltimore, 1980.
2. Ostergard DR, Editor: Gynecologic Urology and Urodynamics: Theory and Practice, Second Edition. Williams and Wilkins, Baltimore, 1985.
3. Ostergard DR and Bent AE, Editors: Urogynecology and Urodynamics: Theory and Practice, Third Edition. Williams and Wilkins, Baltimore, 1991.
4. Sand, PK, Ostergard, DR: Urodynamics and the Evaluation of Female Incontinence: A Practical Guide, Springer-Verlag, London, 1995.
5. Ostergard, DR and Bent, AE, Editors: Urogynecology and Urodynamics: Theory and Practice, Fourth Edition, Williams and Wilkins, Baltimore, 1996.
6. Ostergard, DR, Berman, ML, Yee, B: Atlas of Gynecologic Surgery, W.B. Saunders, New York, NY, 2000.

Ostergard, DR, Berman, ML, Yee, B: Atlante di Chirurgia Ginecologica. CIC Edizioni Internazionali (edizione italiana di G.Scarselli), Roma, 2000.
7. Bent AE, Ostergard DR, Cundiff J, Swift SE, eds: Urogynecology and Pelvic Floor Dysfunction, Fifth Edition, Lippincott Williams & Wilkins, Philadelphia, PA, 2003.
8. Bent AE, Ostergard DR, Cundiff J, Swift SE, eds: Uroginecología y Disfunción del Piso Pélvico, Quinta edición, McGrall-Hill Interamericana, Mexico, 2004.

BOOK CHAPTERS, PEER REVIEWED:

1. Townsend, DE, Ostergard, DR, and Hirose, F: "The Effect of Cryosurgery on the Cervix Uteri, "in Rand, RW, et al (eds) S Natelson, A Scommegna, Charles C. Thomas, Publisher, 1968, pp 327-333.
2. Townsend, DE, Ostergard, DR, Hirose, FM: Cryosurgery for Gynecologic Disease, The Surgery Annual, P Cooper (ed) New York, Appleton, Century and Crofts, 1969.
3. Ostergard, DR: The Physiology and Clinical Importance of Amniotic Fluid, in Amniotic Fluid, John Wiley & Sons, Publisher, (ed) S Natelson, A Scommegna, MB Epstein, New York, 1974.
4. Ostergard, DR: Carcinoma of the Uterine Cervix. Clinical Invasive Carcinoma: Clinical Features, Staging, Diagnosis and Pretreatment Evaluation. In: Gynecologic Oncology, Malcolm Coppleson, (ed) Churchill Livingstone, London, 1980.
5. Ostergard, DR: Anatomy and Embryology of the Lower Urinary Tract. In: Gynecologic Urology and Urodynamics: Theory and Practice, Williams and Wilkins, Baltimore, 1980.
6. Ostergard, DR: The Neurology of Micturition and Integral Voiding Reflexes. In: Gynecologic Urology and Urodynamics: Theory and Practice, Williams and Wilkins, Baltimore 1980.

7. Ostergard, DR, Hodgkinson, CP: Selection of Patients for Incontinence Surgery. In: Gynecologic Urology and Urodynamics: Theory and Practice, Williams and Wilkins, Baltimore, 1980.
8. Ostergard, DR: The Urethral Syndrome. In: Gynecologic Urology and urodynamics: Theory and Practice, Williams and Wilkins, Baltimore, 1980.
9. Ostergard, DR: Pharmacology and the Effect of Drugs on the Lower Urinary Tract. In: Gynecologic Urology and Urodynamics: Theory and Practice, Williams and Wilkins, Baltimore, 1980.
10. Ostergard, DR, Hodgkinson, CP: Retropubic Procedures for the Surgical Repair of Genuine Stress Incontinence. In: Gynecologic Urology and Urodynamics: Theory and Practice, Williams and Wilkins, Baltimore, 1980.
11. Ostergard, DR, Hodgkinson, CP: Incontinence Surgery After Previous Operative Failures. In: Gynecologic Urology and Urodynamics: Theory and Practice, Williams and Wilkins, Baltimore, 1980.
12. McCarthy, TA, Ostergard, DR: Office Urethroscopy. In: Gynecologic and Obstetric Urology, 2nd Edition, Herbert J Buchsbaum, (ed) WB Saunders, Philadelphia, 1982.
13. Bhatia, NN, McCarthy, TA, Ostergard DR: Urethral Diverticula: Urethral Closure Pressure Profiles, a Preliminary Report. In: Female Incontinence, NR Zinner, and A Sterling, eds, 1982. Progress in Clinical and Biological Research, Vol 78.
14. Bent, AE, Ostergard, DR: Urinary Incontinence. Current Therapy in Obstetrics and Gynecology 2, Quilligan, EJ, Editor, Saunders, 1983.
15. Ostergard, DR: Pharmacology: Theory. In: Clinical Gynecological Urology, Stuart L Stanton, ed CV Mosby Co, St Louis, pp 29-34, 1984.
16. Bhatia, NN, Ostergard, DR: Use of Ultrasound in Management of Stress Incontinence. Clin of Diag Ultrasound. Gynecologic Ultrasonography Edition: Chapter 6, pp 73-83, 1984.
17. Scotti, RJ and Ostergard, DR: The Urethral Syndrome, Clin Obstet Gynec 27:515-539 (Jun) 1984.
18. Bowen, LW, Sand, PK, Ostergard, DR: Interstitial Cystitis. Gynecologic Urology and Urodynamics: Theory and Practice. Ostergard, DR (editor).
19. Sand, PK, Bowen, LW, Ostergard, DR: Lower Urinary Tract Abnormalities in the Adolescent. Gynecologic Urology and Urodynamics: Theory and Practice. Ostergard, DR (editor). Williams and Wilkins, 1985.
20. Sand, PK, Bowen, LW, Ostergard, DR: The Urinary Tract in Pregnancy, in Gynecology Urology and Urodynamics: Theory and Practice. Ostergard, DR (editor). Williams and Wilkins, 1985.
21. Ostergard, DR: Embryology and Anatomy of the Female Bladder and Urethra. Gynecologic Urology and Urodynamics: Theory and Practice. Williams and Wilkens, 1985.
22. Ostergard, DR: Neurological Control of Micturition and Integral Voiding Reflexes. Gynecologic Urology and Urodynamics: Theory and Practice. Williams and Wilkins, 1985.

23. Scotti, RJ and Ostergard, DR: Practical Guide for Triage of Patients with Lower Urinary Tract Symptoms. Gynecologic Urology and Urodynamics: Theory and Practice. Williams and Wilkins, 1985.
24. Ostergard, DR, Hodgkinson, CP: Preoperative Evaluation of Patients for Incontinent Surgery. Gynecologic Urology and Urodynamics: Theory and Practice. Williams and Wilkins, 1985.
25. Scotti, RJ and Ostergard DR: Urethral Syndrome. Gynecologic Urology and Urodynamics: Theory and Practice. Williams and Wilkins, 1985.
26. Ostergard, DR: Effect of Drugs on Lower Urinary Tract. Gynecologic Urology and Urodynamics: Theory and Practice. Williams and Wilkins, 1985.
27. Richardson, DA and Ostergard, DR: Anterior Vaginal Repair versus Retro-pubic Urethropexy: A Review of the Literature. Gynecologic Urology and Urodynamics: Theory and Practice. Williams and Wilkins, 1985.
28. Ostergard, DR and Hodgkinson, CP: Retropubic Procedures for Surgical Repair of Genuine Stress Incontinence - Sling Operations. Gynecologic Urology and Urodynamics: Theory and Practice. Williams and Wilkins, 1985.
29. Ostergard, DR and Hodgkinson, CP: Incontinence Surgery Subsequent to Operative Failures. Gynecologic Urology and Urodynamics: Theory and Practice. Williams and Wilkins, 1985.
30. Cutner, LP and Ostergard, DR: Modified Pereyra Procedure: Vaginal Approach to Retropubic Urethropexy. Gynecologic Urology and Urodynamics: Theory and Practice. Williams and Wilkins, 1985.
31. Ostergard, DR: Preoperative Workup for Urinary Incontinence. Gynecology and Obstetrics. Edited by H. Ludwig and K. Thomsen. Springer - Verlag Berlin Heidelberg, 1986.
32. Ostergard, DR and Bent, AE: Urethrocystoscopy. Gynecologic Endoscopy: Pelviscopic Surgery and Laser Laparoscopy. Edited by Dr. Joseph Sanfilippo and Dr. Ronald Levine, 1989.
33. Ostergard, DR and Bent, AE: Urogynecology, Danforth's Obstetrics and Gynecology, Sixth Edition, J.B. Lippincott Company, Philadelphia, 1990.
34. Farrell, SA and Ostergard, DR: Choice of Surgical Procedure for Stress Incontinence. In: Benson JT, ed. Female Pelvic Floor Disorders: Investigations and Management. New York: Norton, 1992.
35. Swift, SE, and Ostergard, DR: "Cryosurgery", in Ambulatory Gynecology, ed. Nichols, DH, Sweeny PJ. J.B. Lippincott, Philadelphia PA, 1992.
36. Montella, JM, Ostergard, DR: Office Urethroscopy, in Gynecologic and Obstetric Urology, Third Edition, WB Saunders CO., 1993.
37. Swift, SE, Ostergard, DR: "Evolution of Procedures for Stress Urinary Incontinence", Gynecologic Surgery, ed. Sanz, LE, Blackwell Scientific, Cambridge, MA, 1993.
38. Jensen, JK, Ostergard, DR: Approach to Urogynecologic Problems in Elderly Females. In: Guia Practica de Urologia Ginecologica. Sociedad Mexicana de Urologia Ginecologica, 1994.
39. Lubner, KM and Ostergard, DR: Assessment of Female Patients: Routine

Procedures. The Pelvic Floor, Investigations, Methods of Management.
Fribourg, Suisse: Vigot.

40. Swift, SE and Ostergard, DR: "Cryosurgery" in Ambulatory Gynecology, Second edition, ed Nichols, DH, Sweeny PJ., J.A. Lippincott, Philadelphia PA, 1995
41. Jensen, JK, Ostergard, DR: Suprapubic Needle Cystoscopy: A New Technique to Detect Iatrogenic Injuries to the Lower Urinary Tract. In: Szabo Z, Kernstein M, eds. Surgical Technology International III. San Francisco: Universal Medical Press, Inc, 1994.
42. Noblett, KL, Ostergard, DR: Gynecologic Disorders. In: Principles of Geriatric Medicine and Gerontology. McGraw Hill, 1998.
43. Wallach SJ, Ostergard DR: Etiologies of Pelvic Organ Prolapse. In: Atsuo Kondo, ed. Female Pelvic Floor Pathology and Reconstructive Surgery. Medical View, Japan, 2003.
44. Wallach SJ, Ostergard DR: Urodynamic Assessment: Urethral Pressure Profilometry and PTR. In: Appell R, Raz S, Sand P, eds. Female Urology, Urogynecology and Voiding Dysfunction. Marcel-Dekker, Inc., NY, 2005.

BOOK CHAPTERS, OTHER:

1. Ostergard, DR, Marshall, JR: Physicians Assistants in Reproductive Oriented Women's Health Care, in Paramedical Personnel in Family Planning - A Creative Partnership, JE Moorehead, ed, The Pathfinder Fund Monograph Series, 1974, pp 23-35.
2. Wallach, SJ, Ostergard, DR: Anatomia Pélvica Feminina, In: Aplicações Clínicas da Urodinamica, 3rd ed. Atheneu, 2001, pp 125-138.

JOURNAL ARTICLES, PEER REVIEWED:

1. Ostergard, DR, Townsend, DE, and Hirose, FM: The Treatment of Chronic Cervicitis by Cryotherapy: A Preliminary Report, Cryobiology 4:97 (Sept-Oct) 1967.
2. Ostergard, DR, Morton, DG: Multifocal Carcinoma of the Female Genitals, Amer J Obset & Gynec 99:1006 (Dec) 1967.
3. Ostergard, DR, Townsend, DE: The Treatment of Malignant Melanoma of the Female Urethra by Cryosurgery Combined with Radical Vulvectomy and Anterior Exenteration: A Case Report, Obstet Gynec 31:75 (Jan) 1968.
4. Ostergard, DR, Townsend, DE: The Use of Freon for the Cryosurgical Treatment of Chronic Cervicitis: A Preliminary Report, J. Cryosurgery 1:67 (June) 1968.
5. Ostergard, DR, Towensend, DE and Hirose, FM: The Treatment of Chronic Cervicitis by Cryotherapy, Amer J Obstet Gynec 102:426 (Oct) 1968.
6. Ostergard, DR, Bryon, RL: The Symptomatic Pelvic Lymphocyst: Problems in Differentiation from Recurrent Carcinoma, Obstet Gynec 32:677 (Nov) 1968.
7. Ostergard, DR, Townsend DE, and Hirose, FM: A Comparison of Electro-cauterization and Cryosurgery for the Treatment of Chronic Cervicitis, Obstet Gynec 33:58 (Jan) 1969.

8. Ostergard, DR, Townsend, DE, and Hirose, FM: The Long Term Effects of Cryosurgery of the Uterine Cervix, J Cryosurgery 2:17 (Feb) 1969.
9. Ostergard, DR, Townsend, DE: The Cryosurgical Treatment of Vulvar Condyloma Acuminata, Cryobiology 5:340 (Mar-Apr) 1969.
10. Byron, RL, Ostergard, DR: Sartorius Muscle Interposition for the Treatment of the Radiation Induced Vaginal Fistula, Amer J Obstet Gynec 104:104 (May) 1969.
11. Honda, K, Ostergard DR, Kushinsky, S: Gas Chromatographic Analysis of Estrogens: Estriol in Late Pregnancy, Amer J Obstet Gynec 104:528 (June) 1969.
12. Perrin, LE, Ostergard, DR, Mishell, Jr., DR: The Use of Hyperbaric Oxygen in the Treatment of Clostridial Septicemia Complicating Septic Abortion: Report of a Case, Amer J Obstet Gynec 106:666 (Mar) 1970.
13. Ostergard, DR: The Physiology and Clinical Importance of Amniotic Fluid: A Review, Obstet Gynec Surv 25:297 (Apr) 1970.
14. Ostergard, DR, Bradley, JG: Septic Incomplete Abortion: A Retrospective Study of Twenty Years Experience, Obstet Gynec 35:709 (May) 1970.
15. Bradley, JG, Ostergard, DR: Septic Threatened Abortion: A Retrospective Study of Twenty Years Experience, Obstet Gynec 35:714 (May) 1970.
16. Ostergard, DR, Parlow, AF, Townsend, DE: The Effect of Acute Castration on Serum FSH and LH in the Human Female, J Clin Endo Metab 31:43 (July) 1970.
17. Ostergard, DR: A comparison of Two Antibiotic Regimens in the Treatment of Septic Abortion, Obstet Gynec 36:473 (Aug) 1970.
18. Ostergard, DR, Contopoulos, AN: A Technique for Selective Fetal Hypophysectomy in utero, Amer J Obstet Gynec 108:322 (Sept) 1970.
19. Townsend, DE, Ostergard, DR, Hirose, FM, Mishell, Jr., DR: Abnormal Papanicolaou Smears: Evaluation by Colposcopy, Biopsies and Endocervical Curettage, Amer J Obstet Gynec 108:429 (Oct) 1970.
20. Townsend, DE, Ostergard, DR: Cryocauterization for Preinvasive Cervical Neoplasia, J Repro Med 6:171 (Apr) 1971.
21. Gondos, B, Townsend, DE, Ostergard, DR: Cytologic Diagnosis of Squamous Dysplasia and Carcinoma of the Cervix, Amer J Obstet Gynec 11:107 (May) 1971.
22. Ostergard, DR, Gondos, B: The Incidence of False Negative Cervical Cytology as Determined by Colposcopically Directed Biopsies, Acta Cytol 15:292 (May-June) 1971.
23. Ostergard, DR, Kushinsky, S: Urinary Estriol as an Indicator of Fetal Well Being, Obstet Gynec 38:74-78 (July) 1971.
24. Ostergard, DR, Broen, EM, Marshall, JR: A Training Program for Allied Health Personnel in Family Planning and Cancer Screening, J Repro Med 7:40-41 (July) 1971.
25. Townsend, DE, Ostergard, DR, Lickrish, GM: Cryosurgery for Benign Disease of the Cervix, J Obstet Gynec Brit Comm 78:667-670 (July) 1971.

26. Ostergard, DR: Cryosurgery in the Treatment of Abnormal Cervical Lesions, An Invitational Symposium, J Repro Med 7:147-168 (Oct) 1971.
27. Broen, EM, Ostergard, DR: Toulidine blue and Colposcopy for Screening and Delineation of Vulvar Neoplasia, Obstet Gynec 38:775-778 (Nov) 1971.
28. Ostergard, DR, Broen, EM: The Dalkon Shield: A Clinical Evaluation, Contraception 4:313-371 (Nov) 1971.
29. Veltman, LL, Ostergard, DR: Thrombosis of Vulvar Varicosities During Pregnancy: Report of a Case, Obstet Gynec 39:55-56 (Jan) 1972.
30. Ostergard, DR, Broen, EM, Marshall, JR: The Family Planning Specialist, Clin Obstet Gynec 15:370-378 (June) 1972.
31. Ostergard, DR, Broen, EM, Marshall, JR: The Family Planning Specialist as a Provider of Health Care Services. Fertility Sterility 23:505-507 (July) 1972.
32. Gondos, B, Marshall D, Ostergard DR: Endocervical Cells in Cervical Smears, Amer J Obstet Gynec 114:833-834 (Nov 15) 1972.
33. Ostergard, CM, Ostergard DR: Are Registered Nurses the Best Family Planning Specialist Recruits?, J Obstet Gynec Neonatal Nursing 2:64-66 (Jan/Feb) 1973.
34. Ostergard, DR, Broen, EM: The Insertion of Intrauterine Devices by Physicians and Paramedical Personnel, Obstet Gynec 41:257-258 (Feb) 1973.
35. Ostergard, DR, Gondos, B: Outpatient Therapy of Preinvasive Cervical Neoplasia: Selection of Patients Using Colposcopy, Am J Obstet Gynec 115:783-785 (Mar) 1973.
36. Ostergard, DR: Estriol in Pregnancy, Ob-Gyn Survey 28:215-231 (Apr) 1973.
37. Ostergard, DR: The Role of Colposcopy in Gynecologic Practice. Epitomes of Progress in Obstetrics and Gynecology. Calif Med 119:66 (Jul) 1973.
38. Ostergard, DR: Intrauterine Contraception in Nulliparas with the Dalkon Shield, Amer J Obstet Gynec 116:1088-1092.
39. Gondos, B, Ostergard DR: Cytologic Evaluation Following Cryosurgical Treatment for Severe Dysplasia and Carcinoma In Situ, J Repro Med 11:67-70 (Aug) 1973.
40. Ostergard, DR: The Cervical Relaxant Properties of Prostaglandin E2, Prostaglandins 4:701-2 (Nov) 1973.
41. Ostergard, DR: The Potential for Paramedical Personnel in Family Planning: An Analysis Based on the Department of Health, Education and Welfare Five Year Plan for Family Planning Services, Amer J Public Health 64:27-31 (Jan) 1974.
42. Ostergard, DR: Intrauterine Contraception in Multiparas with the Dalkon Shield, Am J Obstet Gynec 119:1033-1037 (Aug 15) 1974.
43. Ostergard, DR: The Dalkon Shield Intrauterine Device. A Review of Current Status. J Repro Med 14:64-67, 1975.
44. Ostergard, DR: A Comparison of Event Rates in Nulligravid and Nulliparas Women Using the Small Dalkon Shield for Intrauterine Contraception,

Contraception 11:61-68, 1975.

45. Ostergard, DR, Gunning, JE, Marshall JR: Training and Function of a Women's Health Care Specialist: A Physician's Assistant or Nurse Practitioner in Obstetrics and Gynecology, Amer J Obstet Gynec 121:1029-1037 (Apr 15) 1975.
46. Gunning, JE, Ostergard, DR: The Value of Screening Procedures for the Detection of Vaginal Adenosis, Obstet Gynec 47:268-271 (Mar) 1976.
47. Ostergard, DR: A Prospective Comparison of the Cooper T 200 and the Small Dalkon Shield for Intrauterine Contraception in Nulligravid Women, J Repro Med 17:172-174 (Sept) 1976.
48. Ostergard, DR: The Effect of Age, Gravidity and Parity on the Cervical Squamocolumnar Junction, Amer J Obstet Gynec 129:59-60 (Sept) 1977.
49. Ostergard, DR: The Neurological Control of Micturition and Integral Voiding Reflexes, Ob-Gyn Survey 34:417-423 (Jun) 1979.
50. Ostergard, DR: The Effect of Drugs on the Lower Urinary Tract, Ob-Gyn Survey 34:424-432 (Jun) 1979.
51. Ostergard, DR, Nieburg, R: Evaluation of Abnormal Cervical Cytology During Pregnancy with Colposcopy, Amer J Obstet Gynec 134:756-758 (Aug) 1979.
52. Ostergard, DR: The Effect of Pregnancy on the Cervical Squamocolumnar Junction, Amer J Obstet Gynec 134:759-760 (Aug) 1979.
53. Ostergard, DR: Bladder Pillar Block Anesthesia for Urethral Dilatation in Women, Amer J Obstet Gynec 136:187-188 (Jan) 1980.
54. Ostergard, DR, McCarthy, TA: Diagnostic Procedures in Female Urology, Amer J Obstet Gynec 137:401-411 (Jun) 1980.
55. Ostergard, DR: DES Related Vaginal lesions, Clin Obstet Gynec 24:379-384 (Jun) 1980.
56. Ostergard, DR: The Prediction of Clearance of Cervical Intraepithelial Neoplasia by Conization, Obstet Gynec 56:77-80, 1980.
57. Ostergard, DR: Cryosurgical Treatment of Cervical Intraepithelial Neoplasia by Conization, Obstet Gynec 56:231-233 (Aug) 1980.
58. White, RD, McQuown, D, McCarthy, TA, Ostergard, DR: Real Time Ultrasonography in the Evaluation of Urinary Stress Incontinence, Amer J Obstet Gynec 138:235-237 (Sept) 1980.
59. Ostergard, DR: Endocervical Strip Biopsy Instrument: An Alternative to Endocervical Curettage. Obstet Gynec 56:658-660 (Nov) 1980.
60. Bhatia, NN, Ostergard DR: Urodynamic Effects of Retropubic Urethropexy in Genuine Stress Incontinence. Amer J Obstet Gynec 140:936-941 (Aug) 1981.
61. Bhatia, NN, McCarthy, TA, Ostergard, DR: Instruments and Methods: Urethral Pressure Profiles of Women with Urethral Diverticula. Obstet Gynec 58:375-378 (Sept) 1981.
62. Hebert, DB, Ostergard, DR: Vesical Instability. Urodynamic Parameters by Microtip Transducer Catheters. Obstet Gynec 60:331-337 (Sept) 1982.
63. Bhatia, NN, Ostergard, DR: Urodynamics in Women with Stress Urinary Incontinence. Obstet Gynec 60:552-559 (Nov) 1982.

DONALD R. OSTERGARD, M.D.

64. Hebert, DB, Francis, LN, Ostergard, DR: Significance of Urethral Vascular Pulsations in Genuine Stress Urinary Incontinence. Amer J Obstet Gynec 144:7 828-835 (Dec) 1982.
65. Bent, AE, Richardson, DA, Ostergard DR: Diagnosis of Lower Urinary Tract Disorders in Postmenopausal Patients. Amer J Obstet Gynec 145:218-222 (Jan) 1983.
66. Richardson, DA, Bent, AE, Ostergard DR: The Effect of Uterovaginal Prolapse on Urethrovesical Pressure Dynamics. Amer J Obstet Gynec 146:901-905, 1983.
67. Alvarez, RS, Richardson, DA, Bent, AE, Ostergard, DR: Central Nervous System Toxicity Related to Prolonged Metronidazole Therapy. Amer J Obstet Gynec 145:640-641 (Mar) 1983.
68. Richardson, DA, Bent, AE, Ostergard DR, Cannon D: Delayed Reaction to the Dacron Buttress Used in Urethropexy. J Reprod Med 29:689-692 (Sept) 1984.
69. Bowen, LW, Sand, PK, Ostergard, DR: Toxic Shock Syndrome Following Co 2 Laser of Genital Tract Condyloma Acuminatum. Am J Obstet Gynec 154:145-146.
70. Sand, PK, Bowen LW, Ostergard, DR: Voiding Dysfunction in the Adolescent. Obstet Gynec Surv 41:342-347 (Jun) 1986.
71. Scotti, RJ, Bergman, A, Bhatia, NN, Ostergard, DR: Urodynamic Changes in Urethrovesical Function after Radical Hysterectomy. Obstet Gynec 68:111-120 (July) 1986.
72. Sand, PK, Bowen, LW, Blischke, SO, Ostergard, DR: Evaluation of Male Consorts of Women with Genital Human Papilloma Virus Infection. Obstet Gynec 68:679-681 (Nov) 1986.
73. Sand, PK, Bowen, LW, Ostergard, DR: Uninhibited Urethral Relaxation: An unusual cause of incontinence. Obstet Gynec 68:645-648 (Nov) 1986.
74. Bhatia, NN, Ostergard, DR, McQuown, D: Ultrasonography in Urinary Incontinence. Urology 29:90-94 (Jan) 1987.
75. Sand, PK, Shen, W, Bowen, LW, Ostergard, DR: Cryotherapy for the Treatment of Intraurethral Condyloma Acuminatum. J Urol 137:874-6 (May) 1987.
76. Francis, LN, Sand, PK, Hamrang, K, Ostergard, DR: A Urodynamic Appraisal of Success and Failure After Retropubic Urethropexy. J Reprod Med 32:693-696 (Sept) 1987.
77. Sand, PK, Bowen, LW, Panganiban, R, Ostergard, DR: The Low Pressure Urethra as a Factor in Failed Retropubic Urethropexy. Obstet Gynec 69:399-402 (Mar) 1987.
78. Sand, PK, Hill, RC, Ostergard, DR: Supine Urethroscopic and Standing Cystometry as Screening Methods for the Detection of Detrusor Instability. Obstet Gynec 70:57-60 (July) 1987.
79. Sand, PK, Bowen, LW, Ostergard, DR, Nakanishi, AM: Hysterectomy and Prior Incontinence Surgery as Risk Factors for Failure of Retropubic Urethropexy. J Reprod Med 33:171-174 (Feb) 1988.

80. Sand, PK, Hill, RC, Ostergard, DR: The Incontinence History as a Predictor of Detrusor Instability. Obstet Gynec 71:257-260 (Feb) 1988.
81. Horbach, NS, Blanco, JS, Ostergard, DR, Bent, AE, Cornella, JL: A Suburethral Sling Procedure with Polytetrafluoroethylene for the Treatment of Genuine Stress Incontinence in Patients with Low Urethral Closure Pressure. Obstet Gynec 71:648-652 (April) 1988.
82. Bent, AE, Ostergard, DR: Recurrent Stress Incontinence: Causes and Treatment in the Female Patient. Post Graduate Medicine 83:113-117 (May) 1988.
83. Sand, PK, Bowen, LW, Ostergard, DR, Brubaker, LT, Panganiban, R: The Effect of Retropubic Urethropexy on Detrusor Stability. Obstet Gynec 71:8181-822 (June) 1988.
84. Ostergard, DR: Education and Training in Urogynecology. Int Urogynec J, initial copy, 1:21-22 (October) 1988.
85. Summitt, RL, Jr, Bent, AE, Ostergard, DR, Harris, TA: Correlation of Preoperative Q-tip Tests with Success Using a Suburethral Sling Procedure for Stress Urinary Incontinence and Low Urethral Closure Pressure, Int Urogynec J, 1:29, (October) 1988.
86. Sand, PK, Brubaker, L, Bowen, LW, Ostergard, DR, Panganiban, R: The Effect of Retropubic Urethropexy on Detrusor Stability. Int Urogynec J, 1:33, (October) 1988.
87. Sand, PK, Pierson, CA, Ostergard, DR, Atad, J, Panganiban, R: The Correlation Between Pad Tests and Urodynamics. Int Urogynec J, 1:35, (October) 1988.
88. Scotti, RJ, Ostergard, DR, Guillaume, AA, Kohatisu, KE: Predictive Value of Dynamic Urethroscopy in Urethral Syndrome, Genuine Stress Incontinence and Vesical Instability, Int Urogynec J, 1:42, (October) 1988.
89. Bowen, LW, Sand, PK, Ostergard, DR, Franti, CE: Unsuccessful Burch Retropubic Urethropexy. A Case Controlled Urodynamic Study. Am J Obstet Gynec 160:452-458 (Feb) 1989.
90. Richardson, DA, Scotti, RJ, Ostergard, DR: Surgical Management of Uterine Prolapse in Young Women. J of Repro Med 34:388-392 (June) 1989.
91. Sand, PK, Bowen, LW, Ostergard, DR, Bent, AE, Panganiban, R: Cryosurgery Versus Dilation and Massage for the Treatment of the Urethral Syndrome J of Repro Med 34:499-504 (Aug) 1989.
92. Cornella, JL, Bent, AE, Ostergard, DR, Horbach, NS: A Prospective Study Utilizing Transdermal Scopolamine in the Treatment of Detrusor Instability. Urology 35:96-97 (Jan) 1990.
93. Summitt, RL, Jr., Bent, AE, Ostergard, DR: The Pathophysiology of Genuine Stress Incontinence, Int Urogynecol J 1:12-18 (March) 1990.
94. Bent, AE, Ostergard, DR: Endometrial Ablation with the Neodymium:YAG Laser. Obstet Gynecol 75:923-925 (June) 1990.
95. Scotti, RJ, Ostergard, DR, Guillaume, AA, Kohatsu, KE: Predictive Value of Urethroscopy Compared to Urodynamics in the Diagnosis of Genuine Stress Incontinence. J of Repro Med 35:7720776 (Aug) 1990.
96. Sand, PK, Bowen, LW, Ostergard, DR: The Effects of a Filling Catheter

- During Urodynamics. Int Urogynec J 1:124-27 (Sept) 1990.
97. Summitt, RL, Jr, Bent, AE, Ostergard, DR, Harris, TA: Stress Incontinence and Low Urethral Closure Pressure. J Repro Med 35:877-880 (Sept) 1990.
 98. Cornella, JL, Ostergard, DR: Needle Suspension Procedures for Urinary Stress Incontinence: A Review and Historical Perspective. Obstet Gynec Surv 45:805-816 (December) 1990.
 99. Sand, PK, Bowen, LW, Ostergard, DR: The Prognostic Significance of Augmentation of Urethral Closure Pressure and Functional Length. Int J Gynecol Obstet 33:135-139, 1990.
 100. Summitt, RL, Jr, Bent, AE, Ostergard, DR, Harris, TA: Suburethral Sling Procedure for Genuine Stress Incontinence and Low Urethral Closure Pressure: A Continued Experience. Int Urogynec J 3(1):18-21, 1992.
 101. Summitt, RL, Jr, Stovall, TG, Bent, AE, Ostergard, DR: Urinary Incontinence: Correlation of History and Brief Office Evaluation with Multichannel Urodynamic Testing, Am J Obstet Gynec 166(6):1835-1844 (June) 1992.
 102. Bent, AE, Sand, PK, Ostergard, DR, Brubaker, LT: Transvaginal Electrical Stimulation in the Treatment of Genuine Stress Incontinence and Detrusor Instability. In Urogynec J 4:232-236, 1993.
 103. Swift, SE, Ostergard, DR: Effects of Progesterone on the Urinary Tract. Int Urogynec J 4:232-236, 1993.
 104. Bent, AE, Ostergard, DR, Zwick-Zaffuto, M: Tissue Reaction to Gore-Tex (tm) Suburethral Sling for Incontinence: Clinical and Histologic Study. Amer J Obstet Gynec 169:1198-1204, 1993.
 105. Scotti, RJ, Ostergard, DR: Predictive Value of Urethroscopy in Genuine Stress Incontinence and Vesical Instability. Int Urogynec J 4:(5) 255-258, 1993.
 106. Jensen, JK, Neilsen, FR, Jr., Ostergard, DR: The Role of Patient History in the Diagnosis of Urinary Incontinence. Obstet Gynec 83:(5) 904-910, 1994.
 107. Summitt, RL, Sipes, DR II, Bent, AE, Ostergard, DR: Evaluation of Pressure Transmission Ratios in Women with Genuine Stress Incontinence and Low Urethral Pressure: A Comparative Study, Obstet Gynecol 83:6 984-988, 1994.
 108. Horbach, NS, Ostergard, DR: Predicting Intrinsic Urethral Sphincter Dysfunction in Women with Stress Urinary Incontinence. Obstet Gynecol 84:2 188-192, (August) 1994.
 109. Swift, SE, Ostergard, DR: Vaginal Wall Retropubic Urethropexy: Results at One Year Follow-up, Int Urogynec J. 5:291-295, 1994.
 110. Swift, SE, Ostergard, DR: A Comparison of Stress Leak-Point Pressure and Maximal Urethral Closure Pressure in Patients with Genuine Stress Incontinence. Obstet Gynec 85:5:(1):704-708 (May) 1995.
 111. Weinberger, MW, Ostergard, DR: Long-term Clinical and Urodynamic Evaluation of the Polytetrafluoroethylene Suburethral Sling for Treatment of Genuine Stress Incontinence. Obstet Gynecol 86(1):92-96, (July) 1995.

112. Swift, SE, Ostergard, DR: Evaluation of Current Urodynamic Testing Methods in the Diagnosis of Genuine Stress Incontinence. Obstet Gynecol 86:(1):85-91, (July) 1995
113. Sand, PK, Richardson, DA, Ostergard, DR, et al: Pelvic Floor Electrical Stimulation in the Treatment of Genuine Stress Incontinence: A Multicenter, Placebo-Controlled Trial, Am J Obstet Gynec 173: 72-79, (July) 1995.
114. Handa, VL, Jensen, JK, Ostergard, DR: The Effect of Patient Position on Proximal Urethral Mobility. Obstet Gynecol 86:273-276 (August) 1995.
115. Handa VL, Jensen JK, Ostergard DR. Federal Guidelines for the Management of Urinary Incontinence in Adults: Which Patients Should be Referred for Urodynamic Testing? Int Urogynec J. 6:198-203, 1995.
116. Farrell, SA, Bent, AE, Cholhan, HJ, Ostergard, DR: Urethral Closure Pressure Profiles in the Standing Position: Are They Necessary? Int Urogynec J, 6:6 343-345, 1995.
117. Weinberger, ME, Ostergard, DR: Postoperative Catheterization, Urinary Retention, and Permanent Voiding Dysfunction Following Polytetrafluoroethylene Suburethral Sling Placement. Obstet Gynecol. 8:50-54 (January) 1996.
118. Handa, VL, Harris, TA, Ostergard, DR: Protecting the Pelvic Floor: Obstetric Management to Prevent Incontinence and Pelvic Organ Prolapse Obstet Gynecol 88:3 470-478 (September) 1996.
119. Handa, VL, Jensen JK, Germain, MM, Ostergard, DR: Banked Human Fascia Lata for the Suburethral Sling Procedure: A Preliminary Report. Obstet Gynecol. 88:6 1045-1049 (December) 1996.
120. Swift, SE, Rust, PF, Ostergard, DR: Intrasubject Variability of the Pressure-Transmission Ratio in Patients with Genuine Stress Incontinence. Int Urogynec J, 7:6, 312-316, 1996.
121. Noblett, KL, Jensen, JK, Ostergard, DR: The Relationship of Body Mass Index to Intra-abdominal Pressure as Measured by Multichannel Cystometry. Int Urogyn J, 8:323-326, 1997.
122. Handa, VL, Jensen, JK, Ostergard, DR: Stress Urinary Incontinence at Rest. Int Urogynec J. 10:290-294, 1999.
123. Cassidenti, AP, Ostergard, DR: Multichannel Urodynamics: Ambulatory Versus Standard Urodynamics. Curr Opin Obstet Gynecol. 11:485-487, 1999.
124. Lose G, Ostergard DR. Medical Technology Assessment and Surgery for Stress Incontinence. Int Urogyn J 10:351, 1999.
125. Huggins, ME, Bhatia NN, Ostergard DR: Urinary Incontinence: Newer Pharmacotherapeutic Trends. Curr Opin Obstet Gynecol, 15:419-427, 2003.
126. Le TH, Ostergard DR, Bhatia NN, Huggins ME: Newer pharmacologic options in the management of overactive bladder syndrome. Curr Opin Obstet Gynecol, 17:495-506 (October) 2005.
127. Le TH, Kon L, Bhatia NN, Ostergard DR: Update on the utilization of grafts in pelvic reconstruction surgeries. Curr Opin Obstet Gynecol, 19:1-10, 2007.
128. Toglia MR, Ostergard DR, Appell RA, Andoh M, Fakhoury A, Hussain IF. Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. Int Urogyn J 21:847-54, 2010.

129. Ostergard DR. Polypropylene Mesh Grafts in Gynecology. Obstet Gynec 116:962-966, 2010.
130. Ostergard DR. Vaginal Mesh Grafts and the Food and Drug Administration. Int Urogyn J 21:1181-1183, 2010.
131. Lucente V, Ostergard D, Davila GW, He W, Forero-Schwanhaeuser S. Efficacy of solifenacin on symptom bother and health-related quality of life in patients with acute, early chronic and late chronic overactive bladder: secondary analysis of data from VOLT. Fem Pelvic Med Recon Surg 16:320-326, 2010.
132. Ostergard DR. Degradation, Infection and Heat Effects on Polypropylene Mesh for Pelvic Implantation: What was known and when it was known. Int Urogyn J 22:771, 2011.
133. Ostergard DR. Mentors in urogynecology: Reflections on my career as a urogynecologist. Int Urogyn J. 23:15-7, 2012.
134. Ostergard DR. Evidence based medicine for polypropylene mesh use compared to native tissue vaginal prolapse repair. Urology 79:12-15, 2012.
135. Sternschuss G, Ostergard DR, Patel H. Post-Implantation alterations of polypropylene in the human. J Urol 2012;May 12 (epub ahead of print)
136. Patel H, Ostergard DR, Sternschuss G. Polypropylene Mesh and the Host Response. Int Urogyn J 23:669-79, 2012.
137. Deprest J, Slack M, Cervigni M, Ostergard D. A standardized description of graft-containing meshes and recommended steps before the introduction of medical devices for prolapse surgery: consensus of the 2nd IUGA Grafts round table. Int Urogyn J 23:Suppl 1:S15-16, 2012.
138. Azadi A, **Ostergard DR**, Dassel M, Yeganeh T, P Heyl. 22 Weeks Pregnancy in Rudimentary Horn of Uterus. Journal of Gynecologic Surgery, August 2013.
139. Ostergard DR, Azadi A. To mesh or not to mesh with polypropylene: Does carcinogenesis in animals matter? Int Urogyn J 2014; Epub 11 March 2014
140. Francis SL, Agrawal A, Azadi A, Ostergard DR, Deveneau NE. Robotic Burch Colposuspension: A Surgical Case and Instructional Video. Int Urogyn J 2015;26:148-148.
141. Devaneau NE, Greenstein M, Mahalingashetty A, Herring NR, Lipetskaia L, Azadi A, Ostergard DR, Francis SL. Surface and bony landmarks for sacral neuromodulation: a cadaveric study. Int Urogyn J 26:263-268, 2015.

JOURNAL ARTICLES, OTHER:

1. Ostergard, DR: The Dalkon Shield, The Medical Letter 14:97-98 (Dec) 1972.
2. Buster, JE, Ostergard, DR: Current Status of Plasma Estriol in the Assessment of Pathological Pregnancies, Ob-Gyn Digest 15:33-38 (Feb) 1973.
3. Ostergard, DR: Lower Urinary Tract Symptoms: The Role of the Urethra. The Female Patient 4:30-34 (Oct) 1979.
4. Ostergard, DR: Pharmacology of the Lower Urinary Tract, Contemp Ob-Gyn 17:41 (Feb) 1981.

5. Bent, AE and Ostergard, DR: Urgency Incontinence. Gynecologic Urology Society Newsletter (June) 1982.
6. Richardson, DA and Ostergard, DR: Evolution of Surgery for Stress Urinary Incontinence. Contemp Ob-Gyn 21:52-64 (Mar) 1983.
7. Bent, AE and Ostergard, DR: Why Women are Prone to Incontinence. Contemp Ob-Gyn 83-104 (Jan) 1984.
8. Francis, LN, Ostergard, DR and Westermoe, K: Treatment of Vaginal Inversion with Sacrospinous Fixation. The Female Patient 10:123-125 (Apr) 1985.
9. Sand, PK, Bowen, LW, Ostergard, DR: Laser Therapy: Guide to New Outpatient Gynecologic Procedures - A Primer on Laser Use in Gynecology. The Female Patient 10:91-108 (Oct) 1985.
10. Ostergard, DR, Bent, AE: Abdominal Approach for Surgical Correction of Genuine Stress Incontinence. Obstet Gynecol Forum, Vol II, No. 6, (Nov-Dec) 1988.
11. Ostergard, DR: Vestibulitis: A Cause of Dyspareunia, Med Aspects of Human Sexuality 36-39 (March) 1990.
12. Cholhan, HJ, Ostergard, DR: The Abdominal Retropubic Urethropexy -- The Optimal Surgical Approach. OB Gyn Report Vol. 2 #3, Summer 1990.
13. Cholhan, HJ, Ostergard, DR: Urinary Tract Infections in Postmenopausal Women. Clinical Advances in the Treatment of Infections 4:1-3 (October) 1990.
14. Appell, RA, Ostergard, DR: Practical Urodynamics. Illustrated Medicine 2:2, 1992.
15. Ostergard, DR: The International Urogynecology Journal: Four Years of Progress (editorial). Int Urogynec J. 4:333-334, 1993.
16. Ostergard, DR, Jensen, JK: Treatment of Recurrent Endometriosis, International Correspondence Society of Obstetricians & Gynecologists Collected Letters, 31(11); 9-10, 1993.
17. Jensen JK, Ostergard, DR. Treatment of Menorrhagia and Dysmenorrhea in the Face of Anti-phospholipid Syndrome, International Correspondence Society of Obstetricians & Gynecologists Collected Letters, Vol 35(8):11,1994.
18. Ostergard, DR: The International Nature of Urogynecology (editorial) Urogynaecologia International J. 8:3, 107-108, 1994.
19. Ostergard, DR: Urogynecology and Pelvic Reconstructive Surgery: Office Preoperative Evaluation of the Incontinent Female. Int J of Gynecol Obstet: 49:S43-S47, (July) 1995.
20. Resnick, NM, Blaivas, JG, Ostergard, DR: Practical Pointers on Urinary Incontinence. Patient Care 29: 103-131, (Oct 15) 1995.
21. Jensen, JK, Ostergard DR: Avoiding Complications During Operative Hysteroscopy. The Female Patient 21:15-24, 1996.
22. Jensen, JK, Ostergard, DR: Female Retropubic Anatomy for Gynecologic Surgery. The Female Patient 1:33-37, 1996.
23. Ostergard, DR: Primary Slings for Everyone with Genuine Stress Incontinence?

The Argument Against (editorial). Int Urogynec J. 8:6, 321-322, 1997.

24. Ostergard, DR: Lessons from the Past: Directions for the Future Do New Marketed Surgical Procedures and Grafts Produce Ethical, Personal Liability and Legal Concerns for Physicians? Int Urogyn J 18:591-8, 2007.

CONFERENCE PROCEEDINGS PAPERS, OTHER:

1. Ostergard, DR: A Developmental Training Program for Family Planning Specialists. Proceedings of the December 3, 1971 Meeting of the California Interagency Council on Family Planning.
2. Ostergard, DR, Broen, EM, Marshall, JR: Family Planning and Cancer Screening Services as Provided by Paramedical Personnel: A Training Program, Advances in Planned Parenthood, Vol. VII, pp 59-61, 1972, Editors: AJ Sobrero and RM Harvey, ICS 246, Excerpta Medica, Amsterdam.
3. Ostergard, DR, Broen, EM: Clinical Experience with the Dalkon Shield, in Advances in Planned Parenthood, Vol. VII, pp 81-83, 1972. Editors: AJ Sobrero and RM Harvey, ICS 246, Excerpta Medica, Amsterdam.
4. Ostergard, DR: Colposcopy and Cryosurgery for the Treatment of Preinvasive Cervical Neoplasia, in Latest Developments in Cryosurgery, Proceedings of the International Congress of Cryosurgery, Vienna, June 4-7, 1972, Verlag der Wiener Medizinischen Akademie, Vienna, 1972.
5. Ostergard, DR, Broen, EM, Marshall, JR: Family Planning and Cancer Screening as Provided by Paramedical Personnel, Proceedings of the Seventh World Congress on Fertility and Sterility, Excerpta Medica, ICS 278, 1973, pp 987-988.

ABSTRACTS (conference proceedings, other):

1. Ostergard, DR, Townsend, DE, Hirose, FM: The Treatment of Chronic Cervicitis by Cryotherapy, Cryobiology 3:362, 1967.
2. Hirose, FM, Townsend, DE, Ostergard, DR: The Histology of the Cervix Following Cryosurgery, Cryobiology 3:362, 1967.
3. Ostergard, DR, Townsend, DE: The Cryosurgical Treatment of Vulvar Condyloma Acuminata, Cryobiology 4:273, 1968.
4. Townsend, DE, Ostergard, DR, Moyer, DL, Norum M: Comparison of Freeze-Thaw-Induced Ultrastructural Changes of Normal and Neoplastic Human Ectocervical Epithelium, Cryobiology 4:273, 1968.
5. Bradley, JG, Ostergard, DR: Septic Threatened Abortion: A Survey of Twenty Years Experience in a County Hospital, Inter J Obstet Gynec 8: Abstract #64, 1970.
6. Townsend, DE, Ostergard, DR: Treatment of Cervical Dysplasia by Cryosurgery, Inter J Obstet Gynec 8: Abstract #120, 1970.
7. Ostergard, DR, Kushinsky S: Urinary Estriol as a Test of Fetal Well Being, Excerpta Medica, International Congress Series 189: #210 Third International Congress of Hormonal Steroids, September, 1970.
8. Broen, EM, Ostergard, DR: Toluidine Blue and Colposcopy for Screening and

- Delineation of Vulvar Neoplasia, Obstet Gynec 37:637, 1971.
9. Ostergard, DR, Parlow AF, Townsend, DE: Acute Effect of Castration on Serum FSH and LH in Adult Women, Symposium on Gonadotropins in Endocrine Disorders of Human Reproduction, 1971. (Collection of Abstracts p 35).
 10. Ostergard, DR: A Development Training Program for Family Planning Specialists. Proceedings of the December 3, 1971 Meeting of the California Interagency Council on Family Planning.
 11. Ostergard, DR, Broen, EM: The Family Planning Specialist, Abstracts of Main Sessions, VII World Congress on Fertility and Sterility, Excerpta Medica (#234-A) 1973.
 12. Ostergard, DR, Broen, EM, Marshall, JR: Family Planning and Cancer Screening as Provided by Paramedical Personnel, Proceedings of the VII World Congress on Fertility and Sterility, Excerpta Medica, ICS 278:987-988, 1973.
 13. Ostergard, DR: Cervical Colposcopy and the Abnormal Pap Smear, Excerpta Medica, ICS 396, VIII World Congress of Gynecology and Obstetrics, Mexico, D.F., 17-22 (October) 1976.
 14. Ostergard, DR, Bhatia, NN, McQuown, D: Ultrasonography in the Evaluation of Urethrovesical Dynamics in Genuine Stress Incontinence and Detrusor Instability, Proceedings 10th Annual Meeting of the International Continence Society and Joint Meeting with the Urodynamics Society, (October 9-12), 1980, Los Angeles, California.
 15. Ostergard, DR, Bhatia, NN, McCarthy, TA: Urethral Pressure Profiles in Women with Urethral Diverticula, Proceedings 10th Annual Meeting of the International Continence Society and Joint Meeting with the Urodynamics Society, (October 9-12), 1980, Los Angeles, California.
 16. Ostergard, DR, Bhatia, NN: Urodynamic Effects of Retropubic Urethropexy in Genuine Stress Incontinence, Proceedings 10th Annual Meeting of the International Continence Society and Joint Meeting with the Urodynamics Society, (October 9-12), 1980, Los Angeles, California.
 17. Ostergard, DR, Bhatia, NN: Urodynamics in Genuine Stress Incontinence, Gynecologic Urology Society, Book of Abstracts, October 16, 1980, New Orleans, Louisiana.
 18. Ostergard, DR, Bhatia, NN: Urodynamic Effects of Retropubic Urethropexy in Genuine Stress Incontinence, Gynecologic Urology Society, Book of Abstracts, October 16, 1980, New Orleans, Louisiana.
 19. Bent, AE, Richardson, DA, Ostergard, DR: Diagnosis of Lower Urinary Tract Disorders in Postmenopausal Women, Annual Meeting, Society of Obstetricians and Gynecologists of Canada, Toronto, Ontario, Canada, (June), 1982.
 20. Bent, AE, Harris, LR, Richardson, DA, Ostergard, DR: Urethral Closure Pressure Profile in Stress Incontinent and Non Stress Incontinent Women, Proceedings International Continence Society, Twelfth Annual Meeting, Leiden, The Netherlands, (Sept 2-4), 1982.
 21. Richardson, DA, Bent, AE, Ostergard, DR: Comparison of Urodynamic Findings in Patients With and Without Prolapse Who Demonstrate Genuine Stress Incontinence, Proceedings International Continence Society, Twelfth Annual Meeting, Leiden, The Netherlands, (Sept 2-4), 1982.
 22. Bent, AE, Harris, LR, Richardson, DA, Ostergard, DR: Urethral Closure Pressure Profiles in Stress Incontinent and Continent Women, Proceedings

- Gynecologic Urology Society, Santa Barbara, California, (October 25-27), 1982.
23. Richardson, DA, Bent, AE, Ostergard, DR: The Effect of Uterovaginal Prolapse on Urethrovesical Pressure Dynamics, Proceedings Gynecologic Urology Society, Santa Barbara, California, October 25-27, 1982.
 24. Richardson, DA, Bent, AE, Ostergard, DR, Cannon, D: Delayed Complications of the Stamey Needle Urethropexy, Proceedings Gynecologic Urology Society, Santa Barbara, California, October 25-27, 1982.
 25. Bent, AE, Ostergard, DR: The Effect of Aging on Urethral Closure Pressure Profiles in Stress Incontinent and Continent Women, Proceedings Annual Meeting, Society of Obstetricians and Gynecologists of Canada, Vancouver, British Columbia, Canada, June, 1983.
 26. Bent, AE, Ostergard, DR: The Effect of Aging on Urethral Closure Pressure Profiles in Stress Incontinent and Continent Women, Proceedings Gynecologic Urology Society, New Orleans, Louisiana, 1983.
 27. Cutner, LP, Ostergard, DR: The Method of Pereyra Procedure, Proceedings Gynecologic Urology Society, New Orleans, Louisiana, 1983.
 28. Scotti, RJ, Ostergard, DR: Urodynamic Changes in Urethrovesical Function After Radical Hysterectomy, Proceedings Gynecologic Urology Society, New Orleans, Louisiana, 1983.
 29. Scotti, RJ, Bergman, A, Bhatia, NN, Ostergard, DR: Urodynamic Changes in Urethrovesical Function After Radical Hysterectomy. Proceedings Gynecologic Urology Society, Palm Beach, Florida, 1984.
 30. Ostergard, DR: Neuropharmacology, Proceedings Gynecologic Urology Society, Palm Beach, Florida, 1984.
 31. Scotti, RJ, Bergman, A, Bhatia, NN, Ostergard, DR: Urodynamic Changes in Urethrovesical Function After Radical Hysterectomy. Proceedings ACOG, Scottsdale, Arizona, 1984.
 32. Sand, PK, Bowen, LW, Ostergard, DR: Uninhibited Urethral Relaxation: An Unusual Cause of Incontinence, Proceedings International Continence Society, London, England, September, 1985.
 33. Sand, PK, Bowen, LW, Ostergard, DR: The Effect of a Filling Catheter During Urodynamics, Proceedings International Urogynaecological Association, Budapest, Hungary, September 1985.
 34. Bhatia, NN, Bergman, A, Scotti, RJ, Ostergard, DR: Urinary Incontinence Following Radical Hysterectomy, Proceedings International Urogynaecological Association, Budapest, Hungary, September 1985.
 35. Pierson, CA, Meyer, CB, Ostergard, DR: Vesical Instability: A Stress Related Entity, Proceedings International Continence Society, London, England, September 1985.
 36. Sand, PK, Bowen, LW, Ostergard, DR: The Effect of a Filling Catheter During Urodynamics, Proceedings Gynecologic Urology Society, San Diego, California, November 1985.
 37. Sand, PK, Bowen, LW, Ostergard, DR: Uninhibited Urethral Relaxation: An Unusual Cause of Incontinence, Proceedings Gynecologic Urology Society, San Diego, California, November 1985.
 38. Sand, PK, Bowen, LW, Ostergard, DR: The Low Pressure Urethra, Proceedings

ACOG Annual Meeting, New Orleans, Louisiana, May 1986.

39. Bowen, LW, Sand, PK, Ostergard, DR, et al: Urodynamic Effects of a Vaginal Pessary in Women with Genital Prolapse, Proceedings ACOG Annual Meeting, New Orleans, Louisiana, May 1986.
40. Bowen, LW, Sand, PK, Ostergard, DR, Franti, CE: Unsuccessful Burch Retropubic Urethropexy: A Case Controlled Urodynamic Study, Proceedings International Continence Society, Boston, Mass, September 1986.
41. Sand, PK, Bowen, LW, Ostergard, DR: The Low Pressure Urethra as a Factor in Failed Retropubic Urethropexy, Proceedings International Continence Society, Boston, Mass, September 1986.
42. Bowen, LW, Sand, PK, Ostergard, DR, Franti, CE: Urodynamic Effects of a Vaginal Pessary in Women with Genital Prolapse, Proceedings International Continence Society, Boston, Mass, September 1986.
43. Sand, PK, Bowen, LW, Ostergard, DR, et al: Hysterectomy and Prior Incontinence Surgery as Risk Factors for Failure of Retropubic Urethropexy, Proceedings Gynecologic Urology Society, Montreal, Canada, October 1986.
44. Sand, PK, Hill, RC, Ostergard, DR: Supine Urethroscopic and Standing Cystometry as Screening Methods for the Detection of Detrusor Instability, Proceedings Gynecologic Urology Society, Montreal, Canada, October 1986.
45. Bowen, LW, Sand, PK, Ostergard, DR, et al: Correlation of Urethroscopic Findings and Lower Urinary Tract Symptomatology, Proceedings Gynecologic Urology Society, Montreal, Canada, October 1986.
46. Bowen, LW, Sand, PK, Ostergard, DR, et al: Unsuccessful Burch Retropubic Urethropexy: A Case Controlled Study, Proceedings Gynecologic Urology Society, Montreal, Canada, October 1986.
47. Horbach, NS, Blanco, JS, Ostergard, DR, Bent, AE, Cornella JL: A Suburethral Sling Procedure with Polytetrafluorethylene for the Treatment of Genuine Stress Incontinence in Patients with Low Urethral Closure Pressure: A Preliminary Report, Poster Presentation, ACOG, Las Vegas, Nevada, April 1987.
48. Ostergard, DR, Horbach, NS, Bent, AE, Cornella, JL: Gore-Tex Sling Procedure for the Treatment of Genuine Stress Incontinence in Patients with Low Urethral Closure Pressures, Proceedings International Urogynaecological Association, San Francisco, California, August 1987.
49. Horbach, NS, Bent, AE, Cornella, JL, Ostergard, DR: The Low Pressure Urethra in Patients with Genuine Stress Incontinence: Clinical and Urodynamic Characteristics, Proceedings American Urogynecologic Society Annual Meeting, San Francisco, California, September 1987.
50. Sand, PK, Bowen, LW, Ostergard, DR, Bent, AE, Panganiban, R: Cryosurgery versus Dilatation and Massage for the Treatment of the Urethral Syndrome, Proceedings American Urogynecologic Society Annual Meeting, San Francisco, California, September 1987.
51. Horbach, NS, Blanco, JS, Ostergard, DR, Bent, AE, Cornella, JL: A Sub-urethral Sling Procedure with Polytetrafluorethylene for the Treatment of Genuine Stress Incontinence in Patients with Low Urethral Closure Pressure: A Preliminary Report, Proceedings American Urogynecologic Society, San Francisco, California, September 1987.
52. Ostergard, DR: The Unstable Bladder: Medical, Psychological, Electronic and Surgical Therapy, Proceedings International Symposium on Urogynecology,

Zagreb, Yugoslavia, May 1987.

53. Ostergard, DR: The Urethral Syndrome - New Concepts in Diagnosis and Therapy, Proceedings International Symposium on Urogynecology, Zagreb, Yugoslavia, May 1987.
54. Ostergard, DR, Horbach, NS, Bent, AE, Cornella, JL: Gore-Tex Sling Procedure for the Treatment of Genuine Stress Incontinence in Patients with Low Urethral Closure Pressures, Proceedings International Symposium on Urogynecology, Zagreb, Yugoslavia, May 1987.
55. Sand, PK, Bowen, LW, Ostergard, DR, et al: The Effect of Retropubic Urethropexy on Detrusor Instability, Proceedings ACOG District VI Junior Fellows Meeting, Chicago, Illinois, September 1987.
56. Scotti, RJ, Ostergard, DR, Guillaume, A, Kohatsu, KE: Predictive Value of Dynamic Urethroscopy in Urethral Syndrome, Genuine Urinary Stress Incontinence and Vesical Instability, Proceedings American College of Obstetricians and Gynecologists, Boston, Mass, May 1988.
57. Horbach, NS, Ostergard, DR, Bent, AE, Cornella, JL: Complications of Suprapubic Catheter Drainage of the Bladder, Poster Presentation ACOG, Boston, Mass, May 1988.
58. Pierson, CA, Sand, PK, Ostergard, DR, et al: The Correlation Between 12 Hour Pad Tests, Urodynamic and Subjective Grading of Incontinence, Abstracts Annual Meeting of the International Continence Society, Oslo, Norway, September 1988.
59. Sand, PK, Bowen, LW, Ostergard, DR: The Prognostic Significance of Augmentation of Urethral Closure Pressure and Functional Length, Proceedings American Urogynecological Society, Charleston, South Carolina, November 1988.
60. Sand, PK, Brubaker, L, Bowen, LW, Ostergard, DR, Panganiban, R: The Effect of Retropubic Urethropexy on Detrusor Stability. Proceedings American Urogynecological Society, Charleston, South Carolina, November 1988.
61. Scotti, RJ, Ostergard, DR, Guillaume, AA, Kohatsu, KE: Predictive Value of Dynamic Urethroscopy in Urethral Syndrome, Genuine Stress Incontinence and Vesical Instability, Proceedings American Urogynecological Society, Charleston, South Carolina, November 1988.
62. Summitt, RL, Jr, Bent, AE, Ostergard, DR, Harris, TA: Correlation of Preoperative Q-tip Tests with Success Using a Suburethral Sling Procedure for Stress Urinary Incontinence and Low Urethral Closure Pressure, Proceedings American Urogynecological Society, Charleston, South Carolina, November 1988.
63. Cornella, JL, Bent, AE, Ostergard, DR, Horbach, NS: A Prospective Study Utilizing Transdermal Scopolamine in the Treatment of Detrusor Instability, Proceedings American Urogynecological Society, Charleston, South Carolina, November 1988.
64. Sand, PK, Pierson, CA, Ostergard, DR, Atad, J, Panganiban, R: The Correlation Between Pad Tests and Urodynamics. Proceedings American Urogynecological Society, Charleston, South Carolina, November 1988.
65. Summitt, RL, Jr, Bent, AE, Ostergard, DR, Harris, TA: Correlation of Preoperative Q-tip Tests with Success Using a Suburethral Sling Procedure for Stress Urinary Incontinence and Low Urethral Closure Pressure, Int Urogynec J, 1:29, October 1988.

66. Sand, PK, Brubaker, L, Bowen, LW, Ostergard, DR, Panganiban, R: The Effect of Retropubic Urethropexy on Detrusor Stability. Int Urogynec J, 1:33, October 1988.
67. Sand, PK, Pierson, CA, Ostergard, DR, Atad, J, Panganiban, R: The Correlation Between Pad Tests and Urodynamics. Int Urogynec J, 1:33, Oct 1988.
68. Scotti, RJ, Ostergard, DR, Guillaume, AA, Kohatisu, KE: Predictive Value of Dynamic Urethroscopy in Urethral Syndrome, Genuine Stress Incontinence and Vesical Instability, Int Urogynec J, 1:42, October 1988.
69. Bent, AE, Sand, PK, Ostergard, DR: Transvaginal Electrical Stimulation in the Treatment of Genuine Stress Incontinence and Detrusor Instability. Proceedings International Continence Society, September 1989.
70. Summitt, RL, Jr, Bent, AE, Ostergard, DR, Harris, TA: Suburethral Sling Procedure for Genuine Stress Incontinence and Low Urethral Closure Pressure: A Continued Experience, Proceedings 37th Annual Clinical Meeting American College of Obstetricians and Gynecologists, May 22-25, 1989, Atlanta, Georgia.
71. Scotti, RJ, Ostergard, DR, Guillaume, AA, Kohatsu, KE: Predictive Value of Dynamic Urethroscopy in Urethral Syndrome, Genuine Stress Incontinence and Vesical Instability, Proceedings 38th Annual Clinical Meeting American College of Obstetricians and Gynecologists, May 7-10, 1990, San Francisco, California.
72. Ostergard, DR: Surgery for Urinary Incontinence. Proceedings Annual American College of Obstetricians and Gynecologists Clinical Meeting, May 4-5, 1991, New Orleans, Louisiana.
73. Preacher, JF, Luber, KM, Ostergard, DR, Bent, AE: Vaginal Wall Retropubic Urethropexy and Vaginal Retropubic Urethropexy. Twelfth Annual Meeting American Uro-Gynecologic Society, October 23-26, 1991.
74. Sand, PK, Utrie, J, Summitt, R, Jr., Ostergard, DR: The Effect of a Suburethral Sling on Detrusor Instability. 18th Annual Meeting of the International Uro-Gynecologic Association, Nimes, France, September 1993.
75. Swift, SE, Ostergard, DR: Retropubic Vaginal Urethropexy: Results of One Year Follow-up. Poster Abstract-Scientific Meeting of the American Uro-Gynecology Society and the Urodynamics Society, San Antonio, Texas, October 1993.
76. Jensen, JK, Nielsen, FR., Jr., Ostergard, DR: The Role of Patient History in the Diagnosis of Urinary Incontinence. Poster Abstract - Scientific Meeting of the American Uro-Gynecologic Society and the Urodynamics Society. San Antonio, Texas, October 1993.
77. Sand, PK, Richardson, DA, Staskin, DR, Ostergard, DR, Swift, SE, Appell, RA, Whitmore, KE, Lavin, PT: Pelvic Floor Stimulation in the Treatment of Genuine Stress Incontinence: A Multicenter, Placebo Controlled Trial. Poster Abstract - Symposium on Women's Urological Health Research, Bethesda, Maryland, March 1994.
78. Sand, PK, Richardson, DA, Staskin, DR, Ostergard, DR, Swift, SE, Appell, RA, Whitmore, KE, Lavin, PT: Pelvic Floor Stimulation in the Treatment of Genuine Stress Incontinence: A Multicenter, Placebo Controlled Trial. International Continence Society Annual Meeting, Prague, Czech Republic, Printed in Neurology & Urodynamics, August 1994.

79. Sand, PK, Richardson, DA, Staskin, DR, Ostergard, DR, Swift, SE, Appell, RA, Whitmore, KE, Lavin, PT: Pelvic Floor Stimulation in the Treatment of Genuine Stress Incontinence: A Multicenter, Placebo Controlled Trial. American Uro-Gynecologic Society Annual Meeting and International Urogynecological Association Meeting, Toronto, Canada, September 1994.
80. Handa, VL, Jensen, JK, Ostergard, DR: Potential Stress Incontinence in Severe Vaginal Vault Prolapse: The Economic Impact of Preoperative Urodynamics. Poster Abstract. American Uro-Gynecologic Society Annual Meeting, Toronto, Canada, September 1994.
81. Handa, VL, Jensen, JK, Ostergard, DR: The Federal Incontinence Guidelines do not Adequately Triage Women With Symptoms of Stress Incontinence. Annual Scientific Meeting of the American Urogynecologic Society, Toronto, Canada, September 1994.
82. Handa, VL, Jensen, JK, Ostergard, DR: The Effect of Patient Position on Urethral Mobility. Poster Abstract. Annual Scientific Meeting of the American Urogynecologic Society, Toronto, Canada, September 1994.
83. Jensen, JK, Downes, J, Handa, VL, Ostergard, DR: Changes in Detrusor Over-activity Following Surgical Correction of Severe Pelvic Prolapse. Annual Scientific Meeting of the American Urogynecologic Society, Toronto, Canada, September 1994.
84. Swift, SE, Ostergard, DR, Miller, MC, III: Comparison of Stress Leak Point Pressure and Maximal Urethral Closure Pressure in Patients with Genuine Stress Incontinence. Annual Scientific Meeting of the American Urogynecologic Society, Toronto, Canada, September 1994.
85. Weinberger, ME, Ostergard, DR: Postoperative Catheterization, Urinary Retention, and Voiding Dysfunction Following Suburethral Sling Replacement, Annual Scientific Meeting of the American Urogynecologic Society, Toronto, Canada, September 1994.
86. Swift, SE, Ostergard, DR: Evaluation of Current Urodynamic Testing Methods in the Diagnosis of GSI. Annual Scientific Meeting of the American Urogynecologic Society, Toronto, Canada, September 1994.
87. Sand, PK, Ostergard, DR: Urethral-Hymenal Fusion: Effects on Urinary Symptomatology. Annual Scientific Meeting of the American Urogynecologic Society, Toronto, Canada, September 1994.
88. Germain, MN, Handa, VL, Jensen, JK, and Ostergard, DR: Supine Urine Leakage as a Predictive Test for Intrinsic Sphincter Deficiency. Poster Abstract. American Urogynecologic Society 16th Annual Scientific Meeting, Seattle, Washington, October 1995.
89. Handa, VL, Jensen, JK, Germain, MM, Ostergard, DR. Banked Human Fascia Lata for the Suburethral Sling Procedure in Incontinent Women, Presented at the 17th Annual Scientific Meeting. The American Urogynecologic Society, New Orleans, Louisiana, October 4-7, 1996.
90. Noblett KL, Jensen, JK, Ostergard, DR. The Incidence of Urinary Symptoms in Relation to Pregnancy and Delivery in a Predominantly Hispanic Population: A One-Year Follow-up. Presented at the 17th Annual Scientific Meeting, The American Urogynecologic Society, New Orleans, Louisiana, October 4-7, 1996.

91. Germain, MM, Jensen, JK, Handa, VL, Ostergard, DR. Age as a Risk Factor in Surgical Repair of Genital Prolapse, Presented at the 17th Annual Scientific Meeting, The American Urogynecologic Society, New Orleans, Louisiana, October 4-7, 1996.
92. Noblett, KL, Jensen, JK, Ostergard, DR. The Relationship of Body Mass Index to Intra-abdominal Pressure as Measured by Multichannel Cystometry, Poster presentation at the 17th Annual Scientific Meeting, The American Urogynecologic Society, New Orleans, Louisiana, October 4-7, 1996.
93. Noblett, KL, Jensen JK, Germain, MM, Ostergard, DR: Relationship of Cystocele Grade to Bladder Volume Status and Patient Position, Presented at the 18th Annual Scientific Session, The American Urogynecologic Society, Tucson, Arizona, September 25-28, 1997.
94. Noblett, KL, Saenz, R., Jensen, JK, Ostergard, DR: Cystitis Glandularis: Incidence, Presentation and Natural History in a Referral Population, Presented at the 19th Annual Scientific Meeting, The American Urogynecologic Society, Washington, D.C., November 12-15, 1998.
95. Ostergard DR: Evaluation of Pelvic Floor Dysfunction Paravaginal Repair Using a Subvesical Sling, Presented at the XVI FIGO World Congress of Gynecology and Obstetrics, Washington D.C., September 3-8, 2000.
96. Ostergard DR: New Target for Intervention: The Neurourology Connection, Proceedings from symposium held in conjunction with American Urogynecologic Society, Hollywood FL September 11-13, 2003. Published in Advanced Studies in Medicine, Johns Hopkins University School of Medicine, Vol.4, March 2004.
97. Vincent Lucente, Donald Ostergard, G. Willy Davila, Sergio Forero-Schwanhaeuser: Patient-reported outcomes in 3 cohorts of patients defined by length of time as acute or chronic overactive bladder: an analysis of more than 2200 patients in the VESicare Open-Label Trial (VOLT). Presented at the International Continence Society Annual Meeting, Rotterdam, The Netherlands, August 2007.
98. Vincent Lucente Donald Ostergard, G. Willy Davila, Sergio Forero-Schwanhaeuser: Improvement in patient-reported outcomes in 3 cohorts of overactive bladder patients defined as acute or chronic by length of time with the condition: an analysis of patients in the VESicare Open-Label Trial (VOLT). Presented to the American Urogynecology Society, Hollywood, Florida, September, 2007.
99. Ostergard D, Dmochowski R, Hussain I: Significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin. Presented to the Western Section of the American Urological Association, Scottsdale, Arizona, October 2007.
100. Ostergard DR, Togliola MR, Hussain IF. Urgency outcomes for continent and incontinent patients treated with solifenacin for overactive bladder (VESicare Efficacy & Safety in Patients with Urgency Study). . Presented to the Western Section of the American Urological Association, Scottsdale, Arizona, October 2007.
101. Azadi A, Jasinski j, Francis SL, Deveneau N, Lei Z, Heyl A, Ostergard D. Scanning electron microscopy (SEM) of vaginal mesh removed due to pelvic pain. Fem Pelvic Med Recon Surg 2013;19:Supplement, Abstract, S99.
102. Lipetskaia L, Deveneau N, Azadi A, Ostergard D, Francis SL. Low urinary tract dysfunction in endometrial cancer patients after robotic hysterectomy with lymph node dissection. Fem Pelvic Med Recon Surg 2013;19:Supplement, Abstract, S150.
103. Deveneau N, Azadi A, Cornwell L, Lipeskaia L, Francis SL, Ostergard D. Anatomic variation of ureter in patients undergoing sacrocolpopexy: Case

reports and review of the literature. Fem Pelvic Med Recon Surg 2013;19:Supplement,Abstract,S182.

104. Azadi A, Jasinski JB, Francis SL, Lipetskaia LV, Deveneau NE, Yehaneh T, **Ostergard DR**. Evaluation of Surgical Instrument Handling On Polypropylene Mesh Using Scanning Electron Microscopy (SEM). International Urogynecology Association. 38th Annual Meeting. Dublin, Ireland. May 2013.
105. Azadi A, **Ostergard DR**. Vaginal Mullerian Cyst Mimicking Cystocele. American Urogynecologic Society (AUGS). 33rd Annual Scientific Meeting. Chicago, IL. October 2012.
106. Azadi A, Cornwell LB, Diaz S, Lipetskaia L, **Ostergard DR**. The Effect of Body Mass Index (BMI) in Perioperative Outcomes in Patients Undergoing Robotic Assisted Sacrocolpopexy for Pelvic Organ Prolapse. International Urogynecological Association (IUGA). 37th Annual Meeting. Brisbane, Australia. September 2012.
107. Azadi A, Diaz S, Owings E, Lipetskaia L, Yeganeh T, Tate S, **Ostergard DR**. Universal Cystoscopy at the Beginning of Urogynecologic Procedures. American Urogynecologic Society (AUGS). 32nd Annual Scientific Meeting. Providence, RI. September 2011.
108. Azadi A, Francis SL, Taylor KC, Diaz S, Yeganeh, T, **Ostergard DR**. The Anatomical Outcome of Robotic Sacrocolpopexy for Treatment of Pelvic Organ Prolapse: A Comparison of Obese and Non-Obese Patients. International Urogynecology Association. 38th Annual Meeting. Dublin, Ireland. May 2013.
109. Azadi A, Cornwell LB, Diaz S, Lipetskaia L, **Ostergard DR**. The Effect of Body Mass Index (BMI) in Perioperative Outcomes in Patients Undergoing Robotic Assisted Sacrocolpopexy for Pelvic Organ Prolapse. American Association of Gynecologic Laparoscopists. 41st Global Meeting. Las Vegas, NV. November 2012.
110. Azadi A, Jasinski JB, Francis SL, **Ostergard DR**. Scanning electron microscopy (SEM) of vaginal mesh removed due to pelvic pain. American Urogynecology Association. 34th annual scientific meeting. Basic science interest group. Las Vegas, NV. October 2013.

MONOGRAPHS:

1. Ostergard, DR, Gunning, JE: Medical Procedure Manual for Women's Health Care Specialists, University of California Press. (Monograph).
2. Ostergard, DR, et al: Syllabus for Women's Health Care Specialists, University of California Press, 1973.

3. Ostergard, DR: Manual de Gineco-Obstetricia, Editorial Pax-Mexico, Mexico City, 1975 (Spanish Translation of numbers 1 and 2).

FILMS, VIDEOTAPES & OTHER:

1. "Gynecologic Urology Phase III (Urodynamics)", Donald R. Ostergard, M.D., produced by Women's Hospital and Memorial Hospital Medical Center, Long Beach, California and Division of Gynecologic Urology, University of California, Irvine, 1979.
2. "Retropubic Urethropexy", Donald R. Ostergard, M.D., Narender N. Bhatia, M.D., produced by Women's Hospital and Memorial Hospital Medical Center, Long Beach, California and Division of Gynecological Urology, University of California, Irvine, 1980.
3. "Distal Urethral Meatoplasty, Spence Procedure and Dissection of Urethral Diverticulum", Donald R. Ostergard, Narender N. Bhatia, M.D., produced by Women's Hospital and Memorial Hospital Medical Center, Long Beach, California and Division of Gynecologic Urology, University of California, Irvine, 1982.
4. "Urethroscopy", Alfred E. Bent, M.D. and Donald R. Ostergard, M.D., produced by Women's Hospital and Memorial Hospital Medical Center, Long Beach, California and Division of Gynecologic Urology, University of California, Irvine, 1982.
5. "The Pereyra Procedure, A Modification", Larry P. Cutner, M.D. and Donald R. Ostergard, M.D., produced by Women's Hospital and Memorial Hospital Medical Center, Long Beach, California and Division of Gynecologic Urology, University of California, Irvine, 1983.
6. "Evaluation of Urinary Incontinence", Larry P. Cutner, M.D. and Donald R. Ostergard, M.D., produced by Women's Hospital and Memorial Hospital Medical Center, Long Beach, California and Division of Gynecologic Urology, University of California, Irvine, 1983.
7. "Sacrospinous Vaginal Vault Suspension", Donald R., Ostergard, M.D., produced by Women's Hospital and Memorial Hospital Medical Center, Long Beach, California and Division of Gynecologic Urology, University of California, Irvine, 1983.
8. "Practical Applications of the Carbon Dioxide Laser in Gynecology", Peter K. Sand, M.D. and Donald R. Ostergard, M.D., produced by Women's Hospital and Memorial Hospital Medical Center, Long Beach, California and Division of Gynecologic Urology, University of California, Irvine, 1985.
9. "Laser Laparoscopy with KTP Laser", Donald R. Ostergard, M.D., and Alfred E. Bent, M.D., produced by Women's Hospital and Memorial Hospital Medical Center of Long Beach, California and Division of Gynecologic Urology, University of California, Irvine, 1987.
10. "YAG Laser in Gynecology", Donald R. Ostergard, M.D. and Alfred E. Bent, M.D., produced by Women's Hospital and Memorial Hospital Medical Center, Long Beach, California and Division of Gynecologic Urology, University of California, Irvine, 1987.
11. "Sling Procedure", Donald R. Ostergard, M.D. and Alfred E. Bent, M.D., produced by Women's Hospital and Memorial Hospital Medical Center, Long Beach, California and Division of Gynecologic Urology, University of California, Irvine, 1987.

12. "The Gore-Tex Sub-Urethral Sling Procedure", Donald R. Ostergard, M.D. and Hilary Cholhan, M.D., produced by Women's Hospital and Memorial Hospital Medical Center, Long Beach, California and Division of Urogynecology, University of California, Irvine, 1990.
13. "Urogynecology Overview" - Postgraduate Targeted Education Series, Director Roger K. Freeman, M.D. and featuring Donald R. Ostergard, M.D. - Medical Economics Co. 1992.
14. "Medical and Surgical Management of Urinary Incontinence," Donald R. Ostergard, M.D. (Author), W. Glenn Hurt, M.D. (Commentator) Produced by Cine'-Med for American College of Obstetricians and Gynecologists, 1993.
15. "Burch Retropubic Urethropexy", Donald R. Ostergard, M.D. and Steven E. Swift, M.D., produced by Women's Hospital and Memorial Hospital Medical Center, Long Beach, California and Division of Urogynecology, University of Irvine, June 11, 1993.
16. "Sacrospinous Vaginal Vault Fixation", Donald R. Ostergard, M.D. and Steven Swift, M.D., produced by Women's Hospital and Memorial Hospital Medical Center, Long Beach, California and Division of Urogynecology, University of California, Irvine, June 24, 1993.
17. "Urogynecology: Evaluation and Treatment of Urinary Incontinence" Jeffrey S. Levy, M.D., Medical Director. Featuring Bruce Rosenzweig, M.D., Donald R. Ostergard, M.D. and C.Y. Liu, M.D. CD-ROM, IMR, Corporate Technology Ventures and Omnia, Inc. 1995.
18. "Bilateral Sacrospinous Vaginal Vault Fixation", John B. Devine II, M.D., Donald R. Ostergard, M.D., Laurus Medical Corporation, Sept. 1997.
19. Ostergard DR: Advances in Therapies for Stress Urinary Incontinence(SUI)-Focus on the Female Patient, *MedScape*. Posted on-line May 30, 2003.

AUDIOCASSETTES:

"Surgery for Urinary Incontinence", ACOG Update, Donald R. Ostergard, M.D. (Moderator), Arie Bergman, M.D. and W. Glenn Hurt, M.D. (Discussants) published by Medical Information Systems, Inc. for the American College of Obstetricians and Gynecologists, 17:4, 1991.

Exhibit B

Ostergard's Medical Literature As of May 14, 2014

1. Abed H. IUJ 2011;22:789.
2. Abdel-Fattah M. BJOG 2008;115:22.
3. Abdel-Fattah M. BJOG 2006;98:594.
4. Abou-ZEla A. Adv Urol 2009;34:1268.
5. Abrams P. Eur Urol 2011;60:1207.
6. ACOG 2011 Committee Opinion 513.
7. ACOG POP Pract Bull Feb 2007
8. Afonso J. Act Bioeng Biomech 2009;11:27.
9. Afonso J. Int Urogyn J 2008;19:375
10. Al Nakib M. Prog Urol 2005;15:707
11. Alexander J. Ann Surg 1967;165:192.
12. Ali S. Internat Urogyn J 2006;17 (Suppl 2):S171.
13. Alperin M. Internat Urogyn J 2008;19:1617.
14. Alperin M. IUJPF 2008;19:1617.
15. Altman D. IUJPF 2008;19:787
16. Altman D. Obstet Gynec 2006;107:59.
17. Altman D. Obstet Gynec Survey 2005;60:753.
18. Amblard J. IUJ 2006;17 (suppl 1):S164
19. Amblard J. J Gynecol Obstet Biol Reprod (Paris) 2009;38:186.
20. Amblard J. Pelv Perineol 2007;2:3.
21. Amid P. Hernia 1997;1:15.
22. Amid P. Langenbecks Arch fur Chir 1994;379:168.
23. An YH. J Biomed Mater Res (Appl Biomater) 1998;43:338.
24. Anderson J. Biomaterials 2007;28:5114.
25. Anderson J. Ann rev Mater Res 2001;31:81.
26. Anderson J. Semin Immunol 2008;20:86.
27. Anding R. Biomed Res Int 2013;2013:401417.
28. Andonian S. Eur Urol 2007;52:245.
29. Atherton MJ. BJOG 2005;112:534.
30. Anger J. Curr Urol Rep 2007;8:394.
31. Araco F. Internat Urogyn J 2008;19:473.
32. Araco F. Acta Ob Gyn 2009;88:772.
33. Argirovic R. Eur J Ob Gyn Repro Biol 2001;153:104
34. Argirovic R. Vojnosanit Pregl 2011;68:583
35. Aungst MJ. Am J Obstet Gynec 2009;201:73.e1-7
36. Aydinuraz K. J Surg Res 2009;157:e79.

37. Azadi A. IUJ 2014;25:651.
38. Azais H. IUJ 2012;23:1421
39. Babalola E. IUJ 2005;27:1.
40. Baessler K. Curr Opin Obstet Gynec 2006;18:560.
41. Baessler K. Obstet Gynec 2005;106:713.
42. Baessler K. World J Urol 2011;Nov 16 epub
43. Bafghi A. BJOG 2005;112:376.
44. Bafghi A. Eur J Obstet Gynec 2005;122:232.
45. Bafghi A. J Gynecol Obstet Biol Reprod (Paris) 2009;38:77
46. Balakrishnan S. Aust NZ J Obstet Gynec 2007;47:496.
47. Balakrishnan S. J Ob Gyn 2008;28:618.
48. Balique J. Hernia 2005;9:68.
49. Benassi G. IUJ 2007;18:697.
50. Bank H. Contraception 1984;29:65.
51. Barber M. Obstet Gynec 2008;111:611
52. Barber M. Obstet Gynec 2009;114:600
53. Barksdale PA. IUJ PFD 1997;8:121.
54. Barone W. Fem Pelvic Med Reprod Surg 2013;19:p. S56
55. Barry C. IUJ PFD 2008;19:171.
56. Bartelink L. Int Urogyn J 2011;22:889
57. Basu S. NEJM 2012;367:485
58. Bazi T. Eur Urol 2007;51:1364.
59. Beets G. Eur J Surg 1996;162:823.
60. Bekker M. Int Urogyn J 2010;21:1301
61. Bekker M. J Sex Med 2012;9:1566.
62. Bellon J. Biomat 1998 ;19 :669
63. Bellon J. Br J Surg 2004;91:489.
64. Bellon J. Biomat 2001 ;22 :2021.
65. Belot F. Gynecol Obstet Fertil (Fr) 2005;33:970.
66. Benassi G. Int Urogyn J 2007;18:697
67. Benhaim Y. J Gynecol Obstet Biol Repro (Paris).2006;35:219.
68. Bent A. Am J Obstet Gynec 1993;169:1198.
69. Blaivas J. J Urol 1995;154:1015.
70. Blandon R. Internat Urogyn J 2009;20:523.
71. Blandon RE. IUJ 2009;20:523.
72. Blandon R. Obstet Gynec 2009;113:601.
73. Blomstedt B. Acta Chir Scand 1977;143:71.
74. Bollapragada S. BJOG 2007;114:917.

75. Boukerrou M. Eur J Obstet Gynec 2007;134:262.
76. Boulanger L. Internat Urogyn J 2008;19:827.
77. Boyles S. Internat Urogyn J 2007;18:19.
78. Boyles S. Obstet Gynec 2008;111:969.
79. Boyles SH. Obstet Gynec 2008;111:969
80. Bracco P. Hernia 2005;9:51.
81. Brennand EA. BJOG 2014 ;13 Jan 2014
82. Brodbeck W. J Lab Clin Med 2002;139.
83. Brubaker L. Fem Pelvic Med Recon Surg 2010;16:9.
84. Brubaker L. Am J Ob Gyn 2011;205:498.
85. Bryans F. Am J Ob Gyn 1979;133:292
86. Bucknall T. Euro Surg Res 1983;15:59.
87. Butrick C. Internat Urogyn J 2010;21:133.
88. Cacciari I. App Environ Bicrobial 1993;59:3695
89. Califano J. J Pelv Med Surg 2008;14:273 abst
90. Caquant F. Eur Urol 2005;47:108
91. Carey M. BJOG 2009;116:1380.
92. Cayrac M. IUJ 2012;23:335.
93. Cervigni M. Eur J Ob Gyn Repro Biol 2011;156:223.
94. Cetinel B. Curr Opin Obstet Gynec 2005;17:530.
95. Chai J. Food Drug Law J 2000;55:58
96. Chai TC. J Urol 2014;191:703.
97. Chen C. Clin Obstet Gynec 2007;50:383.
98. Chen G. Am J Ob Gyn 2007;197:666.
99. Chen HY. IUJ PFD2008;19:117.
100. Cheng-Liao A. Neurourol Urodyn 2008; supplement:abstract 457
101. Cheng-Yu, L. IUJ 2011;22-233.
102. Chi M. J Min Invas Gyn 2012; Jan 26 epub
103. Chmielewski L. Am J Ob Syn 2011;205:69
104. Chmielewski L. Int Urogyn J 2010;21 (Suppl 1):S114
105. Choi S. Eur Urol 2008;7:288.
106. Chowbly P. Surg Endosc 2010;24:3073
107. Chu C. Am J Surg 1984;147:197
108. Chu C. J Appl Biomat 1993;4:169
109. Chu LC. IUJ 2011 Aug 6
110. Cindolo L. Minerva Urol Nefrol 2004;56:89
111. Claerhout F. Am J Obstet Gynec 2008;198:94.
112. Clave A. Internat Urogyn J 2010;21:261.

113. Clemens JQ, Urology 2000;56:589
114. Clemons JL. Fem Pelv Med Recon Surg 2013;19:191.
115. Cobb W. J Surg Res 2006 ;136 :1.12
116. Coda a. Hernia 2003;7:29. SEM's with degraded prolene mesh
117. Colin X. Compos Sc Tech 2005;65:411
118. Collinet P (Cosson) Neurourol Urodyn 2004; 23:supplement:abstract 336.
119. Collins SA. IUJ 2009;20:505.
120. Corcos J. Eur Urol 2002;52:145.
121. Cosson M. Internat Urogyn J 2003;14:169.
122. Cosson M. IUJ 2006;17 (Suppl 1):S139. Abst
123. Cosson M. J Gynec Obstet Biol Reprod (Fr) 2004;33:559.
124. Cosson M. Neurourol Urodyn 2005;24: supplement:abstract 121.
125. Cosson M. Neurourol Urodyn 2005;24:590
126. Cosson M. Neurourol Urodyn 2010; 29:supplement:abstract 56.
127. Costa L. Biomaterials 2002;23:1613.
128. Costa P. Eur Urol 2004;46:102
129. Costello C. J Biomed Mater Res Part B: Appl Biomater 2007;83B:44.
130. Costello C. Surg Innov 2007 ;14 :168.
131. Coughlin R. J Biomat Sci Polym Ed. 1999;10:827.
132. Coutty N. IUJ 2006;17 (Suppl 2):S321.
133. Cozad M. J Biomed Mater Res Part B: Appl Biomater 2010;94B:455.
134. Culligan P. Am J Obstet Gynec 2002;187:1473
135. Culligan P. Infect Dis Obstet Gynec 2003;1 :161.
136. Culligan P. Am J Ob Gyn 2010 ;203 :506.
137. Cumberland V. Med J Australia 1952;1:143.
138. Daneshgari F. J Urol 2008;180:1890.
139. Davila G. Internat Urogyn J 2006;17:S51.
140. Delorme E. Prog en Urol 2001;11:1306.
141. De Leval. Eur Urol 2004;44:724
142. De Ridder D. Curr Opin Urol 2008;18:377.
143. de Tayrac R. Int Urogyn J 2011;22:775
144. de Tayrac R. Internat Urogyn J 2006;17:100.
145. de Tayrac R. IUJPF 2006;17:483.
146. de Tayrac R. J Gynecol Obstet Biol Repro (Paris) 2002;31:597
147. de Tayrac R. J Repro Med 2005;50:75
148. de Tayrac R. Gyn Ob Fertil 2004;32:1031
149. de Tayrac R. Gyn Ob Fertil 2004;32:104
150. de Tayrac R. IUJ 2007;18:251.

151. de Tayrac R. IUJ 2013;24:1651.
152. De Tayrac. IUJ 2010;21:293.
153. De Tayrac. IUJ 2009;20(Suppl 2):S239.
154. Debodinance P. Eur J Obstet Gynec 1999 ;87 :23
155. Debodinance P. J Gynecol Obstet Biol Reprod (Paris) 2006;35:429
156. Debodinance P. J Gynecol Obstet Biol Reprod (Paris) 2007;36:267
157. Debodinance P. J Gynecol Obstet Biol Reprod (Paris) 2010;39:507
158. Debova E. Bull Exp Biol Med 2006;142:719.
159. Deffieux X. IUJ 2012;Apr 18.
160. Deffieux X. IUJPDF 2007;18:73.
161. Deffieux X. J Gynecol Obster Biol Reprod (Paris) 2006;35:678
162. Deffieux X. J Gynecol Obster Biol Reprod (Paris) 2011;40:82
163. Deffieux, X J Gynecol Obstet Biol Repro (Paris) 2005;34:745
164. Deitz H. Internat Urogyn J 2003;14:239.
165. deLandshere L. Am J Obstet Gynec 2012;206:83.
166. Deligiannidis N. New Zea Med J 2008;121:19
167. Delorme E. Prog Urol 2001;11:1306.
168. Delorme E. Eur Urol 2004;45:203
169. Delorme E. Prog Urol 2003;13:656
170. Deng D. Neurourol Urodyn 2007;26:46.
171. Deprest J. Internat Urogyn J 2006;17:S16.
172. DeSouza R. IUJ Pelvic Fl Dysfxn 2007;18:817
173. Deval B. Europ Urol 2006;49:373.
174. Deval B. Pelviperin 2008;27:68 abstract 84
175. Dindo D. Ann Surg 2004;240:205
176. Dobson A. Internat Urogyn J 2006;18:27.
177. Domingo S. J Urol 2005;173:1627.
178. Dwyer P. Internat Urogyn J 2006; 17:S10.
179. Dwyer P. Internat Urogyn J 2014;25:567.
180. Eboue C. Internat Urogyn J 2010;21:85.
181. Ek M. Neurourol Urodyn 2010;29:527.
182. Elmer C. J Urol 2009;181:1189.
183. Elmer C. J Urol 2009;181:1189.
184. Elmer C. Obstet Gynec 2009;113:117. 261 pts
185. Engelsman A. Brit J Surg 2008;95:1051.
186. Falagas M. Clin Microbiol Infect 2005 ;11 :3.
187. Falagas M. Eur J Obstet Gynec 2007;134:147.
188. Farnsworth B. Pelviperineology 2007;26:70.

189. Fattah M. BJU Internat 2006;98:594.
190. Fatton B. IUJ 2006;17 (Suppl 2):S212.
191. Fatton B. IUJ PFD 2007;18:743.
192. Fayyad A. IUJ 2011;22:157.
193. FDA Update on Surgical Mesh: July 2011 and 2008
194. Feifer A. Internat Urogyn J 2007;18:1087
195. Feiner B. BJOG 2009;116:15
196. Feiner B. BJOG 2009;116:15.
197. Feiner B. Internat Urogyn J 2010;21:203.
198. Feiner B. IUJ 2012;23:279
199. Feiner B. IUJ 2011;Oct 6
200. Feiner B. Obstet Gynec 2010;115:325.
201. Feiner B. Obstet Gynec 2010;115:325.
202. Feola A. BJOG 2013;120:224.
203. Finamore PS. IUJ 2010;21:285.
204. Finaqmore P. Internat Urogyn J 2010;21:285.
205. FitzGerald M. J Urol 2010;183:431.
206. Foon R. Internat Urogyn J 2008;19:1697.
207. Frankel J. Internat Urogyn J 2007;18:1249.
208. Freeman R. Internat Urogyn J 2009;20:889.
209. French Health Authorities Report, November 2006.
210. Frostling H. Scand J Work Environ Health 1984;10:163.
211. Gagnon LO. Can Urol Assn J 2010;4:188.
212. Game X. J Urol 2004;171:1629.
213. Gandhi S. IUJ 2006;17:125.
214. Ganj F. Int Urogyn J 2009;20:919
215. Garcia S. Arch Esp Urol 2011;64:620
216. Garcia-Urena M. Am J Surg 2007;193:538.
217. Gauruder-Burmester A. Eur J Ob Gyn Repro Biol 2009;142:76.
218. Gauruder-Burmester A. IUJ PFD 2007;18:1059.
219. Geoffrion R. J Ob Gyn Can 2008;30:143.
220. George A. Fem Pel Med 2013;19:202.
221. Givenin M. J Ob Gyn Can 2011;33:36
222. Glavind K. Internat Urogyn J 2004;15:179.
223. Glavind K. Internat Urogyn J 2008;19:1081.
224. Goldberg RP. Ob Gyn 2001;98:199.
225. Goldman H. IUJ 2005;17:295.
226. Goldman H. J Urol 2010;183:430.

227. Goldstein HS. *Hernia* 1999;3:23
228. Gomelsky A. *J Urol* 2007;178:1171.
229. Gomelsky A. *J Urol* 2004;171:1581.
230. Gomelsky A. *IUJ PFD* 2007;18:1337.
231. Gonzales R. *Word J Surg* 2005;29:1038.
232. Greca F. *Hernia* 2001;5:59-64.
233. Grgic O. *Int J Ob Gyn* 2012;116:72.
234. Grimes C. *IUJ* 2012;23:597.
235. Gristina A. *Science* 1987;237:1588.
236. Groutz A. *Neuro Urol* 2002;21:470.
237. Gugumus F. *Polymer Degrad Stabil* 1993;40:167
238. Gutman R. *Obstet Gynec* 2013;122:770.
239. Hal C. *Int Urogyn J* 2009;20:1519
240. Halaska M. *Ceska Gynekol* 2010;75:126.
241. Hefni M. *Arch Gynecol Obstet* 2007;276:499.
242. Hermieu JF. *Prog Urol* 2003;13:636.
243. Herschorn S. *Curr Opin Urol* 2007;17:408.
244. Higgins D. *Am J Path* 2009;175:161.
245. Higgins E. *Am J Obstet Gynec* 2009;210:505.
246. Hinoul P. *IUJ PFD* 2007;18:1201.
247. Hiltunen R. *Obstet Gynec* 2007;110:455
248. Holli I. *Bratisl Lek Listy* 2009;110:692.
249. Homsy C. *JADA* 1973;86:817.
250. Horbach N. *Obstet Gynec* 1988;71:648.
251. Houwert R. *Am J Ob Gyn* 2009;Oct 19 epub
252. Huang WC. *IUJ* 2011;22:197.
253. Huber A. *J Biomed Mat Res Pt B* 2012;1003:145
254. Huffaker RK. *IUJ PFD* 2009;20:1383
255. Hung M. *Int Urogyn J* 2004;15:399
256. Hurtado E. *IUJ PFD* 2009;20:11.
257. Hussain S. *Nature* 2003;3:296.
258. Hviid U. *Internat Urogyn J* 2010;21:529.
259. Iglesia C. *Ob Gyn* 2010;116:293.
260. Igijatovic I. *Eur J OB Gyn Repro Biol* 2008;141:79
261. Igijatovic I. *Eur J OB Gyn Repro Biol* 2010;150:97
262. Igijatovic I. *IUJ PFD* 2007;18:1495
263. Ismail S. *J Obstet Gynec* 2007;27:94
264. *IUJ Supplement 1, 2006.*

265. Jacquetin B. IUJ 2009;20:893
266. Jacquetin B. J Gynecol Obstet Biol Repro (Paris) 2004;33:577
267. Jacquetin B. Neurourol Urodyn 2006; supplement:abstract 291
268. Jakus M. Obstet Gynec Survey 2008;63:253.
269. Jallah ZC. Fem Pelvic Med Reprod Surg 2013;19:p. S54
270. Jaquetin B. Internat Urogyn J 2009;20:893.
271. Jeffrey ST. IUJ 2013; Jul 2
272. Jeon M. Am J Ob Gyn 2008;199:76
273. Jia X. BJOG 2008;115:1350.
274. Jo H. J Ob Gyn Res 2007;33:700
275. Jones KA. IUJ 2009;20:847.
276. Jongebloed W. Doc Ophthalmol 1986;64:143-52.
277. Jorgensen L. Surg 1998;123:450
278. Julian T. Am J Obstet Gynec 1996;175:1472.
279. Juma S. Neurouro Urodyn 2007;26:37
280. Junge K. Hernia 2001;5:113.
281. Junge K. Hernia 2005;9:115.
282. Junge K. Hernia 2005;9:212.
283. Kannan K. J Ob Gyn 2010;30:524.
284. Kapoor D. Internat Urogyn J 2010;21:37.
285. Karateke A. J Minim Invasive Gynecol 2010;7:232.
286. Karsenty G. Internat Urogyn J 2007;18:207.
287. Kasturi S. Am J Obstet Gynec 2010;203:504.e1-5.
288. Katz S. Ann Surg 1981;194:35
289. Kaufman Y. IUJ 2011;22:307.
290. Kaupp H. Arch Surg 1979;114:1419.
291. Kavvadias T. Internat Urogyn J2009;20:1473.
292. Keys T. Urology 2012;80:237
293. Khandwola S. Int Urogyn J 2011;22:1405
294. Khanuengkitkong S. IUJ 2012;June 27.
295. Khatoon N. J Basic Micro 2013;53:1.
296. Kim T. Korean J Urol 2008;49:844.
297. Kim T-H. IUJ 2014;25:695.
298. King A. Eye (Lond) 1994;8:676.
299. Klinge U. Biomaterials 2002;23:3487
300. Klinge U. Chirurg 1996;67:229.
301. Klinge U. Eur J Surg 1998;164:965.
302. Klinge U. J Biomed Mater Res 2002;63:765.

303. Klinge U. J Surg Res 2002;103:208.
304. Klosterhalfen B. Biomaterials 1998;19:2235.
305. Klosterhalfen B. Chirurg 2000;71:43.
306. Klosterhalfen B. Expert Rev Med Devices 2005;2:103.
307. Kociszeski J. IUJ 2010;21:795.
308. Krause H. Aust Nz J Obstet Gynecol 2006;46:42.
309. Krause H. Curr Opin Obstet Gynec 2009;21:419.
310. Krause H. Internat Urogyn J 2008;19:1677.
311. Krause H. Neurourol Urodyn 2004;23:425.
312. Krauth JS. Eur Urol 2005;47:102.
313. Lau HY. Eur J Ob Gyn Repro Biol 2011;156:228.
314. Lazarou G. Pelvic Med Surg 2005;11:297.
315. Lazarou G. IUJ PFD 2008;19:649.
316. Le T. Curr Opin Obstet Gynec 2007;19:480.
317. Lensen E. Eur J Ob Gyn Repro Biol 2012 ;Mar 5 epub
318. Letouzey V. Internat Urogyn J 2009; 20 (Suppl 2):S73.
319. Letouzyey V. Eur J Obstet Gynecol Repro Biol 2010;151:101
320. Liang C. J Gyn Obstet 2011;112:182
321. Liang R. Fem Pelvic Med Reprod Surg 2013;19:p. S58
322. Liapis A. Eur Urol 2002;41:469.
323. Liapis A. Gyn Ob Invest 2006;62:160.
324. Liebert T. j Biomed Mater Res 1976 ;10 :939
325. Lim YN. Aust NZ J Obstet Gynec 2005 ;45 :52.
326. Lim YN. IUJ 2010 ;21 :1157.
327. Lin T. J Min Inv Gyn 2010;17:473
328. Littman P. The Female Patient 2009;34:2.
329. Littman PM. Female Patient 2009;34:2
330. Lo TS. J Minim Invasive Gynecol 2010;17:473.
331. Lo Ts. IUJ 2011;22:299.
332. Long C. Curr Op Ob Gyn 2009;21:342
333. Long CY. IUJ 2011;22:233.
334. Lord HE. BJU Int 2006;98:367.
335. Lowery W. Internat Urogyn J 2010;21:125.
336. Lowman JK. Am J Obstet Gynec 2008;199:707.e1-6
337. Lucenti V. Neurourol Urodyn 2005; supplement:abstract 406.
338. Lucioni A. Can J Urol 2008;15:4004—12 pts for 42 weeks
339. Luck A. Internat Urogyn J 2008;19:795.
340. Lui X. Zhorghua Yi Xue Za Chi 2010;90:2907

341. Lukban JC. IUJ 2012;23:1314.
342. Lukban JC. Ob Gyn Internat 2012;354897.
343. Mahakkanukrauh P. Clin Anat 2005;18:200.
344. Mahdy A. IUJ PFD 2008;19:1647.
345. Maher C. Cochrane Database of Systematic Reviews 2009;Issue 3.
346. Maher C. Cochrane Database of Systematic Reviews 2010;Apr 14.
347. Maher C. Cochrane Database of Systematic Reviews 2007;July 18.
348. Maher C. Am J Obstet Gynec 2004;190:20.
349. Maher C. Neurourol Urodyn 2008;27:3.
350. Mahmoud W. J Biomet Sci Poly Ed 1993;4:567.
351. Mahmoud WM. J Biomater Sci Polym Ed 1996;7:751.
352. Mamy L. Internat Urogyn J 2009;20 (Suppl 2):S73.
353. Manchana T. IUJ 2007;18 (Suppl 1):S54
354. Mandell G. J Cardiovasc Pharmacol 1995;25 (Suppl 2):S2
355. Mani D. Fem Pelvic Med Reprod Surg 2013;19:p. S89
356. Marcus R. J Chromatogr A 2003;986:17.
357. Margulies R. Am J Obstet Gynec 2008;199:678.
358. Marques AL IUJ Pelvic Fl Dysfxn 2007;18:821
359. Martan A. Ceska Gynekol 2010;75:118.
360. Mathe ML. Gynecol Obstet Fertil 2007;35:398
361. Matyszewski A. Prz Menopauz 2006;4:239
362. McDermott C. Aust New Z J Ob Gyn 2011;51:61
363. McIntyre M. Curr Opin Urol 2010;20:490.
364. Melki E. Gynecol Obstet Fertil 2007;35:96
365. Melki E. Gynecol Obstet Fertil 2007;35:96
366. Mellior G. IUJ 2004;15:227
367. Mendonca TM. IUJ 2011;22:37
368. Merritt K. J Biomat Applic 1991;5:185
369. Merritt K. J Biomed Mater Res 1999;44:261.
370. Meschia M. Am J Obstet Gynec 2004;190:609.
371. Meschia M. Am J Obstet Gynec 2006;195:1338.
372. Meschia M. IUJ 2007;18 (Suppl 1):S51
373. Meschia M. J Urol 2007;177:192.
374. Miedel A. Internat Urogyn J 2008;19:1593.
375. Milani A. Internat Urogyn J 2009;20:1203.
376. Milani AL. Am J Obstet Gynec 2011;204:74.e1-8.
377. Milani AL. IUJPFD 2009;20:1203.
378. Milani R. BJOG 2005;112:107.

- 379. Miller D. Fem Pelvic Med Repro Surg 2011;17:139
- 380. Miller D. IUJ 2009;20(Suppl 2):S215-6.
- 381. Miller D. IUJ 2009;20(Suppl 2):S73-4.
- 382. Miller K. J Biomed Meter Res 1988;22:713.
- 383. Miniffee S. Ob Gyn 2011;118:1337
- 384. Moalli P. IUJ 2014;25:573.
- 385. Moalli P. IUJ 2008;19:655.
- 386. Mokrzycki ML. IUJPF 2007;18:813
- 387. Moore R. Scient World J 2009;9:163.
- 388. Moore R. IUJ 2012;23:85.
- 389. Moore R. IUJ 2012;23:1379.
- 390. Moore RD. IUJ 2010;21:545.
- 391. Moore RD. Adv Urol 2009;Aug 24.
- 392. Morgan J. J Urol 1995;154:1013.
- 393. Morreim H. Ann Thorac Surg 2006;82:1957.
- 394. Morrisroe S. Curr Opin Urol 2010;20:275
- 395. Mourtzinis A. Cur Opin Ob Gyn 2006;18:555
- 396. Mucowski S. Am J Obstet Gynec 2010;203:103.
- 397. Muhl T. J Biomat Res Pt B 2008;84B:176.
- 398. Murray S. IUJ 2011;22:447.
- 399. Murphy M. Obstet Gynec 2008;1112:1123.
- 400. Naidu A. Aust NZ J ob Gyn 2005;45:446.
- 401. Natale F. Internat Urogyn J 2009;20:75.
- 402. Naumann G. IUJ 2006;17(Suppl 2):S94
- 403. Nazemi T. Indian J Urol 2007;23:153.
- 404. Nechiporenko NA. Urologiia 2010;Jan-Feb:25.
- 405. Nejadnik MR. Biomat 2008;29:4117.
- 406. Nerli R. Indian J Urol 2009;25:321
- 407. Neuman M. Harefuah 2007;146:923
- 408. Neuman M. Urology 2012;79:1020
- 409. Nguyen J. Obstet Gynec 2008;111:891.
- 410. Nieminen K. Acta Ob Gyn 2003;82:471
- 411. Nieminen K. Am J Obstet Gynec 2010;203:235.
- 412. Nieminen K. IUJ 2008;19:1611.
- 413. Niro J. Gynecol Obstet Fertil 2010;38:648
- 414. Nolfi A. Fem Pelvic Med Reprod Surg 2013;19:p. S98
- 415. North C. BJOG 2010;117:356.
- 416. Novara G. Eur Urol 2008;53:288.

417. Novi JM. IUJ PFD 2007;18:1163.
418. Ogah J. Coch Data System Rev 2009, Issue 4.
419. Olsen A. Ob Gyn 1997;89:501
420. Olsson I. IUJ 2010;21:679.
421. Onol F. Urology 2012;80:273
422. Onol Y. BJOG 2011;118:1180
423. Ordorica R. BJUI 2008;102:333
424. Orenstein S. Hernia 2010;14:511.
425. Osterberg B. Acta Chir Scand 1979;145:431-4.
426. Osterburg B. Acta Chir Scand 1983;149:663-8.
427. Osterburg B. Acta Chir Scand 1983;149:751-7.
428. Ostergard D. Internat Urogyn J 2002;13:1.
429. Ostergard D. Internat Urogyn J 2007;18:591.
430. Ostergard D. Internat Urogyn J 2010;21:1181.
431. Ouzaid I. Prog Urol 2010;20:578
432. Oversand SH. IUJ 2014;25:81.
433. Ozel B. Internat Urogyn J 2010;21:121
434. Pacquee S. Acta Obstet Gynec Scand 2008;87:972.
435. Padmanabhan P. J Urol 2012 ;187 :1685
436. Palma PC. Int Braz J Urol 2002 ;28 :458.
437. Palma P. Actas Urol Esp 2005 ;29 :89.
438. Papadimitriou J. Hernia 2005 ;9 :75.
439. Papadimitriou J. Proceeedings 6th Annual Meeting AAVIS, 2004.
440. Paparella R. IUJ 2006;17(Suppl 2):S199
441. Paraiso M. Obstet Gynec 2004;104:1249.
442. Paraiso M. Am J Obstet Gynec 2006;195:1762.
443. Pariente JL. Prog Urol 2005;15:1106
444. Paris-Browne P. Pelviperineology 2007;26:124.
445. Patel H. Int Urogyn J 2012;Mar 20 epub
446. Peterson T. Internat Urogyn J 2010;21:483.
447. Petros P. Aust NZ J Obstet Gynec. 1999;39:354.
448. Petros P. BJOG 1999;106:345.
449. Petros P. Hernia 2005;9:75.
450. Petros P. Internat Urogyn J 1997;8:270.
451. Petros P. Internat Urogyn J 1998;9:19.
452. Petros P. Pelviperineology 2007;26:136.
453. Petros P. Neuro Urol Urodyn 2012;DOI 10.1002/nau.
454. Pierce L. Am J Obstet Gynec 2009;200:546.

455. Pigne A. Arch Esp Urol 2011 ;64 :168.
456. Piguet P. J Exp Med 1987;166:1280.
457. Porena M. Eur Urol 2007;52:1481.
458. Poulose T. BJOG 2010;117:369.
459. Prieto A. Anal Chim Acta 2012 ;716 :119.
460. Queimadelos. ICS/IUGA Abstract #59.
461. Quiroz L. Internat Urogyn J 2008;19:261.
462. Raalte H. IUJ 2007;18 Suppl 1):S49.
463. Ramanah R. Int Urogyn J 2010;21:1151
464. Rane A. Aust NZ J Ob Gyn 2008;48:427.
465. Rapp DE. Nat Clin Prac Urol 2008;5:194.
466. Rardin C. J Min Inv Gyn 2009;16:84.
467. Rardin C. J Min Inv Gyn 2009;16:360.
468. Raz S. Urology 2008;72:1044.
469. Rechberger T. Ginek Pol 2008;79:835.
470. Rechberger T. Internat Urogyn J 2003;14:432.
471. Rechberger T. IUJ 2007;18(Suppl 1):S149.
472. Reisenauer C. Eur J Obstet Gynec Repro Biol 2007;131:214
473. Reisenauer C. IUJ 2007;18:343.
474. Reitsma A. J Am Coll Surg 2005;200:103.
475. Reslinski A. Hernia 24 Dec 2013
476. Reynolds W. J Urol 2012;187:1680.
477. Ridgeway B. Am J Ob Gyn 2008;199:703.
478. Ricetto. Internat Urogyn J 2008;19:1117.
479. Ricci Arriola P. Actas Urol Esp 2008;32:827.
480. Richter HE. NEJM 2010;362:2066.
481. Ridgeway B. Am J Obstet Gynec 2008;199:703.
482. Riva D. IUJ 2006;17(Suppl 2):S93
483. Robert M. IUJ 2013;24(Suppl 1):S239-40.
484. Robert M. Obstet Gynec 2014;123:288.
485. Rodehever G. Internat Urogyn J 2006;17(Suppl1):S31S
486. Rodriguez L. J Urol 2003;170:857.
487. Rodriguez L. J Urol 2004;172::210.
488. Rodriguez L. Urology 2005;66:57.
489. Rodriguez L. Tech Urol 2001;7:87.
490. Rodriguez L. Urology 2001;58:783.
491. Rogowski A. IUJ 2013;24:2087
492. Roos D. Klin Wochenschr 1991;69:975.

493. Rosengren A. J Biomed Mater Res A 2003;67:918.
494. Roshanravan SM. Am J Ob Gyn 2007;197:660.
495. Ross J. J Min Inv Gyn 2008;15:459.
496. Ross S. Obstet Gynec 2009;114:1287.
497. Roth C. Curr Opin Urol 2006;16:234.
498. Roy S. J Sex Med 2012;Feb 21, epub
499. Rudnicki M. BJOG 2013;1 Oct 2013.
500. Rutman M. J Urol 2006;175:1794.
501. Rutman M. J Urol 2006;175:610.
502. Sachdeva A. Surg Cl N Am 2007;87:753.
503. Salvatore S. Neurourol Urodyn 2009;28:301.
504. Sanses TV. Am J Obstet Gynec 2009;201:519.e1-9.
505. Sarbold T. Internat Urogyn J 2006;17:S26.
506. Savary D. J Obstet Gynec Repro Biol 2009;38:11.
507. Scales J. Proc Royal Soc Med 1953;46:647,
508. Scales J. Phys Ther 1950 ;36 :83
509. Scales J. Lancet 1950 ;Apr 29 :796
510. Scales J. J Bone Jt Surg 1956 ;38B :754.
511. Schacktrupp A. Br J Surg 2003;90:114.
512. Schraut W. Cytokine 1997;9:206.
513. Serbetci K. Am J Surg 2007;194:375.
514. Sergeant F. Acta Obstet Gynec 2010;89:223,
515. Shaffer RM. Fem Pelvic Med Reprod Surg 2013;19:p. S75
516. Shek KL. Ultrasound Ob Gyn 2008;32:82.
517. Siegel A. Urology 2005 ;66 :995.
518. Siegel A. IUJ PFD 2006 ;17 :661.
519. SIFUD Mentor poster, no authors, 2002
520. Simon M. Eur J Ob Gyn Repro Biol 111;158:104
521. Siniscalchi RT. IUJ 2013;24:1747.
522. Sivaslioglu A. Internat Urogyn J 2007;18:1015
523. Sivaslioglu A. Internat Urogyn J 2008;19:417.
524. Slack M. Internat Urogyn J 2006;17:106.
525. Sokol A. Am J Ob Gyn 2011;205:epub
526. Sokol A. Am J Obstet Gynec 2012;206:86
527. Sola Dalenz V. Actas Urol Esp 2007;31:850
528. Sola V. Int Braz J Urol 2006;32:410
529. Song Y. Int J Gynec Obstet 2009;106:53.20
530. Sorensen L. Arch Surg 2005;140:119

531. South M. Am J Obstet Gynec 2007;197:615.
532. Spinosa J. Eur J Ob Gyn Repro Biol 2005;123:212
533. Stanford EJ. J Min Inv Gyn 2008;15:132.
534. Starczewski A. Pol Merkur Lekarski 2008;25:74.
535. Stav K. IUJ 2010;21:149.
536. Sternschuss G. J Urol 2012;206:27
537. Stoodley P. FEMS Immun Med Micro 2012;65:283.
538. Su T. Int Urogyn J 2011;22:585
539. Su T. J Sex Med 2009;6:3201
540. Summitt R. Internat Urogyn J 1992;3:18.
541. Svabik K. Ceska Gynekol 2010;75:132.
542. Svabik K. IUJ 2011;22:529.
543. Tahtinen RM. Ob Gyn 2011;118:643.
544. Takejama M. Int J Urol 2011;18:555
545. Takeyama M. IUJ 2008;19:559.
546. Tan PF. Saudi Med J 2014;35:20.
547. Tarasov NI. Urologiia 2008;Nov-Dec:33.
548. Thompson JR. Ob Gyn 1999;94:973.
549. Thunes JR. Fem Pelvic Med Reprod Surg 2013;19:p. S47
550. Touboul C. BJOG 2009;116:708.
551. Trabuco E. Int UroGyn J 2007;18:555
552. Trabuco EC. IUJ PFD 2007;18:555.
553. Troy M. Am J Surg 1996;171:391.
554. Tunn R. Ultrasound Obstet Gynecol. 2007;29:449.
555. Ulmsten U. Internat Urogyn J 1995;6:2.
556. Ulmsten U. Scand J Urol Neph 1995;29:75.
557. Unger CA. IUJ 2013 Dec 7.
558. Urbankova I. IUJ 2013;24(Suppl 1):S46-7
559. Urdjik P. Ceska Gynekol 2011;76:321
560. Usher FC. JAMA 1962;179:780-2.
561. Vaivapuri G. Int Urogyn J 2011;22:869
562. Valpas A. Acta Ob Gyn Scand 2003;82:665.
563. VandeVord PJ. Urol 2010;75:1228.
564. Van Raalte HM. Am J Obstet Gynec 2008;199:694.e1-6.—97
565. Van Raalte HM. IUJ 2007;18 (suppl 1):S49.
566. Van Winkle W Jr. Surg Gynecol Obstet 1975;140:933.
567. Vardy M. 2008. Unpublished
568. Vardy M. Am J Obstet Gynec 2007;197:104e1.

569. Vasavada S. Scien World J 2004;4 (Suppl 1):357.
570. Velemir L. Ultrasound Ob Gyn 10;35:474
571. Verdeja AM. Am J Ob Gyn 1995;173:1478.
572. Visco A. Am J Obstet Gynec 2001;184:297.
573. Vollebregt A. Internat Urogyn J 2009;20:1345.
574. Volmer J. Arch Klin Chir 1961;298:729.
575. von Theobald P. J Gynec Obstet Bio Repro (Paris) 2003;32:562.
576. von Theobald P. Rev Med Univ Navarra 2004;48:70.
577. Wadie BS Int Urogyn J Pelvic Fl Dysfunct 2009;20:255
578. Walid MS. Arch Gynecol Obstet 2009;280:347.
579. Wall L. Am J Ob Gyn 2010;202:30
580. Wall L. Int Urogyn J 2009;20:1525
581. Wall L. Int Urogyn J 2009;20:765
582. Walter A. J Urol 2003;169:1907.
583. Walter J-E. J Ob Gyn Can 2011;33:168.
584. Wang F. Arch Gyn Ob 2010;28:279
585. Wang H. Zhonghua Fu Chan Ke Za Zhi 2009;44:825.
586. Ward KL. BJOG 2008;115:226.
587. Weber A. Am J Obstet Gynec 2001;185:1299.
588. Weber A. Int Urogyn J 2009;20:1523
589. Weinberger M. Obstet Gynec 1995;86:92.
590. Wetta LA. IUJPF 2009;20:1307
591. Wheeler LT. Am J Ob Gyn 2006;194:1486.
592. WHO, IARC 1999;74
593. White RA. Biomaterials 1981;2:171
594. WHO 2003 ISBN 92 4 154618 2
595. Williams D. Biomat 2008;29:2941
596. Williams D. Biomat 2009;30:5897
597. Williams D. J Mater Sci 1982;17:1233
598. Williams DF. IUJ 2014;25:577.
599. Winstanley A. J Clin Path 2002;55:623
600. Winters J. J Urol 2012;187:1529
601. Withagen MI. IUJ 2010;21:271
602. Withagen MI. Obstet Gynec 2011;117:242.
603. Withagen MI. Obstet Gynec 2011;118:629
604. Wong K. Obstet Gyn 2013;122:1239
605. www.nice.org.uk 2008.
606. Yahi Y. IUJ 2007;18 (suppl 1):S149—

- 607. Yahi Y. IUJ 2007;18 (suppl 1):S6
- 608. Yamada B. J Urol 2006;176:651.
- 609. Yamada BS. Urology 2006;68:Nov 7.
- 610. Yan A. Eur J Ob Gyn Repro Biol 2004;115:90.
- 611. Yang X. Arch Gyn Ob 2011;Dec 31 epub
- 612. Yildirim A. J Urol 2005;174:1237.
- 613. Young S. Am J Obstet Gynec 1995;173:1719.
- 614. Yuan ZY. Zhonghua Fu Chan Ke Za Zhi 2008;46:1533
- 615. Zorn K. J Urol 2009;182:1126.
- 616. Zumbe J. Urol Int 2008;81:483

Document Identification
1082002
(P141, P274)
01798401-11
080907 includes partial 510k for Gynemesh
20111213105816100
20111213110058300
CMS-1385-P-15007
Deposition of Aaron Kirkemo, dated Apr. 8, 2012 and exhibits
Deposition of Brigitte Hellhammer, dated Sept. 11-12, 2013 and exhibits
Deposition of Bryan Lisa, dated Dec. 12, 2011, and exhibits
Deposition of Catherine Beath, dated Mar. 27, 2012 and exhibits
Deposition of David Robinson dated Sept. 11, 2013 and exhibits
Deposition of Giselle Bonet, dated Mar. 5, 2012, and exhibits
Deposition of Laura Angelini, dated June 19, 2015
Deposition of Maggie D'Aversa, dated Feb. 28, 2012 and exhibits
Deposition of Meng Chen, Ph.D., dated Oct. 29-30, 2013, and exhibits
Deposition of Piet Hinoul, dated Apr. 6, 2012, and exhibits
Deposition of Scott Jones, dated Nov. 16, 2011 and Jan. 25, 2012, and exhibits
Deposition of Stacy Hoffman, dated March 13-15, 2012, Ex. 541
Deposition of Thomas Barbolt, dated October 10, 2012
ETH.MESH.00000698
ETH.MESH.00002652
ETH.MESH.0000272
ETH.MESH.00003327 (P332)
ETH.MESH.00005098 (P397)
ETH.MESH.00008043
ETH.MESH.00008631
ETH.MESH.00011731 (P269)
ETH.MESH.00012952
ETH.MESH.00015699 (P466)
ETH.MESH.00018890
ETH.MESH.00031323 (P1058)
ETH.MESH.00031359
ETH.MESH.00034875
ETH.MESH.00057832
ETH.MESH.00057832
ETH.MESH.00062409
ETH.MESH.00067354 (P240)
ETH.MESH.00070065
ETH.MESH.00070065
ETH.MESH.00075064-70
ETH.MESH.00075065
ETH.MESH.00077702
ETH.MESH.00077727
ETH.MESH.00078114
ETH.MESH.00080934 (P140)

ETH.MESH.00081000
ETH.MESH.00081006
ETH.MESH.00081035
ETH.MESH.00081083
ETH.MESH.00081168
ETH.MESH.00081180
ETH.MESH.00081288 (P155)
ETH.MESH.00081371 (P159)
ETH.MESH.00081478-9
ETH.MESH.00081484 (P167)
ETH.MESH.00083765
ETH.MESH.000955676
ETH.MESH.00126755 (P169)
ETH.MESH.00129134-36
ETH.MESH.00133497
ETH.MESH.00136420-22
ETH.MESH.00152985-013
ETH.MESH.00164023-00164025
ETH.MESH.00164606-11
ETH.MESH.00264493
ETH.MESH.00267625
ETH.MESH.00267992
ETH.MESH.00269349
ETH.MESH.00271215 (P512)
ETH.MESH.00273968
ETH.MESH.00281482
ETH.MESH.00301446
ETH.MESH.00302665
ETH.MESH.00303310
ETH.MESH.00310205
ETH.MESH.00310206
ETH.MESH.00330066
ETH.MESH.00360781
ETH.MESH.00360785
ETH.MESH.00372341 – ETH.MESH.00372357 (P148)
ETH.MESH.00372664 (P160)
ETH.MESH.00393223-7
ETH.MESH.00401457-58
ETH.MESH.00409158
ETH.MESH.00419571-600
ETH.MESH.00442831-34
ETH.MESH.00455676
ETH.MESH.00455676
ETH.MESH.00540249
ETH.MESH.00548912
ETH.MESH.00573693
ETH.MESH.00575746

ETH.MESH.00575766
ETH.MESH.00578261-63
ETH.MESH.00578325 (P500)
ETH.MESH.00582305
ETH.MESH.00582442
ETH.MESH.00584846-47
ETH.MESH.00585228 (P483)
ETH.MESH.00585672
ETH.MESH.00585937 (P527)
ETH.MESH.00591127 (P652)
ETH.MESH.00593165
ETH.MESH.00594767 (P695)
ETH.MESH.00596225-64
ETH.MESH.00631782
ETH.MESH.00681364 (P468)
ETH.MESH.00720002-3
ETH.MESH.00738636-38
ETH.MESH.00738769-71
ETH.MESH.00741137-40
ETH.MESH.00747379
ETH.MESH.00757011
ETH.MESH.00776993
ETH.MESH.0080928 (P138)
ETH.MESH.0081273 (P150)
ETH.MESH.00820718
ETH.MESH.00825415
ETH.MESH.00827953 (P333)
ETH.MESH.00831896
ETH.MESH.00832749
ETH.MESH.00832920 (P325, P714)
ETH.MESH.00840480
ETH.MESH.00841557 (P511)
ETH.MESH.00847816
ETH.MESH.00850335
ETH.MESH.00851319
ETH.MESH.00857821
ETH.MESH.00858888
ETH.MESH.00869907
ETH.MESH.00869976 (P1024)
ETH.MESH.00870466 (P670)
ETH.MESH.00871431
ETH.MESH.00889543
ETH.MESH.00900574-75
ETH.MESH.00906445
ETH.MESH.00925068
ETH.MESH.00926546
ETH.MESH.00959923, T-3743

ETH.MESH.01154031
ETH.MESH.01156032
ETH.MESH.01160158-59
ETH.MESH.01184009
ETH.MESH.01184119 (P1023)
ETH.MESH.01217925
ETH.MESH.01218361
ETH.MESH.01218423-24
ETH.MESH.01220710
ETH.MESH.01220730
ETH.MESH.01264260
ETH.MESH.01274738 (P484)
ETH.MESH.01280816-18
ETH.MESH.01280858-60
ETH.MESH.01310586
ETH.MESH.0133497 (P409)
ETH.MESH.01383-01637
ETH.MESH.01411040
ETH.MESH.01590407
ETH.MESH.01590413
ETH.MESH.01595614
ETH.MESH.01611832 (Robinson Ex. 495)
ETH.MESH.01760853
ETH.MESH.01765748
ETH.MESH.01775482
ETH.MESH.01782114 (P662)
ETH.MESH.01785258 (P671)
ETH.MESH.01798410 (P501)
ETH.MESH.01816988
ETH.MESH.01821586
ETH.MESH.01992233
ETH.MESH.01992234
ETH.MESH.02001398
ETH.MESH.02010834
ETH.MESH.02017152 (P1029)
ETH.MESH.02050884
ETH.MESH.02052858
ETH.MESH.02091867 (P712)
ETH.MESH.02095523 (T2005)
ETH.MESH.02105710
ETH.MESH.02156777
ETH.MESH.02157552
ETH.MESH.02157878 (P698)
ETH.MESH.02178164
ETH.MESH.02212838
ETH.MESH.02227224
ETH.MESH.02227366

ETH.MESH.02252055
ETH.MESH.02252055
ETH.MESH.02252056
ETH.MESH.02270857
ETH.MESH.02277482
ETH.MESH.0228
ETH.MESH.02280771-72
ETH.MESH.02282833
ETH.MESH.02286052 (P619)
ETH.MESH.02286053
ETH.MESH.02289896
ETH.MESH.02312097-98
ETH.MESH.02316434-36
ETH.MESH.02318553
ETH.MESH.02341398
ETH.MESH.02341454-65
ETH.MESH.02341458
ETH.MESH.02341522
ETH.MESH.02341526
ETH.MESH.02341526
ETH.MESH.02341658
ETH.MESH.02341734
ETH.MESH.02342097
ETH.MESH.02342101
ETH.MESH.02342102
ETH.MESH.02342194
ETH.MESH.02342218
ETH.MESH.02342250
ETH.MESH.02342278
ETH.MESH.02587926
ETH.MESH.02589032-72
ETH.MESH.02589066-8
ETH.MESH.02590434
ETH.MESH.02592810
ETH.MESH.02614726-33
ETH.MESH.02615519
ETH.MESH.02616825
ETH.MESH.02650481
ETH.MESH.02658539
ETH.MESH.02770857-8
ETH.MESH.02923305 (P1143)
ETH.MESH.02923305-6
ETH.MESH.02999594
ETH.MESH.03019355
ETH.MESH.03021946
ETH.MESH.03048782
ETH.MESH.03048943

ETH.MESH.03049713
ETH.MESH.03049713
ETH.MESH.03049945
ETH.MESH.03049945
ETH.MESH.03160750
ETH.MESH.03161116
ETH.MESH.03162936
ETH.MESH.03162936
ETH.MESH.03164978
ETH.MESH.03378923
ETH.MESH.03408082
ETH.MESH.03466382
ETH.MESH.03466382
ETH.MESH.03576207 (P1081)
ETH.MESH.03656855
ETH.MESH.03738826-7
ETH.MESH.03752408
ETH.MESH.03753245
ETH.MESH.03904451-80
ETH.MESH.03905968
ETH.MESH.03905975
ETH.MESH.03905976
ETH.MESH.03905991
ETH.MESH.03905992
ETH.MESH.03906000
ETH.MESH.03906001
ETH.MESH.03906020
ETH.MESH.03906021
ETH.MESH.03906036
ETH.MESH.03906037
ETH.MESH.03906052
ETH.MESH.03909804
ETH.MESH.03910723
ETH.MESH.03912703
ETH.MESH.03912703
ETH.MESH.03915567-72
ETH.MESH.03915588
ETH.MESH.03915790-92
ETH.MESH.03916207
ETH.MESH.03923931
ETH.MESH.03924557-61
ETH.MESH.03959073
ETH.MESH.03960528
ETH.MESH.03960590
ETH.MESH.03960706
ETH.MESH.03960706
ETH.MESH.04020134

ETH.MESH.04039941
ETH.MESH.04082973 (T-3321)
ETH.MESH.04096233-4
ETH.MESH.04098496
ETH.MESH.04098598
ETH.MESH.04098598
ETH.MESH.04098793
ETH.MESH.04099383
ETH.MESH.04236910
ETH.MESH.04420656
ETH.MESH.04420750
ETH.MESH.04474315
ETH.MESH.04530787
ETH.MESH.04543409
ETH.MESH.04543409
ETH.MESH.04554842
ETH.MESH.04554842
ETH.MESH.04567644
ETH.MESH.04569706
ETH.MESH.04569706
ETH.MESH.04945233
ETH.MESH.04945356
ETH.MESH.049512-916
ETH.MESH.05009194
ETH.MESH.05009194
ETH.MESH.05160713
ETH.MESH.05237350
ETH.MESH.05237350
ETH.MESH.05240144
ETH.MESH.05246527-28
ETH.MESH.05336822
ETH.MESH.05337790
ETH.MESH.05467804
ETH.MESH.05572810
ETH.MESH.05603617
ETH.MESH.05603793
ETH.MESH.05675417
ETH.MESH.05692235
ETH.MESH.05743318
ETH.MESH.05797232
ETH.MESH.05798123
ETH.MESH.05810485
ETH.MESH.05819585
ETH.MESH.05819668
ETH.MESH.05992137
ETH.MESH.05992152

ETH.MESH.06086551
ETH.MESH.06087267
ETH.MESH.06132977
ETH.MESH.06148459
ETH.MESH.06148459
ETH.MESH.06312970
ETH.MESH.06312970
ETH.MESH.06611235
ETH.MESH.06772938
ETH.MESH.06773944
ETH.MESH.06774040
ETH.MESH.06900451
ETH.MESH.06900544
ETH.MESH.06900544
ETH.MESH.07174521
ETH.MESH.07174956
ETH.MESH.07215395
ETH.MESH.07223489
ETH.MESH.07224059
ETH.MESH.07233856
ETH.MESH.07268259
ETH.MESH.07506983
ETH.MESH.07506983
ETH.MESH.07506984
ETH.MESH.07506985
ETH.MESH.07903682
ETH.MESH.08158-20115
ETH.MESH.08565137
ETH.MESH.08576887
ETH.MESH.08791917
ETH.MESH.08791918
ETH.MESH.08791921
ETH.MESH.08985561
ETH.MESH.08985566
ETH.MESH.08985591
ETH.MESH.08985597
ETH.MESH.09052531
ETH.MESH.09052531
ETH.MESH.09052533
ETH.MESH.09089306
ETH.MESH.09268043
ETH.MESH.09268043
ETH.MESH.09279161
ETH.MESH.09346417
ETH.MESH.09346419
ETH.MESH.10376374
ETH.MESH.10608341

ETH.MESH.10629579
ETH.MESH.10629583
ETH.MESH.11790162
ETH.MESH.11915987
ETH.MESH.11915987
ETH.MESH.12009027
ETH.MESH.12009028-35
ETH.MESH.12608542-51
ETH.MESH.12897430
ETH.MESH.13752696
ETH.MESH.14166558
ETH.MESH.15592352
ETH.MESH.41142
ETH.MESH.80249
ETH.MESH01154031 (P624)
ETH-00252
ETH-00253
ETH-00382
ETH-00383
ETH-00384
ETH-00385
ETH-00639
ETH-01121-2
ETH-01322
ETH-01363 (P15)
ETH-01624
ETH-01626
ETH-01748
ETH-02601
ETH-02654 (P1499)
ETH-03430
ETH-03558
ETH-07153 (P617)
ETH-07154
ETH-08343
ETH-08776
ETH-08894
ETH-08926
ETH-09541
ETH-10127
ETH-20069 (P668)
ETH-37788
ETH-41140 (P625)
ETH-41142
ETH-49659
ETH-59475 (P53)
ETH-60149

ETH-75940
ETH-80249 (P407)
ETH-80647
ETH-83128
ETH-83454-5
ETH-83786
ETH-83788
ETH-83788 (P1567)
ETHC.MESH.00080954
Expert Report of Thomas A. Barbolt, Ph.D., Sept. 14, 2015
Gynecare Gynemesh PS 510k
Hilaire Presentation July 13, 2006
HMESH.ETH.06545936
HMESH_ETH_00152985
HMESH_ETH_00243511
HMESH_ETH_00959923
HMESH_ETH_02085446
HMESH_ETH_02687587
HMESH_ETH_09973200
INCONTINENCE AND PELVIC FLOOR SUMMIT 2/2009
IUGA MEETING 6/09
MDL AMS D2673810
P1028
P1565
P1593, Depo exhibit 127
P1627
P1659
P1706
P314
P331
P485
P495
P519
P520
P59
Pareisi Ex.127 (2005 Professional Education Deck)
Project Gynemesh Vypro PD 00/3
Prolift Global Launch Plan Draft
Prolift Patient Brochure, 12-04-06
Silimed 510k
SP1659
Sunoco 2004 MSDS
Sunoco 2005 MSDS
Sunoco 2006 MSDS

Exhibit C

Donald R. Ostergard, M.D., PSC.

Expert witness fees

Retainer:

\$10,000.00 for initial review of medical records at \$600/hour includes review time and/or consultation time. Payment is due with receipt of electronic records. Further retainers will be requested as the review progresses.

\$600.00 per hour for additional review or consultation time*.

Depositions:

\$1200.00 first hour

800.00 per hour thereafter (or fraction thereof)

or: total amount for reserved time if cancellation criteria not met*

Travel time @ \$600.00/hr + expenses

Retainer to reserve time due 7 days in advance.

Trial &

Arbitration fees: \$4000.00 per half day or fraction thereof or total amount of reserved time*

Travel and down time @ \$600.00/hr + expenses including first/business class air fare.

Payment for anticipated expenses, travel and down time due 3 weeks in advance.

**One week's cancellation notice is required for scheduled consultations, depositions, arbitrations or court time. Fees will be due for time reserved and not used.*

Please make checks payable to: Donald R. Ostergard, M.D., PSC

Tax ID 45-2155762

8557 Mountain View Farms Lane

Salida, CO 81201

Exhibit D

2010

Davison v. Scottsdale Healthcare – Deposition November 15, 2010, Long Beach, CA
Attorney: John Curtin

2011

Giles v. Bonni – Deposition- May 16, 2011 – Long Beach, CA and May 10, 2012 –
Louisville, KY Attorney: Geoffrey Grey, Orange County, CA (Arbitration)

Buchanan v. Li – Deposition - June 10, 2011 – Costa Mesa, CA
Attorney: Anthony Russell, Virginia Circuit Court of the City of Roanoke, CLI0-
1475

Lawson v. Betson - Deposition and Arbitration – August 2011 – Santa Ana, CA
Attorney: Brad McGeer

Ambroff v. American Medical Systems – Deposition – June 21, 2011- Irvine, CA, and
Louisville, KY Attorney: Hirsch and Hirsch, San Francisco, CA

2012

Reid v. UCLA Medical Center – Deposition – February 8, 2012 – Torrance, CA
State of CA, Co of LA, SC112098

Scott v. Bard – Deposition - March 12 and April 10, 2012 –Louisville, KY
Attorney: Gene Lorenz, Bakersfield, CA, California, County of Kern, S-1500-
CV-266034-WDP

Scott v. Bard – Court Testimony-July 2012- Bakersfield, CA

Shugart v. Warren, UCLA Medical Center- Deposition- September 27, 2012-El Segundo,
CA Attorney: Hoyt Hart, Sup Court State of CA, Co of LA, sc100558

Mentor MultiDistrict Litigation Deposition-October 26, 2012-Louisville, KY
Attorney: Mark Mueller, Texas

Carpenter v. AMS – Deposition – November 15, 2012 – Louisville, KY
Attorney: Stuart Albertson, Riverside, CA, Superior Court, State of CA, County
of San Bernardino CIVDS 1007094

2013

Davison v. Scottsdale Healthcare - Trial Testimony by Video from Rineyville, KY – January 31, 2013 Attorney: John Curtin, State of AZ, Co of Maricopa, CV 2009-012359

Mund v. AMS – Deposition in two parts: April 15, 2013 and June 20, 2013— Albuquerque, New Mexico and Louisville, KY respectively Attorney: Mark Mueller, Texas, New Mexico, Co of Bernalillo, Second Jud Dist, D-202-CV-2010-02625S

McMillan v. Slovak – Deposition August 22, 2013, Louisville, KY
Dist Court, Titus Co TX, 36153

Neighbors v. Brown – Deposition, August 27, 2013, Louisville KY
Attorney: Jos Wright III, CA File no 2011-CP-30-1137, So Carolina, Laurens Co.

Jones v. Bard – Deposition in two parts: October 10, 2013, Torrance, CA and October 23, 2013, Irvine, CA
Attorney: Jim Matthews, Athens, GA, US District Court, Southern Division of West Virginia, DL 2187

Thomas v. Saenz and Bard – Deposition: November 1, 2013, Torrance, CA – District Court, Larimer County, Colorado – Attorney Dierdre Ostrowski, 2012 CV 438

Barba, Smothers, Hall, Orozco, Wilson, Albright, Cardenas v. Boston Scientific— Deposition, December 20, 21, 2013, January 29 and 30 2014. Torrance, CA. MDL Litigation, West Virginia.
Attorneys Jon Orent, Boston MA and Kathryn Forgie, Los Angeles, CA

2014

AMS Fact Witness Deposition, MDL Litigation, Torrance, CA, January 31, 2014

Powell v AMS – Deposition: Feb 24, 2014, Torrance, CA – Circuit Court, County of Sebastian, Arkansas. CV-2011-1451 – Civil Division VI – Attorney: Craig Cook

Salazar V BSC – Deposition: February 27, 2014, Torrance, CA - District Court, 95thJudicial District, Dallas County, Texas. DC-12-14349. Attorney: Sheila Bossier

Johnson v Mentor. Deposition: March 5, 2014, Torrance, CA. In the US District Court for the Middle District of Georgia, Columbus Division. MDS Case No. 2004, Individual case No. 4:11-cv-05071 (N. Johnson) Attorney: Jon Orent

Flagg v. Katz – Deposition testimony, June 9, 2014, Torrance, CA – Circuit Court of the Sixth Judicial District in and for Pinellas County, FL, Civil Division. Case No.: 13-005041-CI. Attorney: Henry Valenzuela

Albright v Boston Scientific – Trial testimony, July 15-16, 2014, Woburn, MA – Commonwealth of Massachusetts, Middlesex, SS:Superior Court, Civil Action No.2012-00909. Attorney: Jon Orent

Neighbors v. Brown – Trial testimony, July 22, 2014, Greenville, SC – State of South Carolina in the Court of Common Pleas, County of Laurens, C.A. NO. 2011-CP-30-1137. Attorney Joseph Wright, III.

Carlton v. St Joseph Hospital – DepositionTestimony, September 13, 2014, Torrance, CA – State of Michigan in the Circuit Court County of Wayne, Case No. 13-011544-NH. Attorney Stephen Brzezinski

Boston Scientific Deposition, December 18, 2014. In the United States District Court for the Southern District of West Virginia, Charleston Division. In re: Boston Scientific Corporation Pelvic Repair System Products Liability Litigation, MDL 2326.

2015

Ward v Brown – Deposition testimony, March 30, 2015, Denver, CO - State of South Carolina in the Court of Common Pleas, County of Laurens, C.A. NO. 2011-CP-30-1140. Attorney Joseph Wright, III.

Ward v Brown – Video trial testimony, March 31, 2015, Denver, CO - State of South Carolina in the Court of Common Pleas, County of Laurens, C.A. NO. 2011-CP-30-1140. Attorney Joseph Wright, III.

Steinhoff v. Bard – Deposition, May 4, 2015, Denver, CO –In the United States District Court for the Southern District of West Virginia, Charleston Division. In re: CR Bard. Inc. Pelvic floor repair system products, liability litigation, MDL 2187.

Morales v. Bard – Deposition, May 4, 2015, Denver, CO –In the United States District Court for the Southern District of West Virginia, Charleston Division. In re: CR Bard. Inc. Pelvic floor repair system products, liability litigation, MDL 2187.

Hankemeier v. Bard – Deposition, May 4, 2015, Denver, CO –In the United States District Court for the Southern District of West Virginia, Charleston Division. In re: CR Bard. Inc. Pelvic floor repair system products, liability litigation, MDL 2187.